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The research presented in this thesis puts forth total syntheses of two marine natural products: (-)-
mucosin and (+)-crucigasterin 277. Both syntheses focus on producing enantiopure natural 
products derived from commercially available starting materials. One of the main aims for the 
manufacture of these two marine natural products is to make them both available for biological 
studies.   
 
The first total synthesis focused on producing (-)-mucosin, a C20 fatty acid, isolated and 
elucidated as its methyl ester from a Mediterranean sponge, Reniera mucosa. Utilization of 
commercially available 1,4-cyclohexadiene and its subsequent conversion to a literature known 
meso-ketone in three steps proceeded with effective results. An ensuing enantioselective protocol 
with a chiral base furnished an optically active β-keto ester in excellent enantiomeric excess of 
≥99%. Elaboration of this β-keto ester in a thirteen-step synthesis, involving a copper mediated 
cross-coupling reaction, two consecutive homologations to form a terminal alkyne and a novel 
stereospecific one-pot Negishi cross-coupling protocol to form an E-olefin, gave the literature 
stated structure of (-)-mucosin. On analysis of the relative stereochemistry of a late stage 
intermediate by X-ray crystallography and comparison of the literature NMR and optical rotation 
data of the (-)-mucosin methyl ester with the synthesized methyl ester it was found that the 
relative stereochemistry of the natural product methyl ester had been incorrectly elucidated, as 
well as its previously synthesized enantiomer (+)-mucosin.  
 
The second total synthesis focused on producing (+)-crucigasterin 277, a C18 amino alcohol, 
isolated and elucidated as a diacetyl from a Mediterranean tunicate, Pseudodistoma crucigaster. 
Employment of commercially available eicosapentaenoic acid ethyl ester was reacted in a 
literature known seven-step synthesis, involving an iodolactonization, hydrolysis, oxidative 
cleavage and base catalyzed isomerization to form a C15 allylic bromide. This bromide was then 
converted to a sulfone, which underwent a nucleophilic addition with enantiopure N-Boc-D-
alaninal (Boc = tert-butyloxycarbonyl) to form a mixture of four diastereoisomers. After 
subsequent purification, desulfonation and deprotection, (+)-crucigasterin 277 was synthesised in 
excellent optical purity on comparison with its diacetyl derivative. This is the first reported 




Avhandlingen beskriver totalsyntesene av to marine naturprodukter: (-)-mucosin og (+)-
crucigasterin 277. Begge synteser fokuserer på å fremstille naturproduktene av høy enantiomerisk 
renhet fra kommersielt tilgjengelige startmaterialer. Et av hovedmålene for syntesene var også at 
de skulle ha en kjemisk og optisk renhet tilstrekkelig for fremtidig biologisk testing.  
Den første totalsyntesen beskriver fremstillingen av (-)-mucosin, et C20 fettsyre-derivat, isolert fra 
en svamp, Reniera mucosa, som finnes i Middelhavet. Kommersielt tilgjengelig 1,4-
cycloheksadien ble gjennom tre trinn omdannet til et meso-keton kjent fra litteraturen. Ved å 
benytte en kiral base ble optisk aktiv β-ketoester fremstilt med enantiomerisk overskudd over 
99%. Gjennom 13 reaksjonstrinn, som blant annet involverer Michael-type addisjon, to 
påfølgende homologeringer for å danne et terminalt alkyn, samt en stereospesifikk ”one-pot” 
Negishi krysskobling for å danne E- alkenet, ble den litteratur-foreslåtte strukturen for (-)-
mucosin syntetisert. Våre data viser klart at naturproduktet ikke har den strukturen som er 
foreslått i litteraturen. Røntgen-analyse av et av de siste intermediatene i syntesen av mucosin ga 
den relative stereokjemien til alle fire stereogene sentra på den bisykliske forbindelsen. 
Sammenligning av litteratur-NMR data og optisk rotasjon for (-)-mucosin metylesteren med den 
syntetiserte metylesteren viste at den relative stereokjemien til naturprodukt metylesteren er feil. 
Dette gjelder også enatiomeren som er syntetsert og publisert av andre. 
Den andre totalsyntesen fokuserer på (+)-crucigasterin 277, en C18 aminoalkohol, isolert fra et 
kappedyr, Pseudodistoma crucigaster, fra Middelhavet. Etylesteren av eicosapentaenoic syre av 
ble benyttet som startmateriale, og gjennom en reaksjonsrekke på syv trinn, som blant annet 
inkluderer jodlaktonisering, hydrolyse, oksidativ kløyving og basekatalysert isomerisering, ble 
C15 allylbromidet fremstilt. Dette bromidet ble omdannet til tilsvarende sulfon, og reagert mot N-
Boc-D-alaninal (Boc = tert-butyloksykarbonyl) for å gi blandingen av fire diastereomerer. Etter 
opprensning ble sulfongruppen fjernet, etterfulgt av hydrolyse av Boc-beskyttelsesgruppen, for å 
gi (+)-crucigasterin 277. For å sammenligne med litteraturdata ble (+)-crucigasterin 277 
omdannet til diacetatet, som er den forbindelsen som er beskrevet i litteraturen. Dataene stemte, 











































AA Arachidonic Acid ((5Z,8Z,11Z,14Z)-eicosatetraenoic acid) 
AcOH Acetic acid 
Acyl-CoA Acyl-coenzyme A 
AdA Adrenic acid ((7Z,10Z,13Z,16Z)-docosatetraenoic acid) 
COX-1 Prostaglandin H synthase 
Cp2ZrCl2 bis(Cyclopentadienyl)zirconium(IV) dichloride  
DHA Docosahexaenoic acid ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid) 
DIBAL-H Diisobutyl aluminium hydride 
DIC N,N'-Diisopropylcarbodiimide 
DMC Dimethyl carbonate 
DME 1,2-Dimethoxyethane 
DMF N,N-Dimethylformamide 
DMP Dess-Martin periodinane 
DMSO Dimethyl sulfoxide 
EPA Eicosapentaenoic acid ((5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid) 
EPA-EE Eicosapentaenoic acid ethyl ester 
HETE Hydroxyeicosatetraenioc acid 
HPLC High-Performance Liquid Chromatography 
IsoPs Isoprostanes 
LDA Lithium diisopropylamide 
LiHMDS Lithium bis(trimethylsilyl)amide 
mCPBA meta-Chloroperbenzoic acid 
NaHMDS Sodium bis(trimethylsilyl)amide  
NBS N-Bromosuccinimide 
NCS N-Chlorosuccinimide 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect Spectroscopy 




PMNs Polymorphonuclear Cells 
PUFA Polyunsaturated Fatty Acid 
RAMP (R)-(+)-1-Amino-2-(methoxymethyl)pyrrolidine 
ROESY Rotating Frame Nuclear Overhauser Effect Spectroscopy 
SAMP (S)-(-)-1-Amino-2-(methoxymethyl)pyrrolidine 
TBAF Tetrabutylammonium fluoride 
TEMPO (2,2,6,6-Tetramethyl-piperidin-1-yl)oxyl 
TES Triethylsilyl  
THF Tetrahydrofuran 
TMS Trimethylsilyl  
TMSCl Timethylchlorosilane 
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1. Introduction 
 
1.1 Natural Products 
In nature, many bioactive compounds have been isolated that have helped humanity 
overcome diseases and infections. As early as 4000 years ago, plants such as mandrake were 
prescribed for pain relief; turmeric for blood clotting and wild garlic for circulatory 
problems.1 
During the nineteenth century great strides were made to actually isolate the bioactive 
medicinal compounds in these plants. Friedrich Sertürner was the first scientist to 
successfully acquire and characterize chemically pure morphine (1) in 1806 from the opium 
poppy Papaver somniferum.2 Since then, many thousands of natural products, such as 
strychnine (2) and pacliataxel (3), have been isolated and many have been successfully 
incorporated into the pharmaceutical industry. All three can be seen in Figure 1.1 below. In 
the USA today about 121 certified drugs come from nature and about forty-seven percent of 







1.2 Marine Bioprospecting 
During the last half of the 20th century, marine natural products entered the pharmaceutical 
radar as a possible alternative for extracting bioactive compounds. One potential reason for 






























Figure 1.1 Structures of the natural products morphine (1), strychnine (2) and pacliataxel (3). 
	 	 	2 
species and has been quoted as the earth’s “second rainforest.”4 This is now seen as a rich 
breeding ground for harvesting novel and curative natural products. One way to obtain these 
is by marine bioprospecting, which involves the collection of aquatic organisms and 
subsequent screening for a specific molecule or activity of interest.5 Several potential 
therapeutic compounds from marine bioprospecting are given below in Figure 1.2. All have 
anti-cancer properties and are isolated from various aquatic fauna. Discodermolide (4), a 
polyhydroxylated polyketide lactone from the deep-sea sponge Discodermia sp., is an 
immunosuppressive and cytotoxic agent that stabilizes microtubules.6,7 Luffarin I (5), a 
sesterterpene isolated from an Australian marine sponge Luffariella geometrica, is an 













One of the major problems with isolating and employing these marine natural products is 
sustainability. Simply removing hundreds of kilograms of sponges, sea worms and other 
marine flora and fauna for necessary analysis and biological testing has a huge ecological 

















































Figure 1.2 Structures of the marine natural products discodermolide (4), luffarin I (5) and 
halichondrin B (6). 
	 	 	3 
metabolite isolated from Lissodendoryx sp.9,10 Distribution of the sponge globally is around 
five km2 and only has an estimated total biomass of 289 tons. Employing clinical trials would 
involve the removal of >30 tons of the sponge to yield 1-5 Kg of halichondrin B and around 
3000-17000 tons would be needed annually for commercial drug use.11 This is obviously 
unsustainable and devastating to the marine environment. A synthetic methodology must be 
implemented to garner sufficient volume of the metabolite. The benefits of making this 
possible is seen with the drug discovery effort to synthesize eribulin (7) (Figure 1.3),10,12 
which is an anticancer macrocyclic analogue of halichondrin B. Eribulin has been used to 
treat patients with metastatic breast cancer and inoperable liposarcoma due to its suppression 
of microtubule growth.13 Without synthetically producing halichondrin B it would be very 







1.3 Polyunsaturated Fatty Acids 
In Norway, polyunsaturated fatty acids (PUFAs), which are also marine natural products, 
have been studied for a long time and have some interesting bioactivities. PUFAs such as 
docosahexaenoic acid (DHA) (8) and eicosapentaenoic acid (EPA) (9) are ω-3 fatty acids and 
are abundantly available from various ocean fish, most notably from cod liver oil.14 The 
notoriety of the benefits of cod liver oil, even as far back as the Viking era, has allowed a 
huge industry to evolve in the manufacturing and marketing of these valuable compounds. 
Reduction in coronary heart disease, blood pressure, arthritis, and cancer in humans has 
meant other structurally associated adducts related to PUFAs have been tested for their 
bioactivity.15-19 Another PUFA is arachidonic acid (AA) (10), which differs from EPA and 
DHA due to it comprising of a ω-6 chain and reduced chain saturation. AA is a major 

















Figure 1.3 Structure of the anti-cancer macrocycle eribulin (7). 
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found in the diet.20 However, in the marine environment AA has been shown to be present in 
many metabolic pathways, especially in finfish and echinoderms.21-23 This PUFA, along with 
DHA and EPA, as shown in Figure 1.4, is the parent molecule in the biosynthesis of many 
varying natural products such as prostaglandins and amino alcohols, which can also be 







Prostaglandins (PGs) are a class of physiologically active compounds that have diverse 
hormone-like effects in animals and are a subclass of eicosanoids. The first scientific proof of 
these hormone-like effects was reported in the 1930s with journals, by von Euler24 and 
Goldblatt,25 describing the effect of human semen on the uterus and the reduction of blood 
pressure via injection into animals. However, it was not until the 1960s that great strides were 
taken in understanding the structure of these compounds and how they were employed 
physiologically. Professors Sune Bergström and Bengt Samuelsson successfully elucidated 
four different PGs, PGE1 (11), PGE2 (12), PGE3 (13) and PGF2α (14) (Figure 1.5), from sheep 
semen.26 All four displayed significant bioactivity especially towards muscle stimulation and 
as vasodepressors.26 Professors E. J. Corey and Bengt Samuelsson were able to successfully 
determine and prove the cyclooxygenase (COX-1) pathway forms various PGs from AA.27 
Following the biological testing of a variety of isolated PGs they were shown to lower 












Figure 1.4 Structures of the PUFAs DHA (8), EPA (9) and AA (10). 










The following fifty years up, until the present-day, saw a huge explosion in isolating and 
producing various PGs along with other eicosanoids such as thromboxanes, leukotrienes and 
lipoxins. All have very acute bioactive effects on human and mammalian physiological 
activities varying from anticancer to vasomodulation. Table 1.1 displays a brief outline of the 


































Figure 1.5 Structures of the PGs PGE1 (11), PGE2 (12), PGE3 (13) and PGF2α (14). 


















1.4.1 Biosynthesis of Prostaglandins 
A note must be made with regards to the biosynthesis of PGs, an outline of which is shown in 
Scheme 1.1. PGs are formed by most cells in the human body and in most cases are 
synthesized from the membrane-released prostanoid precursor AA (10).53 This release of AA 






































Ovarian Cancer, Vesicular Stomatitis Virus,
Sendai Virus, Replication of HIV-1.
Improves CNS Ischemia
Reduction in Cardiovascular Activity
Anti-Tumour, Anti-Inflammatory
Anti-Inflammatory, Anti-Asthmatic, 
Renal Regulation, Induces Labour,
Induce Miscarriage,
 Reduction of Glaucoma
Increase Inflammation, Stimulate
Platelet Aggregation and Muscle Contraction
Inhibition of Gastric Acid Secretion, 
Anti-Aggregation of Platelets and
Increased Vasodilation
Anti-Inflammatory, Leukaemia Inhibitor, 
Block Poliovirus Replication
N/A
Type Cyclic Structure* Mammalian and Human Physiological Effects
* R1 and R2 are not repeating units and vary in each cyclic structure.
Table 1.1 Outline of the cyclic skeletons of PGs. 
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is released by the cell membranes it undergoes oxygenation to intermediate prostaglandin 
endoperoxide H2 (PGH2) (15) by an enzyme called prostaglandin H synthase (PGHS or COX-
1).53 Following on from this, the unstable intermediate PGH2 is then converted to various PGs 
inside the cell, such as PGD2 (16), which is mainly found in Mast cells, PGF2α (14), which is 
mainly found in the uterus and PGE2 (12), which is found in most cells in the body, via 
specific synthases.54 Once biosynthesized these PGs leave the cell membranes via a carrier 













1.5 Marine Prostaglandins 
PGs and their derivatives are present in earth’s marine environment, especially in their fauna. 
Many biochemical studies have been focused on how pharmacologically active marine 
autocoids effect the organisms that produce them and subsequently their effect on the 
mammalian physiology. The first prostaglandin isolated from the marine environment, (15R)-
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PGA2 (17), was derived from a coral species Plexaura homomalla in 1969 and contains a 
non-mammalian (R)-configuration at C15.55 However, this compound possessed no 
bioactivity, whilst the mammalian (S)-configured diastereoisomer of 17, PGA2 (18), 
influences vasodilation.55 Today, studies are still being carried out on 17 and investigations 
into comparable adducts of this compound, such as (15R)-PGE2 (19), have shown in vivo anti-
inflammatory effects as well as in vitro reduction of elastase in human polymorphonuclear 






Additional bioactive marine metabolites have shown anti-inflammatory and anti-cancer 
pharmacological propensities. Clavularia viridis, a shore reef soft coral, produces a group of 
novel prostanoids called claviridic acids or clavulones.57 These acids, including compounds 
20 and 21 (Figure 1.7), were tested for their inhibitory effects on inflammation and cancer. 
Slight modifications were also undertaken on their structure with an additional alcohol/acetic 
moiety and stereochemical alteration on C4 (22). These clavulones were especially effective 








Figure 1.6 Structures of the PGs (15R)-PGA2 (17), (15S)-PGA2 (18) and (15R)-PGE2 (19). 
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In 1995, a new eicosanoid metabolite was isolated by Casapullo et al.,58 from the sponge 
Reniera mucosa, which is found in the Mediterranean Sea. After treatment with acetone and 
diazomethane the structure of the optically active methyl ester of (-)-mucosin (23) (Figure 
1.8) was elucidated by 1H and 13C-NMR. A futher detailed analysis of the structure was 
carried out by a NOESY analysis so as to resolve the stereochemistry at the bridgeheads. 
However, the absolute configuration was not determined, which was possibly due to an 
overlap of the H-8 and H-9 environments on analysis by NOESY.  
1.6.1 Elucidated Structure and Comparison with Other Bicyclic Natural Products 
The metabolite 23 was elucidated to contain an unusual bicyclo[4.3.0]nonene skeleton 
including ring unsaturation (∆11,12), cis-fused bridgeheads (C-9 and C-14), trans-related side-
chains (C-8 and C-16) with respective lengths of C7 and C4 and an E-olefin (∆5,6). The 
synthesis of the enantiomer of (-)-mucosin (23), (+)-mucosin (ent-23) (Figure 1.8) has also 
been completed by Whitby et al.,59 employing a zirconium induced co-cyclisation to yield the 
bicyclo[4.3.0]nonene core and install the correct stereochemistry at the four contiguous 
stereocenters. The structure reported for (+)-mucosin shows a direct comparison with that of 
(-)-mucosin from the natural product literature.58 Hypothetically, (-)-mucosin (23) may be 
biosynthesized from AA through an intramolecular cycloaddition, or with Diels-Alder 
enzymes, involving C-8/C-9, C-14/C-15 and isomerization of the ∆5,6 olefin.58 
The bicyclic carbon skeleton of (-)-mucosin is not unique by itself, as other natural products 
contain the bicyclo[4.3.0]nonene ring. Three bioactive sesquiterpenoids, shown in Figure 1.9, 
acutifolone A (24),60 bisacutifolone C (25)60 and pinguisenol (26)61, all produced from 
liverworts, contain the cis-fused ring system.62 The structures of these sequiterpenes have 
various anticancer and antimicrobial bioactivities.62  
 

























With respect to marine metabolites such as (-)-mucosin (23), plakotenin (27), manzamenones 
A (28) and (+)-spiculoic acid A (29), all shown in Figure 1.10, are sequestered from the 
genera of Plaktortis sponges, consist of this bicyclo[4.3.0]nonene ring formation.63,64 
However, only the manzamenones A variant 28 contains the similar cis-fused hydrogens and 






1.6.2 Postulated Bioactivity 
(-)-Mucosins’ bioactivity should be discussed with regard to the structural similarity between 
itself and PGs. No pharmacological testing has been carried out on 23 or its enantiomer (ent-
23). This might be possibly due to a deficiency in biomass of the required sponge (1.35 Kg of 
sponge gave only 8.5 mg of (-)-mucosin methyl ester), or because the isolation of the acid 23 
has proved problematic in extraction, which is why the methyl ester was synthesised.58 The 
arrangement of the trans-related side-chain bears many similarities with the aforementioned 
PG structures, as well as the cyclopentane moiety. The hope is that some of the bioactivity 
present in the PGs as well as metabolite 27, which is anti-arthritic65 metabolite 28, which 
inhibits T-cell protein tyrosine phosphatases66 and metabolite 29, which is cytotoxic64, as well 
as the cis-fused sesquiterpenoids in Figure 1.9, will also be present in 23. 
1.6.3 Postulated Biosynthesis 
The possible biosynthesis of (-)-mucosin (23) raises some interesting questions regarding 
Figure 1.9 Structures of the cis-fused bioactive sesquiterpenoids acutifolone (24), bisacutifolone (25) 
and pinguisenol and (26). 
Figure 1.10 Structures of the bioactive marine metabolites plakotenin (27), manzamenones A 
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natures’ use of enzymes in the formation of the cyclic structures. Since the late 1970s 
discoveries in the use of enzymes to catalyze the [4+2] cycloaddition reaction to create 
natural products have interested many organic chemists. This has given rise to the naming of 
these enzymes as Diels-Alderases.67 One of the first identified naturally occurring Diels-
Alderases was found by Ichihara and co-workers67,68 and is shown in Scheme 1.2. Whilst 
performing feeding studies on the fungal pathogen Alternaria solani there was evidence of an 
oxidation, followed by a subsequent [4+2] cycloaddition on prosolanapyrone (30) to 
biosynthesize solanapyrones A (31) and B (32).69 Ichihara managed to not only isolate the 
enzyme responsible (solanapyrone synthase), but also to monitor the enzymatic and non-
enzymatic pathways by HPLC. The exo product is favored in a 85:15 ratio using the enzyme 
while employing the non-enzymatic pathway yields mainly the endo product in a 97:3 ratio.68 
Not only does the exo/endo selectivity change with respect to which pathway is used, but 










Another biosynthesis system that incorporates a Diels-Alderase is the formation of a decalin 
ring system that uses lovastatin nonaketide synthase (LNKS), as shown in Scheme 1.3. The 
decalin structure is similar to that of (-)-mucosin with the presence of a bicyclic system and a 
cyclohexene moiety. The LNKS catalyzes an internal [4+2] cycloaddition reaction to occur 
with a model thioester 33. This leads to the formation of three different stereoisomers 
34:35:36 in a 15:15:1 ratio,70 as shown in Scheme 1.3. What is interesting to note is that one 
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of the main products is the cis-fused exo analogue (34), which is analogous to (-)-mucosin, 









With respect to marine metabolites, no formal Diels-Alderase enzymes have been isolated 
from the marine environment, which enzymatically catalyzes the formation of the bicyclic 
skeleton, present in many marine natural products, by a [4+2] cycloaddition reaction. 
However, many compounds found from ocean flora and fauna have been postulated to 
undergo one of these Diels-Alder type reactions facilitated by enzymes. The aforementioned 
(+)-spiculoic acid A (29)71,72 is one such compound as is pulo’upone (39),73,74 an 
antimicrobial marine metabolite produced from the mollusk Philinopsis speciosa and (-)-
ircinianin (41),74 a sesterterpene from the marine sponge Ircinia wistarii. Scheme 1.4 below 
details the presupposed enzymatic [4+2] cycloaddition reaction between a Diels-Alderase 













































1.7 Target Marine Prostanoid; (-)-dictyosphaerin75 
In 1996 Rochfort and co-workers75 isolated a unique bicyclic lipid, (-)-dictyosphaerin (42) 
(Figure 1.11), from a southern Australian marine green algae Dictyosphaeria sericea.75  
1.7.1 Structural Elucidation and Comparison with (-)-mucosin 
This novel fatty acid is analogous to (-)-mucosin due to its bicyclo[4.3.0]nonene skeleton, 
cyclohexene moiety (∆13,14), and structurally comparable side-chains containing an E-olefin. 
Conversely, there are some notable differences. Firstly, (-)-dictyosphaerin (42) is a C22 
compound with C8 and C5 side-chains with (-)-mucosin (23), being a C20 compound with C7 
and C5 side-chains. Secondly, there is additional ring unsaturation (∆9,17), contrasting chain 
unsaturation (∆7,8) and three undistinguished chiral centers, the alcohol moiety (C-6) and the 




Figure 1.11 Target molecule (-)-dictyosphaerin (42). 
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1.7.2 Postulated Biosynthesis and Bioactivity 
Biosynthetically, (-)-dictyosphaerin (42) will most probably relate to (-)-mucosin (23) with 
an intramolecular cycloaddition, possibly incorporating the Diels-Alderase reaction 
mentioned previously, but employing most likely adrenic acid (AdA) rather than AA, due to 
(-)-dictyosphaerin being a C22 acid. Interestingly, yet conversely, some similar pentacyclic 
eicosanoids with comparable side-chains, called isoprostanes (IsoPs) present in the myelin of 
human brains, are also generated from in vitro phospholipid bound DHA or AdA, by a free-
radical-catalyzed mechanism.76,77 These novel compounds are used as biomarkers in the 
detection of oxidative neurological stress by Alzheimer and Rett’s disease in humans.76,78 The 
most abundantly detected of these IsoPs are ent-7-epi-7-F2t-dihomo-IsoP (43) and 5-F3t-IsoP 
(44).76 These IsoPs, as well as the bicyclic natural products in Figures 1.9 and 1.10, could 
determine the bioactivity with respect to (-)-dictyosphaerin, as no formal bioactivity studies 







1.8 Naturally Occurring Vicinal Amino Alcohols 
Vicinal amino alcohols are a common unclassifiable component of bioactive natural 
products, which is in contrast to PGs.79 This is mainly due to the spread of these particular 
structural components over a wide range of classifiable natural products. Some of the most 
basic structures of amino alcohols can be found in hydroxy amino acids like L-threonine and 
D-alanine. Adversely, they can also be quite complex, as in the structures of bestatin (45), an 
immunodilator, and the structurally unique AI-77-B (46), which possesses gastroprotective 
activity.80-82 Cyclic amino alcohols also represent another important group containing the 
aforementioned moiety, but this time they are positioned on the ring, as shown with the 
antimalarial agent febrifugine (47) and antibiotic anisomycin (48).83-86 Lipids and lipid-like 
molecules also exemplify the cross-class nature of these vicinal amino alcohols. Bioactive 
natural products sulfobacin B (49), an antithrombotic agent and myriocin (50), a strong 
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immunostimulatory agent, are potent examples of the utility of these lipid-like amino 













1.9 Naturally Occurring Marine Vicinal Amino Alcohols 
Vicinal amino alcohols are present in many marine species especially as lipids. These lipid 
compounds typically contain stereochemically defined amine and alcohol groups on 
neighboring carbons. They have a long alkyl chain with varying degrees of saturation and are 
usually highly pharmacologically active. In 1988, Gulavita and Scheuer90 isolated the first 
marine amino alcohol 2(S)-aminotetradeca-5,7-dien-3(R)-ol from the sponge Xestospongia 
sp., found in the sea off Papua New Guinea. Over the past two decades the quantity of marine 
amino alcohols isolated, synthesised and bio-analysed has grown enormously. Three 
examples are shown in Figure 1.14. Bicycles amaminol A (51) and obscuraminol A (52), are 
cytotoxic against leukemia and lung cancer respectively, whilst pseudoaminol G (53) exhibits 





Figure 1.13 Structures of bioactive vicinal amino alcohols bestatin (45), AI-77-B (46), febrifugine 
(47), anisomycin (48), sulfobacin B (49) and myriocin (50). 
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Structures range from simple, long chain fatty acid type moieties, to polycyclic structures. 
There is no formal nomenclature system, as in PGs, but they are known under their IUPAC 
names and/or trivial names, the latter being derived from the tunicate they were isolated 
from, such as clavaminols (54),97 cruciagasterins (55)98 and obscuraminols (56).92 An example 
of each is given in Figure 1.15. Biosynthetically, many of the amino alcohols are derived 
from either amino acids, like serine or alanine, and the appropriate fatty acyl-CoA, depending 






1.10 Target Marine Vicinal Amino Alcohol; (+)-crucigasterin 277100 
In 1993, Rinehart et al.,100 isolated this novel vicinal amino alcohol (57), as shown in Figure 
1.16, from a Mediterranean tunicate Pseudodistoma crucigaster. These alcoholic extracts of 
the tunicate exhibited cytotoxicity against L1210 murine leukaemia cells.100  
1.10.1 Structural Elucidation 
The number 277 refers to the molecular mass of the compound. The framework of this C18 
compound is interesting, due to the three skipped Z-olefins (∆9,10, ∆12,13, ∆15,16), the E-olefin 
(∆5,6), the (R)-amino moiety (C-2) and (S)-alcohol moiety (C-3). Interestingly, with respect to 
the biosynthesis, the C-2(R) stereochemistry suggests that this compound is biosynthesized 





Figure 1.15 Examples of marine vicinal amino alcohols isolated from their tunicates. 
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1.10.2 Postulated Bioactivity and Biosynthesis 
A number of similar bioactive antimicrobial structures (58, 59, 60), known as 2-amino-3-
tetradecanols, have been independently identified from the sponge Xestospongia sp.90,101 They 
have many similar features to (+)-crucigasterin 277, such as chirality on the amino and 
alcohol substituents and chain unsaturation. However, none of the C14 amino alcohols (58, 59, 
60) possesses the cis-skipped olefin bonds or isolated trans-olefin at ∆5,6 and the 







The biosynthesis of the C14 Pacific amino alcohols is also related to (+)-crucigasterin 277 but 
employs L-alanine (61), with loss of the carboxyl group, and a fatty acid CoA derivative 62. 
An example of the biosynthesis, using compound 58, is shown in Scheme 1.3 below.90,101 An 
initial reaction between a specific enzyme, 62 and activated L-alanine 61 gives the 
intermediate keto-amine 63, which is then selectively reduced at the ketone by a reductase 






Figure 1.17 Structures of three bioactive 2-amino-3-tetradecanols (58,59,60) isolated 
from Xestospongia sp. 
Scheme 1.3 Biosynthesis of compound 58 employing a fatty acid CoA starting material (62) with 
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2. Retrosynthetic Analyses 
 
2.1 Retrosynthetic Analysis of (-)-mucosin58 
The target molecule (-)-mucosin (23), as shown in Scheme 2.1, a C20 natural product, reveals 
four stereogenic centres and two olefins. The two side-chains are attached to the 
bicyclo[4.3.0]nonene skeleton in anti-fashion at C-8 and C-16. The longest side-chain, 
bonded via an S-configuration (C-8), contains an E-olefin (∆5,6) and a carboxylic acid 
terminus at C-1. The shorter side-chain, bonded via an R-configuration (C-16), is a butyl 
group with a methyl terminus at C-20. The bicyclo[4.3.0]nonene skeleton comprises of two 
cis-fused hydrogens on C-9 and C-14 and a cyclohexene moiety (∆11,12). Proceeding from this 
analysis, building the correct stereochemistry at the side-chains and formation of the E-olefin 
moiety must be the main priority. Determination of the appropriate stereogenic reactions and 
reagents must be taken into careful consideration when formulating the retrosynthetic 
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The most complex aspects to synthesize the correct structure of (-)-mucosin are an E-olefin at 
∆5,6 and anti-configuration at C-8 and C-16. Formation of the E-olefin at ∆5,6 can be 
performed in many ways but one of the simplest would be to perform a Wolff-Kishner-type 
reduction102,103 on an α,β-unsaturated hydrazone. This reduction, employing Na(CN)BH3, 
would allow the olefin at ∆6,7 to undergo a hydride shift and move to ∆5,6 and solely furnish 
the E-olefin. The α,β-unsaturated hydrazone can be made directly from an α,β-unsaturated 
ketone 64, which in turn can be synthesised via a Horner-Wadsworth-Emmons reaction,104 
with an optically active aldehyde 65 and a preformed C6 phosphonate-ester 66. This 
phosphonate-ester can easily be produced from a commercially available glutamic acid 
analogue.104 These two main steps would allow for the necessary C7 side-chain to be built.  
 
The next stage would be to insert the butyl side-chain at C-16 with the correct 
stereochemistry. One method would be to undertake a stereoselective Michael addition 
reaction with an α,β-unsaturated ester 67, nBuLi and a suitable cuprate additive, such as 
Cu(I)CN.105 Due to the 3D-structure of the bicyclo[4.3.0]nonene skeleton the postulated 
Michael addition should form an anti-configuration at the bridgehead carbons. At this stage 
in the analysis it could be difficult to resolve in which direction (syn or anti) the butyl and 
ester side-chains could occupy. One possible method to help with this resolution of side-
chain configuration would be the use of a chiral imine to replace the ester moiety before the 
Michael addition step.106 This would help in giving some directional uniformity with respect 
to the butyl side-chain addition. 
 
Following from this the α,β-unsaturated ester can be fashioned from the optically active β-
keto-ester 68. This optically active β-keto-ester can be produced in a number of ways in 
literature but these are quite lengthy.107,108 One simpler method would be to employ the 
literature known meso-ketone109 69 and create an enolate using a chiral base110, such as 
(R,R)-bis(phenylethyl)amine hydrochloride, and inserting the ester with use of a simple 
nucleophile, such as Mander’s reagent (methyl cyanoformate).110 The meso-ketone itself can 
easily be synthesised from the cheap and commercially available cis-1,2,3,6-
tetrahydrophthalic anhydride 70 via the bis-acid intermediate 71 with a literature known five-
step synthesis.111  
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2.2 Retrosynthetic Analysis of (-)-dictyosphaerin75 
The second target molecule (-)-dictyosphaerin (42), in Figure 2.1, presents us with a C22 
natural product containing a bicyclo[4.3.0]nonene skeleton with two side-chains that are C8 
and C5 in length. At a glance, the structure of (-)-dictyosphaerin seems very similar to that of 
(-)-mucosin, especially as the identical cyclohexene moiety, here ∆13,14, and the 
bicyclo[4.3.0]nonene skeleton are present. Discernible similarities with the side-chains of (-)-
dictyosphaerin and (-)-mucosin can also be seen as the longer side-chains, here C8, in both 
natural products contain an E-olefin, here at ∆7,8, with an acid terminus, here C-1 and the 








However, on closer inspection of (-)-dictyosphaerin it has distinct structural differences to (-
)-mucosin. (-)-dictyosphaerin is a C22 natural product as both its side-chains are one carbon 
longer in length (C8 and C5 respectively) when compared with (-)-mucosin, which is a C20 
natural product. The bridgehead stereochemistry at C-11 and C-16 in (-)-dictyosphaerin has 
not been possible to characterize from the natural product analysis, even with NOESY 
experiments and Mosher’s ester analysis.75 This is not the case with (-)-mucosin, as the 
natural product analysis shows the suggested respective bridgehead stereochemistry being 
cis-fused.58  
 
The bridgehead carbons for the side-chains at ∆9,17 have an olefin moiety unlike the (-)-
mucosin bridgehead carbons, which are saturated, and anti in configuration. The C8 side-
chain in (-)-dictyosphaerin also contains an alcohol moiety at C-6, which also has an 
undetermined stereochemistry. This is not present in (-)-mucosin. Finally, the E-olefin in (-)-
dictyosphaerin at ∆7,8 is directly bonded to the bridgehead at C-9. This is not the case with the 
E-olefin in (-)-mucosin, as the bridgehead and olefin moiety, are separated by a methylene 
group. 
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Synthesis of (-)-dictyosphaerin must take into careful consideration the choice of 
stereochemistry at C-11 and C-16, the ring unsaturation at ∆9,17, the E-olefin at ∆7,8 and the 
choice of stereochemistry for the alcohol moiety at C-6. Careful selection of stereogenic 
reactions and preformed reagents must be considered, especially when trying to form separate 
diastereoisomers for the alcohol at C-6, as this chiral center is undetermined. This will be the 


























Due to the unascertained alcohol chiral center at C-6 in the structure of (-)-dictyosphaerin 
(42), it would be necessary to obtain both diastereoisomers 72a and 72b for spectral 
comparison with the natural product data. One of the easiest methods to do this would be a 
Scheme 2.2 Retrosynthetic analysis of (-)-dictyosphaerin (42), incorporating the cis-fused 
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selective reduction of a ketone moiety at C-6 on compound 73 with a chiral hydride 
reagent112 or chiral catalyst113 to form a diastereospecific alcohol. The epimer of which, can 
then be made via employment of the opposite chiral hydride or chiral catalyst adopting the 
starting ketone 73. This ketone, which contains α,β-unsaturation at ∆7,8, can easily be 
synthesised analogously by the Horner-Wadsworth-Emmons method in the retrosynthesis of 
(-)-mucosin.104 The main difference is the synthesis of a preformed C7 phosphonate-ester 74, 
rather than a C6, from a suitable starting material. 
 
This scission at ∆7,8 would then leave us with an α,β-unsaturated aldehyde 75. One method of 
making this would be a cleavage of a terminal olefin with a Pd(0) catalyst.114 This is 
necessary, as ozonolysis would also cleave the cyclohexene ring. This would then leave a 
molecule 76 containing an α,β-unsaturated olefin with a pentyl group attached at C-17. One 
method to insert the pentyl chain would be via a controlled nucleophilic attack,115 with nBuLi 
on an ester moiety to form a ketone at C-18. This ketone could then be reduced with NaBH4 
to an alcohol 77, which in turn can be reduced by a protocol,116 employing 
chlorodiphenylsilane and a catalytic amount of indium trichloride to form the pentyl moiety. 
This alcohol reduction method was chosen over the Wolff-Kishner and Barton-McCombie 
protocols so as to prevent movement of the ∆9,17 olefin. 
 
This would then leave us with an α,β-unsaturated ester 78, containing the terminal olefin 
bonded to C-9. This α,β-unsaturated ester now looks remarkably similar to the enantiomeric 
keto-ester 68 in the retrosynthesis of (-)-mucosin. A simple Stille cross-coupling protocol117 
with an α,β-unsaturated triflic-ester 79 and vinyl tributylstannane will afford 78. This α,β-
unsaturated triflic ester can then easily be formed from the postulated β-keto-ester 68, seen 
previously, using triflic anhydride (Tf2O) .118 The synthesis of this β-keto-ester would then be 
identical to the one discussed from the commercially available cis-1,2,3,6-tetrahydrophthalic 
anhydride (71) in the retrosynthesis of (-)-mucosin.111 With respect to the choice of 
stereochemistry at C-11 and C-16, it was decided to obtain the identical cis-fused partnership 
that is present in (-)-mucosin, due to the structural similarities between the two compounds. 
Once synthesised, we can directly compare the natural product spectral data to the synthetic 
spectral data and elucidate the results accordingly. 
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2.3 Retrosynthetic Analysis of (+)-crucigasterin 277100 
Assessing the structure of (+)-crucigasterin 277 (57) presents a C18 vicinal amino alcohol 
with two stereo-centers at C-2 and C-3 and four olefins, one E-olefin at ∆5,6 and three skipped 
Z-olefins at ∆9,10, ∆12,13 and ∆15,16. The amino group on C-2 has an R-configuration while the 
alcohol group on C-3 has an S-configuration. (+)-crucigasterin 277 also begins and terminates 
with methyl groups. The preliminary retrosynthesis must focus on generating the optically 
active vicinal amino alcohol substituents on C-2 and C-3 in their respective R and S formats. 
Attention must also be concentrated towards the formation of the E-olefin between ∆5,6 and 



























































	 	 	24 
Route A: One way of inserting the optically active amino alcohol substituent onto the 
molecule would be scission of ∆3,4 to give a nucleophilic attack via Grignard reaction with a 
C15 allylic bromide 82 with the necessary E,Z,Z,Z-skeleton and N-Boc-D-alaninal (81).119 
This would produce a mixture of two diastereoisomers 80 at C-3, which could be separated 
by column chromatography and the preferred (S)-diastereoisomer at C-3 could be isolated 
and the Boc-protecting group can then be removed with use of TFA to form (+)-crucigasterin 
277 57.120 Another option to obtain the (S)-diastereoisomer at C-3 would be to oxidise the 
alcohol moieties of both diastereoisomers of 80 to a single ketone and selectively reduce it to 
the necessary (S)-diastereoisomer by a chiral hydride112 or chiral base,113 as mentioned with 
the (-)-dictyosphaerin retrosynthesis. Following on from this, the focus must be towards the 
formation of the C15 allylic bromide 82. This can be easily synthesised by a reduction of a C15 
allylic aldehyde 83 to an alcohol by NaBH4 and a nucleophilic substitution to a bromide with 
Ph3P and Br2 under Appel conditions.119 Formation of N-Boc-D-alaninal (81) can either be 
made by careful reduction by DIBAL-H100 on N-Boc-D-alanine methyl ester or careful 
TEMPO or Parikh-Doering oxidation121-124 on N-Boc-D-alaninol, both of which are 
commercially available. Creation of the C15 allylic aldehyde 83 precursor needs to be 
motivated towards the E-olefin (∆5,6), which will be needed in the final structure. This E-
olefin can be formed from a Z-olefin at ∆6,7 of a C15 aldehyde 84 via a reaction with DBU.125 
Production of this aldehyde can be undertaken from the commercially available EPA-EE 85 
in a four-step literature synthesis.126 Conversion of EPA-EE to EPA and then to an 
iodolactone, subsequent reduction with LiOH.H2O to form a dihydroxyacid and treatment 
with NaIO4 should lead to the desired aldehyde 84 in good yields. 
 
Route B: Another method of inserting the optically active amino alcohol substituent onto the 
molecule would be scission of ∆2,3. This would give the possibility of an anti-selective Henry 
reaction between an aldehyde 87 and nitroethane with employment of a heterobimetallic 
Cu/Sm/aminophenol sulfonamide complex.127 Of note, our group has used an asymmetric 
Henry-reaction in the synthesis of obscuraminol A.96 Once this had been completed to form 
nitro alcohol 86, reduction of the nitro moiety could be carried out with use of SmI2 to form 
(+)-crucigasterin 277.128 Synthesis of the aldehyde precursor 87 for the Henry reaction could 
be carried out from the common aldehyde intermediate 83 with a simple, literature known, 
homologation via a mesylation, cyanation and reduction.129 The synthesis of 83 has already 
been discussed. 
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3. Results & Discussion of the Synthesis of (-)-mucosin 
 
3.1 Synthesis Towards the cis-Fused Bicyclo[4.3.0]nonene Skeleton 
The first key component of the synthesis of (-)-mucosin is the cis-fused bicyclo[4.3.0]nonene 
skeleton. Based on the retrosynthetic strategy in Scheme 2.1, an attempted synthesis of the 
meso-ketone 69 should be tackled first. The formation of this structure can be performed in a 
number of methods. On paper, the simplest method would be a Diels-Alder reaction via 
commercially available 1,3-butadiene (88) and 3-cyclopenten-1-one (89) to form a cis-fused 
meso-ketone 69. This bicyclic meso-ketone, although optically inactive, is open to many 






Even though the cost of purchasing 1,3-butadiene is quite affordable there are several 
drawbacks with this strategy. Firstly, although the electron density on the diene is correct the 
electron density of the dienophile is reversed. The diene is electron-rich while the dienophile 
should be electron poor and this simply is not the case with this starting material and so leads 
to a mismatched pairing for a Diels-Alder reaction. This, ultimately, will give large amounts 
of 4-vinylcyclohexene in addition to the desired bicyclo[4.3.0]nonene compound. Secondly, 
commercially available, 3-cyclopenten-1-one is very expensive and for these reasons alone, a 
more reliable and economical method is required. 
 
3.1.1 Literature Synthesis of meso-Ketone 69 
Mundy and Theodore111 reported one method to form this cis-fused meso-ketone 69 using a 
commercially available acetic anhydride precursor cis-1,2,3,6-tetrahydrophthalic anhydride 
(71) in a five-step synthesis. Initial reduction of the anhydride with LiAlH4, under reflux 
conditions, generates the diol 90. This diol undergoes tosylation at 0 °C to give a bis-tosylate, 
which is then substituted to the bis-nitrile 91 under reflux. Subsequent hydrolysis of 91 under 
reflux forms a bis-acid, which can then undergo a Ruzicka-type cyclisation with basic reflux 
to give the meso-ketone 69 in around 14% total yield over five-steps.  


















This method, although lengthy, succeeds in retaining the necessary cis-fused hydrogens and 
provides the springboard to further manipulation towards (-)-mucosin. However, employing 
this method is laborious, contains multiple steps, involves high carbon expenditure and 
results in a poor total yield of 14% over five steps.  
 
3.1.2 Advances Towards A More Effective Synthesis of meso-Ketone 69 
For the above-mentioned reasons we wanted a more simple and carbon economic procedure 
for the production of 69. The known dichlorobicyclo[4.2.0]octene racemic adduct 94 can be 
easily made in a reasonable yield adding two equivalents of commercially available 
trichloroacetyl chloride (93) to one equivalent of 1,4-cyclohexadiene (92).130 Sonication is 
highly effective at activating the zinc surface so it becomes more reactive to dehalogenation 
of trichloroacetyl chloride. The added benefit of this reaction is the establishment of the cis-
fused hydrogens, which are necessary for the relative configuration of the 






The theory behind this stereospecific [2+2] cycloaddition reaction, although at times 
contradictory, is well documented. This [2+2] cycloaddition is arguably both a concerted and 
a charged process. Initially, the concerted process was the accepted theory due to the 
Scheme 3.2 Mundy and Theodore protocol to synthesize meso-ketone 69. 
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stereospecific addition to the olefins. The readiness of the ketene to react with an olefin is 
seen with the lack of steric hindrance from the planar ketene molecule 95 itself when 
compared with normal olefins 96 and the favorable bonding interactions between both the 






However, later mechanistic studies in the 1970s, by Woodward and Hoffmann, also indicated 
a stepwise reaction involving a dipolar intermediate.132 The intermediate was proposed to be 
involved in an interaction between the cationic carbon and the enolate system of the dipolar 






Contemporary evidence supports both these hypotheses, as certain [2+2] cycloadditions are 
concerted processes while others seem to form dipolar intermediates.131 The strongest 
evidence for a dipolar mechanism is the regioselectivity on non-symmetric olefins, which is 
possible due to the stability of carbocations. As regards the aforementioned cycloaddition 
reaction, in Scheme 3.3, to form 94 a concerted process seems more plausible. Actually, the 
reaction is completely stereoselective as seen by the absence of a trans-fused diastereoisomer 
98 in the final product analysis. This implies that the reaction is carried out in a concerted 
process rather than a dipolar intermediate. If a dipolar intermediate were formed between the 
ketene and diene then both cis and trans-fused diastereoisomers would be detected. This is 





 Figure 4.3 Structures of the cis-fused 94 and trans-fused 98 diastereoisomers of the 
dichlorobicyclo[4.2.0]octene adduct. 
Figure 3.2 The dipolar intermediate 97 postulated to be involved in [2+2] cycloadditions. 
Figure 3.1 Orbital interactions between a planar ketene and olefin 95 and 
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Regarding stereochemistry, the [2+2] cycloaddition reaction is stereospecific, depending on 
which type of olefin is applied. The Z-isomer of the substrate will lead only to cis-bicyclic 
compounds, as seen above in Scheme 3.3. The E-isomer of the same substrate will lead only 
to trans-bicyclic compounds with only a partial loss of stereochemistry.133 Concerning the 
racemic bicyclo[4.2.0]octene compound, this sonicated [2+2] cycloaddition reaction is a very 
convenient method of forming a stereospecific cis-fused bicyclic ring in a 47% yield.  
 
Subsequently, the second step considered a ring expansion of the cyclobutanone to a 
cyclopentanone via a carbon insertion reaction via diazomethane, which is analogous to the 
Bayer-Villiger reaction with ketone 99 to form lactone 100, as shown below in Scheme 






The carbon insertion reaction itself was initiated by utilizing diazomethane (101), formed 
from N-Nitroso-N-methylurea, dissolved in Et2O and adding directly to 94 as shown in 
Scheme 3.5.135-137 This reaction successfully formed the dichlorobicyclo[4.3.0]nonene 







The mechanism of this reaction is analogous to the Büchner–Curtius–Schlotterbeck 
reaction138,139 between a ketone and an aliphatic diazoalkane, here diazomethane (101), as 
can be seen below in Scheme 3.6. The diazomethane molecule is highly polarized with both a 
partly positive and partly negative charge (as shown in Scheme 3.6) and this dielectric charge 
allows diazomethane to become very susceptible to nucleophilic additions. With the 
cyclobutanone precursor a nucleophilic attack occurs directly between the negatively charged 
diazomethane carbon and the carbonyl carbon. This produces a tetrahedral intermediate 103, 
which immediately decomposes to a tertiary carbocation with evolution of nitrogen.140,141 The 
Scheme 3.4 Reaction of a typical Bayer-Villiger reaction using mCPBA. 
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next stage involves the reformation of the carbonyl by a 1,2-alkyl migration. This occurs by 
migration of the bridgehead carbon containing the cis-fused hydrogen onto the newly bonded 







The alternative option for migration would occur from the dichlorinated carbon atom. Due to 
the electron-withdrawing propensity of the chlorine atoms with respect to the carbon, the low 
electron density formed on the dichlorinated carbon atom itself makes the migration seem 
unlikely. The first choice seems the more appropriate as the alkyl substituents present on the 
bridgehead carbon gives this atom more propensity towards this reaction. This gives this 
reaction a high degree of regioselectivity, usually being found to be regiospecific, which is 
also exhibited in analogous synthons attempted by Greene and Deprés.137 
 
A note of interest is the implementation of the diazomethane insertion reaction using the 
dechlorinated bicyclo[4.2.0]cyclobutanone 104, as shown in Scheme 3.7. This was attempted 







Ketone 105 would appear to be susceptible towards esterification at the α-methylene position. 
This would allow elaboration towards (-)-dictyosphaerin (42) in a similar way to the 
proposed synthesis of (-)-mucosin, as given in the retrosynthesis in Scheme 2.1. The reaction 
with diazomethane from compound 105 was ineffective and so this line of thought was 
discontinued.  
 
The retention of stereochemistry of the cis-fused bridgehead hydrogens during the 
rearrangement of the diazo intermediate 103 should also be remarked upon. This could be 
Scheme 3.6 Postulated mechanism of the Büchner–Curtius–Schlotterbeck reaction with 94. 
Scheme 3.7 Attempted diazomethane insertion reaction with dechlorinated ketone 104. 
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converted to a mixture of cis and trans diastereoisomers at the ring-fusion. Analysis of the 
spectral data of the ensuing meso-ketone 69 reveals no trace of such a transformation.109 This 
is also seen in similar cyclobutanone ring expansion reactions where there is retention of 
stereochemistry at the adjacent carbon atom to the inserted methylene carbon atom as shown 
in Scheme 3.8.142 Another interesting observation seen in Scheme 3.8 is that the major isomer 
formed from racemic ketone 106 is the one where migration occurs on the more substituted 
α-carbon to form 107 and 108 in a 25:75 ratio. This observation in reduction of reactivity at 
the less substituted α-carbon would also tie in with the lack of reactivity of the dechlorinated 







The final stage of this three-step meso-ketone synthesis involves the reduction of the 
dichlorobicyclo[4.3.0]nonene 102 via AcOH and Zn under reflux, as shown in Scheme 3.9, to 






This step is highly efficient and yields are around 72% after silica-gel column purification. 
The total yield for this three-step synthesis is 26%, which is a significant improvement to the 
aforementioned Mundy and Theodore synthesis.111 The reduction in time, lower carbon 
expenditure and more economical starting materials also means this unique three-step 
synthesis is much more effective. 
 
3.2 Methods Towards Enantiomeric Desymmetrisation of meso-Ketone 69 
The next stage of the synthesis, towards (-)-mucosin, focused on enantiomeric 
desymmetrisation of the meso-ketone 69 by insertion of a substituent at the α-position to the 
Scheme 3.8 An example of the observed migratory preference for the diazomethane 
insertion reaction. 
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ketone via manipulation with a chiral reagent. This would allow the elaboration of the 
necessary trans-related C7 and C4 side-chains at a later stage.  
 
3.2.1 Initial Attempts Towards Racemic Desymmetrisation Incorporating 69 
Many options were postulated, but initial attempts at desymmetrisation focused on racemic 
model reactions. One of the simplest was to form the lithium enolate 109 of meso-ketone 69, 
via LDA, and react it with nucleophiles such as allyl bromide, pentanal and 1-bromopentane, 
as shown in Scheme 3.10. After numerous attempts with differing conditions, such as 
temperature and solvents, only a mixture of vinylic diastereoisomers 112 was formed in a 














3.2.2 SAMP and RAMP Desymmetrisation Strategy Incorporating 69 
An alternative desymmetrisation strategy was then attempted via employment of a hydrazine. 
This avenue was adopted due to the work carried out by Dieter Enders et al.,143,144 who 
focused on the SAMP/RAMP hydrazone methodology, which can give enantio- and 
diastereoselectivity in alkylation asymmetry reactions, as shown by the example below in 
Scheme 3.11. Formation of the optically active ketone 116 from 3-pentanone (113) via the 
use of SAMP (114) and a subsequent hydrolysis of the hydrazine 115, shows that the yield 
and enantiomeric excess can be sufficient enough to attempt this approach.144 
 
 







































The SAMP auxiliary (114) is commercially available and formed the hydrazone 117 in good 
yield with 69. This would allow the α-protons of the hydrazone 115 to become more acidic 
compared to the lithium enolate 109 and therefore asymmetric induction should occur more 
readily. As shown in Scheme 3.12, the formation of the hydrazone from the meso-ketone 69 
was straightforward and in good yield (79%).143 The next stage was to attempt asymmetric 
addition with a good nucleophile. Initially, 1-bromopentane was chosen, due to the ease of 
availability and to see the compatibility with (-)-dictyosphaerin. The reaction was carried out 
with MeLi and DPA with varying temperature from -78 °C to room temperature over 24 h.143 
The addition was successful and gave diastereomeric mixture 118 in a moderate yield of 
45%. The final step was to hydrolyse the hydrazone back to the diastereomeric mixture of 
ketone 119 using MeI and a mixture of 3M HCl/pentane.143 The desired oxidation did not 














Scheme 3.11 Enantioselective desymmetrisation reaction of 113 employing the SAMP 
methodology. 
Scheme 3.12 Attempted enantioselective desymmetrisation on meso-ketone 69 
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3.2.3 Attempts Towards Racemic Esterification Incorporating 69 
Following on from this outcome, a strategy incorporating NaH (4.0 equiv.), dimethyl 
carbonate (DMC) (3.0 equiv.) and dimethoxyethane (DME) as a solvent was envisioned. The 
meso-ketone 69 was used in a model reaction to insert a methyl ester at the α-position to the 
ketone to form a racemic β-keto ester. The reaction itself was performed by Taber and 
Wang145 and utilised a very similar trans-fused bicyclo[4.3.0]nonane ketone 120 to form a 







Focusing on this procedure, which would have been beneficial, as the ester could then be 
manipulated to the necessary C7 side-chain, the meso-ketone 69 was subjected to this 
acetylation, as shown in Scheme 3.14. Initial attempts proved successful, with yields varying 
from 50-68% as a mixture of racemic diastereoisomers of the β-keto ester 122 (d.r. 90:10). 
An improved method of forming the β-keto ester with fewer diastereomeric impurities 122 
was also exercised. This new method, by Ding et al.,146 which does not utilize DME as a 
solvent, and also reduces the equivalents of NaH (1.1 equiv.) and DMC (0.2 M), led to a 
better d.r. (95:5) but no improvement in yield (45-55%).146 Even with this amalgamation of 
esters it was decided that this could be an acceptable method for asymmetric induction of the 
meso-ketone for elaboration to (-)-mucosin. This was on the basis that a future synthon for 
the racemic β-keto ester 122 would be centered on an enantiomeric strategy to form the 










Scheme 3.13 Racemic esterification of ketone 120, to form β-keto ester diastereomeric mixture 121. 
Scheme 3.14 Attempted racemic esterification on 69 employing the Taber/Wang and 
Ding et al., protocols. 
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3.2.4 Attempted Literature Synthesis of the Optically Active β-Keto Ester 68 
Subsequent reactions with the racemic diastereomeric β-keto ester mixture 122 led to 
promising results for the formation of (-)-mucosin. These will be discussed later in detail. 
The initial problem of forming the enantiomeric β-keto ester 68, as discussed in the 
retrosynthesis, still remained. Investigation into the literature revealed that the desired chiral 
β-keto ester 68 had been synthesised previously by Nagao et al.107,108 This procedure was a 
five-step synthesis starting from the aforementioned bis-acid 70, made via the Mundy and 
Theodore procedure111 and the amino acid L-valine (123) depicted in Scheme 3.15. The 
amino acid was converted into 4(S)-iso-propyl-1-3-thiazolidinone-2-thione (124), (4(S)-
IPTT), in a two-step synthesis with high yields (83%) and identical optical rotation ([α]20D -
36.81°).147 A subsequent reaction between bis-acid 70, 4(S)-IPTT (124) and N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride, (WSC hydrochloride), led to the bis-
amide 125. The final two steps to form the optically active β-keto ester 68 from the bis-amide 
125 involved the use of KH (30% disp. min. oil) and DMF to form a β-keto amide 126, 














The bis-amide 125 was formed in acceptable yields and in high purity. The cyclisation step to 
form the β-keto amide 126 failed repeatedly with the use of KH at varying concentrations and 
temperatures. Other bases were tried with 125, but all failed to form the desired mono amide. 
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The resulting compound was usually impure bis-acid 70, so this methodology was 
abandoned. 
3.2.5 Attempted Synthesis of Optically Active 68 via Employment of a Chiral Base 
Due to these results another program of reactions were then focused towards an enantiomeric 
formation of the racemic enolate 109 as shown above in Scheme 3.10. This time a chiral base 
would be employed to ensure correct enantioselective formation of the lithium enolate on the 
exo-face of the five-membered ring. Following on from this a nucleophile would then be 
inserted into the reaction to form a stable intermediate. This intermediate could then be 
converted into a more versatile structure to produce (-)-mucosin. Gais et al.,110 successfully 
attempted an analogous reaction pathway previously forming a chiral polycyclic azoene 132 
from ketone 127 as seen in Scheme 3.16. The use of the chiral base (+)-bis[(R)-1-
phenylethyl]amine hydrochloride 128 and nBuLi to form a lithium amide allows for the 
enantioselective deprotonation of ketone 127 to form the enantiomeric enolate 129. From 
here the addition of TMSCl gives the stable intermediate 130, which can then be transformed 
into the enantiomeric chloride 131 via NCS with a 90% e.e.110 Direct addition of NCS to the 















Scheme 3.16 Gais et al. protocol, employing a chiral base 128, for an enantioselective 
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Elaboration to the analogous chloride 134 when employing the meso-ketone 69, as a starting 
precursor with the Gais et al. protocol, would allow for a non-racemic synthesis of (-)-
mucosin. This was attempted and the crude chloride 134 was formed in around 70% yield in 
three-steps via intermediate silyl enol ether 133, as shown in Scheme 3.17. The decision was 
then taken to investigate the reaction of other nucleophiles with the enantioselective enolate. 
Our first choice was Mander’s reagent, methyl cyanoformate, as mentioned in the 
retrosynthesis. The initial preference was to isolate the silyl enol ether 133 first and undertake 
the subsequent methyl ester addition reaction with MeLi as a base.148 This was due to the 
poor reactivity and low yield of methyl cyanoformate in THF compared to Et2O. However, 
the silyl enol ether 133 decomposes on silica column purification quite rapidly and removal 
of the chiral base 128 is necessary not only for recovery but also to reduce the unwanted side-
reactions with MeLi in the next step. In spite of this, initial test reactions to form the β-keto 









3.2.6 A More Effective Synthesis Towards the Optically Active β-Keto Ester 68 
Further studying of the literature proved fruitful, as a model acetylation reaction employing 
ketone 135 performed by Mander et al.,149 allows for direct stereoselective addition of a 
methyl ester onto a preformed lithium enolate 136, as shown in Scheme 3.18, without the 
need for a stable intermediate such as the silyl enol ether 133. This stereoselective acetylation 







Scheme 3.17 Attempted synthesis of optically active β-keto ester 68 via the Gais et al. protocol. 
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A test reaction was then carried out on the enantiomeric lithium enolate of 69, formed by the 
chiral base 128 and nBuLi, and substituting TMSCl for methyl cyanoformate, as shown in 
Scheme 3.19. After purification, by silica column and NMR analysis, the optically active β-
keto ester 68 was identified as a mixture of optically active diastereoisomers 138 and analysis 
by 1H and 13C NMR spectra proved that the crude mixture was a duplicate of the racemic 
diastereomeric mixtures of the racemic β-keto ester 122 formed in Scheme 3.14. Further 
purification by crystallization in nhexane afforded pure white crystals of the desired (R)-
diastereoisomer 68 and analysis by optical rotation gave a value of [α]26D -161.2°, which is 
close to the literature value of -159.9° for the enantiomeric (R)-isomer.107,108,150 The yield was 









3.3 Efforts Towards the Elaboration of the trans-Related Side-Chains 
The next stage was to convert this enantiomeric β-keto ester 68 into an intermediate that 
could be stereoselectively augmented to form the correct chiral configuration at the two side-
chains. One option would be to carry out a nucleophilic addition reaction with a butyl 
Grignard reagent with the ketone to insert the necessary butyl side-chain. However, this leads 
to problems with the ester group as this would mean the ester would have to be converted 
into an acetal/ortho-ester or other protecting group, as shown with compound 139, to shield 
itself from the Grignard reagent. The other issue is that the Grignard reaction itself is non-
stereospecific and would form a mixture of diastereoisomers as shown in Scheme 3.20. The 
tertiary alcohol in structure 140 would also have to be removed at some stage. Based on this, 
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3.3.1 Elaboration of the C4 Side-Chain via a Stereoselective Michael Addition 
One methodology for a stereoselective nucleophilic addition is a Michael addition, as shown 
in the retrosynthesis. This uses a carbanion and an α,β-unsaturated carbonyl compound which 
also has the ability to be highly stereospecific if a chiral imine intermediate is employed.106 
To exploit this idea with the β-keto ester 68 the ketone would have to be reduced to an olefin 
and the ester converted to a chiral aldimine. Initial attempts of ketone reduction, on 68 via 
NaBH4 to the diastereomeric alcohol 141 proved successful, as did the reduction to the α,β-
unsaturated ester 67 with POCl3 and pyridine.151,152 The next phase was to convert the ester 
67 to an aldehyde 143, which could then be easily converted to a chiral aldimine. Initial 
attempts with DIBAL-H at low temperatures to form the aldehyde were successful but over-
reduction to the alcohol 142 lowered the yield significantly.153 It was then decided to reduce 
the ester 67 completely to the corresponding alcohol 142 and then oxidize 142 to the 
aldehyde 143 with DMP.154 This proved a less problematic approach with regards to 











Initially, the Michael addition reaction was tested on the α,β-unsaturated ester 67 without any 
chiral modification, with Cu(I)CN and nBuLi, but no reaction occurred.105 The next attempt 
Scheme 3.20 Postulated butyl chain insertion via a Grignard reaction from 68. 
Scheme 3.21 Synthesis of the α,β-unsaturated aldehyde intermediate 143 for the 
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was on the α,β-unsaturated aldehyde 143 again without any chiral modification and this 
proceeded successfully, but as a mixture of four alkylated diastereoisomers 144 (d.r. = 







Subsequently, the α,β-unsaturated aldehyde 143 could then be altered into a chiral aldimine 
146 by a simple condensation reaction with Ti(OEt)4 and an optically active tert-
butanesulfinamide 145 of our choosing.106 A conjugate addition protocol by McMahon and 
Ellman,106 employing the use of a conjugated chiral (R)-tert-butanesulfinyl aldimine with 
Cu(I)CN and nBuLi, as reagents showed the propensity for this reaction to give high 
diastereoselectivity (d.r. 85:15) once the conjugate addition has occurred. Using this as a 
template for a diastereoselective Michael addition the (R)-aldimine 146 was reacted with 










A preliminary result of the conjugate addition showed that mainly one diastereoisomer (d.r. 
80:20), in mixture 147, was formed in satisfactory yields (≈60%). This was purified to the 
main diastereoisomer 147a but stereochemical analysis by NMR proved difficult so no 
formal stereochemical assignment could be made with regards to the butyl and (R)-aldimine 
side-chains. The decision was then taken to continue with the extension of the aldimine 147a 
to the C7 side-chain and examine if the stereochemistry of the final compound equates with 
the literature of the target molecule (-)-mucosin.  
 
Scheme 3.22 Michael addition reaction utilizing 143 without chiral 
modification. 
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3.3.2 Elaboration of the C7 Side-Chain via a Horner-Wadsworth-Emmons Reaction 
Elongation of the (R)-aldimine side-chain should proceed, initially, by removal of the imine 
with AcOH/H2O to form an aldehyde.106 This aldehyde should then have the flexibility to 
undergo C-C addition reactions such as the Horner-Wadsworth-Emmons, as shown in the 
retrosynthesis, to yield a C7 side-chain containing the necessary E-olefin at Δ6,7 as shown on 
intermediate 64. Precedence for this chain elongation, via the Horner-Wadsworth-Emmons 
protocol employing a C6 phosphonate 66, has been attempted on the synthesis of 
conformationally restricted analogues, similar in shape to Leukotrienes B4 and B3, by Gore et 
al.104 One of these conformationally restricted analogues 149, synthesised from the C6 








Removal of the imine substituent on 147a progressed efficiently to an aldehyde in good 
yields of around 70%. However, an inseparable diastereomeric mixture of two aldehydes 150 
(d.r. = 75:25) (two of which were identical to those found in diastereomeric mixture 144) was 
seen by analysis with NMR, similar to the ratio found for 147 after the stereoselective 
Michael addition in Scheme 3.23. This was puzzling as only one diastereoisomer was 
expected, but due to the acidic nature of the α-proton adjacent to the aldimine moiety an 
equilibration must occur under the acidic conditions and produce two sets of diastereoisomers 
with respect to the subsequent aldehyde side-chain. After these initial results a preliminary 
reaction was carried out, as shown in Scheme 3.25, with the mixture of aldehydes 150 and the 
suitable phosphonate intermediate 66. The resulting keto-ester 151 was made as an 
inseparable mixture of two diastereoisomers, corresponding to the diastereomeric aldehyde 
precursors 150, both exclusively with an E-olefin in an acceptable yield of 62%. The 
phosphonate intermediate 66 was made in a three-step synthesis from commercially available 
methyl 5-chloro-5-oxovalerate in a 91% overall yield comparable to the literature yield of 
94%.104 
 
Scheme 3.24 Chain elongation protocol via a Horner-Wadsworth-Emmons reaction 
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3.3.3 Attempted Synthesis of the E-Olefin via a Modified Wolff-Kishner Reaction. 
The next stage was to perform a reduction protocol, as shown in the retrosynthesis, on the 
ketone of the C7 side-chain on 151. This would allow the E-olefin to be selectively 
transferred across to the ketone carbon (Δ5,6) via 1,3-sigmatropic rearrangement in a modified 
Wolff-Kishner reaction, as attempted by Hutchins and Majetich.102,103 This would hopefully 
provide the correct geometric isomer for the C7 side-chain of (-)-mucosin. An initial reaction 
was attempted on the mixture of diastereoisomers 151, formed by the previous Horner-
Wadsworth-Emmons reaction, to form the diastereomeric methyl ester mixture 152 with the 





The initial formation of the hydrazone moiety and subsequent purification by column 
chromatography, although facile, gave repeatedly poor yields (≈25%). The next stage was the 
reduction of the hydrazone under basic conditions employing Na(CN)BH3. This would allow 
for the 1,3-sigmatropic rearrangement to be initiated and transfer the hydride across to the 
∆5,6 position. The hope was that, in line with the literature precedent, the E-olefin would be 
retained during the rearrangement and the hydrazone would be completely reduced to form (-
)-mucosin (23) as one of the two diastereoisomers in the final crude diastereomeric mixture 
of 152. On analysis of the crude spectra and on comparison with the literature spectra of (-)-
mucosin it was discovered that neither of the two diastereoisomers formed gave the matching 
Scheme 3.25 Chain elongation via the Horner-Wadsworth-Emmons reaction to form 151. 
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stereochemical structure, especially with regard to the 13C NMR. The other major 
complication with this reaction was the low yield of around 15%.  
3.3.4 Review and Improvement of the Michael Addition Strategy 
The next alternative was to reinvestigate the Michael addition again, but this time using the 
opposite enantiomer of (R)-tert-butanesulfinamide (145). The employment of the (S)-tert-
butanesulfinamide with the α,β-unsaturated aldehyde 143 gave the corresponding (S)-
aldimine in good yields. The ensuing conjugate addition with Cu(I)CN and nBuLi gave a 
large excess of the minor diastereoisomer formed when using the (R)-aldimine. Successive 
reactions towards the final product of diastereomeric mixture 152 also gave a mixture of the 
same diastereoisomers as previously isolated but in the reverse quantities. This adverse 
development meant that a new pathway had to be sought.  
 
Reviewing the previous strategy it was agreed to continue with attaching the butyl substituent 
on an α,β-unsaturated precursor but via a contrasting modified intermediate. A paper 
published in 2014 by Jolit et al.,118 displays an alternative to the conjugate addition approach. 
Employing vinylic triflate 154 with an ester moiety, formed from β-keto ester 153, undergoes 
a copper mediated cross-coupling with an alkylated lithium reagent (here MeLi), to form an 
α,β-unsaturated ester 155 in an overall yield of 82%, as shown in Scheme 3.27.118 This 
attachment of the desired alkyl chain substituent occurs without formation of any unwanted 
diastereoisomers as seen with the Michael addition in Scheme 3.23. The other benefit of 
forming this electron poor olefin is that it can now be selectively reduced from the least 
hindered face using well-known literature protocols. Once reduced this resulting saturated 
ester could then be equilibrated to one isomer using NaOMe, if necessary, which should yield 
one thermodynamically stable diastereoisomer in an anti-configuration. This will be 







Based on this concept the β-keto ester 68 was reacted directly with NaH and Tf2O to form the 
vinylic triflate 156. This triflate could then be subjected to the copper mediated cross-
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coupling with Cu(I)CN and nBuLi to form the desired α,β-unsaturated ester 157 with the C4 







Conversion to the triflate 156 from 68 proved successful with facile purification and in a 
good yield of 83%. The following cross-coupling reaction with Cu(I)CN and nBuLi also 
proved fruitful and in a high yield 88%. This allowed us to progress rapidly to the next stage, 
which was the selective reduction of the olefin adjacent to the ester on 157.  
3.3.5 Selective Reduction of the Electron-Poor Olefin 
This selective reduction could have been undertaken in many ways due to the olefins 
electron-poor nature. One way is the use of (triphenylphosphine)copper hydride hexamer or 
Stryker’s reagent, which has the propensity to selectively reduce electron poor olefins from 
the least sterically hindered face to give the syn product as the more favored 
diastereoisomer.155 An example of this is shown in Scheme 3.29, where reduction occurs at 
the least sterically hindered face of 158 to yield the syn product 159 as the favored 
diastereoisomer over the anti product 160 (d.r. = 16:1). The other benefit of this reaction is 
the olefin reduction selectivity with regard to α,β-unsaturated carbonyl compounds with 
additional olefin moieties.155 The formation of 162 from 161 leaves the cyclobutene moiety 











Scheme 3.28 Triflation and Copper mediated cross-coupling of 68 to form the α,β-
unsaturated ester 156. 
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With respect to compound 157, the reduction of the electron-poor olefin, adjacent to the ester, 
by Stryker’s reagent would be expected to proceed via the least hindered face and give the 
syn product 163 as the major isomer as well as leaving the cyclohexene moiety intact. The 
advantage of this reaction also meant that we could equilibrate the syn product 163 to the 
thermodynamically more favored anti isomer 164 via NaOMe. This methodology is shown in 
Scheme 3.30. This would then give the desired correct stereochemistry with regards to the 
side-chains, as that of (-)-mucosin. The decision was then taken to attempt this reaction using 
ester 157. Unfortunately, the Stryker method failed to yield the desired product and only left 







Another reduction protocol,156 employing magnesium turnings and MeOH as a solvent, 
selectively reduces α,β-unsaturated carbonyls keeping other olefin moieties intact. This 
method has also been used to reduce various other conjugated olefins such as α,β-unsaturated 
nitriles, amides and lactones. Analyzing the stereoselectivity of this reduction using various 
unsaturated analogues has led to an interesting development, especially when compared to 
the equivalent catalytic hydrogenation reduction. Walkup et al.,157 attempted the olefin 
reduction on polyoxygenated systems using both Mg/MeOH and catalytic hydrogenation. An 
example of this can be seen in Scheme 3.31 with an α,β-unsaturated lactone 165. Using the 
Mg/MeOH protocol gave moderate stereoselectivity towards the syn diastereoisomer 166 in a 
ratio of 87:13 compared to the anti diastereoisomer 167.157 Conversely, the catalytic 
hydrogenation protocol gave a mixture of syn and anti diastereoisomers in a 57:43 ratio.158 
This increased stereoselectivity during the Mg/MeOH reduction is most likely due to the 
formal delivery of hydrogen to the less hindered face of a cyclic complex between the 






Scheme 3.30 Attempted reduction of 157 by Stryker’s reagent to form the syn saturated ester 163 































Another Mg/MeOH reduction carried out on highly strained lactone systems (168 and 171) 
by Bhattacharya and co-workers159 also gave stereoselective reduction from the least 
hindered face, as shown in Scheme 3.32, with only minor side-products 170 or single isomers 
172. An analogous stereoselective reduction via Mg/MeOH, as demonstrated by Zarecki and 
Wicha,160 selectively reduces an α,β-unsaturated ester. Their attempts to reduce the 
pregnadienoic ester 173 to 174 proved successful with no unwanted side-products and in 
quantitative yields (99%), as shown in Scheme 3.32.160 The reduction also leaves the 
cyclohexene moiety, on the B-ring, intact, which has an analogous cyclohexene moiety to the 
















Scheme 3.31 Stereoselective Mg/MeOH reduction of an α,β-unsaturated lactone 165 
favoring the least hindered face. 
Scheme 3.32 Stereoselective Mg/MeOH reduction of various α,β-unsaturated carbonyls 
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The protocol was attempted on the ester 157 (Scheme 3.33) and gave a mixture of two 
diastereoisomeric methyl esters, in a 91% yield, with complete consumption of the starting 
material. This was then equilibrated, as postulated in Scheme 3.30, with NaOMe, under 
reflux, to yield only one diastereoisomer of saturated methyl ester 164 in an excellent yield 
(93%). This equilibrated diastereoisomer was presupposed to be the thermodynamically 







3.3.6 Elaboration of Equilibrated Ester 164 to (-)-mucosin  
The next issue to contemplate was the elongation of the equilibrated ester 164 to the C7 side-
chain. Retrospectively, using the Horner-Wadsworth-Emmons protocol with the 
corresponding aldehyde of 164 and phosphonate intermediate 66 was not ideal due to 
equilibration issues during reductive conversion as shown previously with the aldimine 147. 
Another strategy, employing the corresponding alcohol of 164, could have been the simple 
homologation to an aldehyde via a mesylation, cyanation and a modified reduction protocol 
(replacing Et2O for nhexane and reacting at -78 °C rather than 0 °C), as performed by 
Filippova et al.129 This would allow the removal of the equilibration issues involving the α-
proton of the ester 164. Proceeding from this, a simple Wittig reaction, employing the 
Schlosser modification with a premade phosphonium halide, could have been adopted to 
yield the necessary E-olefin in the correct position (∆5,6). The initial conversion to the 
homologated aldehyde 176, via mesylate 175, was attempted as shown in Scheme 3.34. 







Scheme 3.33 Successful stereoselective Mg/MeOH reduction and subsequent NaOMe 
equilibration of 157 to form the anti-configured saturated ester 164. 
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3.3.7 Attempted Synthesis of the E-Olefin via a Schlosser-Wittig Reaction 
The production of this aldehyde 176 meant that elongation to a C7 side-chain containing an 
E-olefin could now take place. Many methods were considered, such as Pd(0) catalysed 
cross-coupling reactions and the Schlosser-Wittig reaction. Primarily, the shorter route was 
the use of the Schlosser-Wittig reaction. This reaction is shown to be E-selective with respect 
to olefin formation, which is contradictory to the Z-selective Wittig reaction. This Schlosser-
Wittig reaction could be performed directly on the aldehyde with a preformed C5 
phosphonium ylide and yield the elongated C7 side-chain in one step. Precedence for this 
reaction dates back to 1967,161,162 but employment of the protocol is not as common.  
 
The mechanism of the Schlosser-Wittig reaction differs from the typical Wittig reaction due 
to the use of halide salts such as LiBr. This suppresses the dissociation of the α-lithiated 
betaine ylide to an α-metal-free betaine ylide, which occurs readily in the normal Wittig 
reaction.163 The mechanism for the Schlosser-Wittig, using aldehyde 176 and a preformed C5 


















Initial attempts at the Schlosser-Wittig reaction using a protocol by Pettit et al.,164 with 
aldehyde 176 and the preformed C5 phosphonium iodide 177 gave good yields of around 
Scheme 3.35 Mechanism of the Schlosser-Wittig reaction, employing aldehyde 176 and the C5 
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70% of the assumed E-olefinic structure 178 as only one geometric isomer was formed.164 
This intermediate was then subjected to subsequent deprotection,165 oxidation166 and 






On further analysis of this final compound 179, by 1H and 13C NMR, with the literature 
natural product, it was observed that certain peaks in the 1H and 13C NMR had subtle 
differences. This was especially noticeable in the 13C NMR with respect to the bridgehead 
carbons at C-8, C-9 and C-16. The next stage was to try and decipher which olefin was 
present on the C7 side-chain. A Wittig reaction could be carried out on aldehyde 176 and the 
results could be directly compared with those previously obtained from the Schlosser-Wittig 
reaction on 176. This was attempted, as shown in Scheme 3.37, and gave the Z-olefinic 
structure 180 in 63% yield.168 On comparison with the previous olefin NMR data of 178, they 







One foreseeable problem with the literature method by Pettit et al.,164 was the lack of LiBr 
present during the reaction. Another method, by Wang et al.,163 incorporating LiBr, was 
attempted and yielded differing results. This was only attempted on the commercially 
available valeraldehyde (181) and 177 as shown in Scheme 3.38. The reaction itself was very 
temperamental and the results gave the isomeric mixture 182, the majority of which was the 
unwanted Z-olefin in a ratio of 80:20 (Z/E). This methodology was eventually disregarded 




Scheme 3.36 Elaboration of 177 to the postulated (-)-mucosin methyl ester 179. 
Scheme 3.37 Wittig reaction of aldehyde 176 to form the Z-olefinic compound 180. 
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3.3.8 Attempted Synthesis of the E-Olefin via an Iodolactonization 
The decision was then taken to choose another method to generate the E-olefin. Another 
reaction protocol was formulated by utilizing the iodolactone formation procedure with 
naturally occurring fatty acids like EPA (9) to form iodolactone 183 as shown by Filippova et 





The concept was to apply this iodolactonization reaction with the Z-olefin acid analogue of 
179 and promote the ring-opening of the iodolactone via the use of Zn and AcOH. The 
ambition was to only form the E-olefin, as this is always the thermodynamically favored of 
the two geometric isomers. A number of protocols were found that employ the use of 3-
methyl-γ-butyrolactones 184, which after initial conversion to an iodolactone 185, proceed 
via a ring-opening reaction with Zn and AcOH to furnish the E-olefin and the original γ-






The perception was that the reformation of the olefin from the iodolactonization of the Z-
olefin acid analogue of 179 via the use of Zn and AcOH would give the more 
thermodynamically favored E-olefin, which could then be developed to the (-)-mucosin 
methyl ester. The iodolactonization procedure and subsequent iodolactone ring-opening, as 
shown in Schemes 3.39 and 3.40 respectively, was initially performed on commercially 






Scheme 3.39 Iodolactonization reaction by the Filippova and Flock protocols employing EPA (9). 
Scheme 3.40 Iodolactonization and subsequent ring-opening of the iodolactone 185 to furnish 
the initial E-olefinic lactone present on 184. 
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After the initial iodolactonization/ring-opening a mixture 187 was formed and the ratio of E/Z 
isomers was 70:30. This seemed very promising, so the procedure was repeated on the initial 
product 187 twice more. The concept was to reduce the amount of Z-olefin each time to give 
a final ratio, which is comparable to 99:1 (E/Z). Unfortunately, this was not the case, as the 
ratio of E/Z remained the same after repeating the procedure on 187. This reaction was 
attempted at many different temperatures (-78 – 50 °C) and co-solvents (EtOH and THF) but 
no noticeable improvement was seen in the E/Z ratio. After these results it was decided to halt 
with this protocol and look towards cross-coupling approaches. 
 
3.3.9 Synthesis of the E-Olefin via a One-Pot Negishi Cross-Coupling Reaction 
Cross-coupling reactions to form a carbon-carbon bond employing a transition metal catalyst 
is a well-established method. Many cross-coupling reactions have been utilised to selectively 
synthesize E-olefins. The majority of cross-coupling protocols employ Pd(0) or Ni(0) 
catalysts to couple with an organo-halide, which then in turn reacts with an organometallic 
compound to form a carbon-carbon bond. A general catalytic cycle for a cross-coupling 













The reaction mechanism begins with an oxidative addition of an organic halide (R2X) to the 
catalyst (Pd(0)), to form an intermediate 188. Intermediate 188 then undergoes 
transmetallation with R1-M to place both coupling partners on the same metal center to form 
intermediate 189 with elimination of the functional groups M-X.171 The final step is the 
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reductive elimination of the two coupling fragments to regenerate the catalyst (Pd(0)) and the 
new cross-coupled compound R1-R2.171 
 
Synthesizing E-olefins from using various cross-coupling protocols is well known and has 
been previously carried out on numerous occasions to help synthesize natural products. 
Cross-coupling protocols such as the Negishi coupling,172,173 Stille coupling,174 Suzuki 
coupling175 and Kumada coupling176 reactions all have the propensity to produce E-olefins 
with an organohalide and varying organometallic intermediates. The Negishi coupling 
employs an organozinc intermediate, the Stille coupling employs an organotin intermediate, 
and the Suzuki coupling employs an organoboron intermediate with base, whilst the Kumada 
coupling employs an organomagnesium intermediate. All three have a general outline in 
Scheme 3.43 below. Choosing which one to incorporate into our strategy would be crucial in 













To construct the E-olefin, the corresponding halide, on the (-)-mucosin intermediate, would 
have to be synthesised first. The most sensible method would be to make an E-vinyl iodide 
from 176 and then cross-couple it to the necessary C4 organometallic intermediate via a Pd(0) 
of Ni(0) catalyst to form a C7 chain with the E-olefin at ∆5,6. Making a vinyl iodide from an 
aldehyde can occur in three steps. The first step would be a homologation to an alkyne 190 
using the Ohira-Bestmann protocol.177 The second step is the reduction of the alkyne via 
DIBAL-H to an E-specific alkenylaluminum species 191, which can then be converted to an 
E-vinyl iodide 192 with addition of iodine as the final step, as shown in Scheme 3.44.178 
 
Scheme 3.43 General outline for the Negishi, Stille, Suzuki and Kumada cross-coupling 
reactions. 
R1 X + R2 SnBu3
Pd(0) R1 R2 + X SnBu3
R1, R2 = sp2 (allyl, alkenyl, aryl); X = halide
STILLE
R1 X + R2 ZnX Pd(0) or Ni(0) R1 R2 + ZnX2
R1, R2 = sp2 (allyl, alkenyl, aryl); X = halide
NEGISHI
R1 X + R2 MgX Pd(0) or Ni(0) R1 R2 + MgX2KUMADA
R1 = sp2 (aryl, vinyl); R2 = sp2 (aryl, vinyl), sp3 (alkyl); X = halide
SUZUKI R1 X + R2 BY2 R1 R2 +
NaOtBu
NaX + B(Y)2(OtBu)2NaPd(0) or Ni(0)
R1 = sp2 (aryl, vinyl), sp3 (alkyl); R2 = sp2 (aryl, vinyl); X = halide













The simplest method of forming the necessary E-olefin from 192 and an organometallic 
species would be to use the commercially available 4-ethoxy-4-oxobutylzinc bromide (193) 
with a Pd(0) or Ni(0) catalyst in a Negishi-type cross-coupling. This will be able to furnish 
the necessary E-olefin in a stereospecific manner at ∆5,6 and also result in the formation of an 
ethyl ester 194, which can easily be converted to the corresponding acid and methyl ester of 













Alternatives, such as the employment of the corresponding Stille, Suzuki and Kumada cross-
coupling reagents instead of the Negishi-type reagent, could also lead to the correct E-olefin. 
However, the use of the Stille protocol with a suitable organotin reagent can be quite toxic, 
involves quite a high carbon economy, and the reagent itself would have to be synthesized, as 
Scheme 3.44 Postulated synthesis of the E-vinyl iodide 192 from aldehyde 176. 
Scheme 3.45 Postulated synthesis towards mucosin methyl ester 179 via a Pd(0) catalysed 
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it is not commercially available. The same could be said with regards to the Suzuki reaction, 
as the cross-coupling reagent would have to be synthesised beforehand. The use of the 
Kumada magnesium reagents with an ethyl ester terminus is more likely to lead to unwanted 
side products as well as the desired ester and are therefore incompatible with these reagents. 
The ease of availability of the commercially available 4-ethoxy-4-oxobutylzinc bromide 
(193) and the stability of the ethyl ester during the reaction meant that producing the E-
olefinic ethyl ester 194 via the Negishi reagent was the preferred method. 
 
The homologation to the alkyne 190 with the Ohira-Bestmann reagent and aldehyde 176 
proceeded successfully and in a high yield of 86%. The next stage was to reduce the resulting 
alkyne 190 with the use of DIBAL-H and then convert that directly in one-pot to the E-vinyl 
iodide 192. After initial attempts with a model compound of 1-octyne and 193 the E-vinyl 
iodide of 1-octyne was afforded in good yields (72%). However, by using this method on the 
alkyne 190 the reaction did not go to completion and afforded a mixture of starting material 
190 (50%), terminal olefin 195 (30%) and only a small amount of the necessary iodide 192 














It was then decided to use zirconocene dichloride (Cp2ZrCl2) with DIBAL-H to increase the 
reactivity and help in the formation of the iodide.179 This was then tested again on 1-octyne 
(196) and the formation again proceeded in high yields and E-selectivity. Subsequently, an 
attempt was made to use two different catalysts; a Pd(0) species and a Ni(0) species to cross-
couple the E-vinyl iodide 197 of 1-octyne (196) and 4-ethoxy-4-oxobutylzinc bromide (193). 
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The hope was to selectively furnish the desired E-olefin 198 of the model E-vinyl-iodide 197 
and the zinc-bromide reagent 193. Both catalytic species were tested separately and both 
gave the desired E-olefin 198 in quantitative yields with no measurable amount of the Z-








The next aim was to try all three steps (reduction, iodination and catalysed cross-coupling) in  
a one-pot synthesis, as shown in Scheme 3.48. This was to try and increase the yield and 
would also mean not having to isolate the unstable E-vinyl iodide intermediate 192. Another 
added benefit of this is the reduction in steps in the overall synthesis towards (-)-mucosin. 
This was again attempted on 1-octyne (196) and gave the same result as previously stated in 
Scheme 3.47. Employment of this protocol was then used with the alkyne 190, Cp2ZrCl2, 
DIBAL-H, iodine, (Ph3P)4Pd and 193. The reaction gave the E-ethyl ester of (-)-mucosin 194 













Scheme 3.47 Attempted Negishi cross-coupling with 1-octyne (196) and 193 via Cp2ZrCl2. 
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3.3.10 Conversion of Ethyl Ester 194 to (-)-mucosin 
After this success, the ethyl ester 194 was converted in quantitative yields (97%) to the 
corresponding acid 23 with a lithium hydroxide monohydrate protocol.180 The acid 23 was 
then readily converted to the methyl ester of (-)-mucosin 179, which was the isolated natural 
product of (-)-mucosin (23), in nearly quantitative yields (92%), via TMS diazomethane.167 
The total yield for the synthesis, over seventeen steps, of the methyl ester of (-)-mucosin 179, 






The 1H and 13C NMR spectral data of this methyl ester of (-)-mucosin 179 was then directly 
compared to the literature spectra of the methyl ester of the natural product (-)-mucosin (23) 
by Casapullo and the methyl ester of enantiomer (+)-mucosin (ent-23) synthesised by 
Whitby. Again it was discovered, that on comparison of the spectra compound 179 with the 
literature spectra, there were noticeable peak shift differences, especially in the 13C NMR. A 
NOESY NMR was also carried out on the methyl ester 179 and directly compared with the 
tabulated Casapullo NOESY data, but no conclusive stereochemical interactions could be 
deduced from the data. 
3.3.11 Conversion of the Intermediate Alcohol for X-Ray Crystal Analysis 
Based on this analysis it was concluded that we have made another diastereoisomer of the 
methyl ester of (-)-mucosin (23), which is different than that found in literature.58,59 Due to 
the complexity of the spectra themselves it was decided to synthesize a crystal from a late 
stage intermediate to determine the relative stereochemistry with X-ray crystallography. The 
intermediate alcohol 199 was chosen and reacted with 3,5-dinitrobenzoyl chloride (200) to 
form a dinitro-ester 201, which was re-crystallized with MeOH and pentane, as shown in 






Scheme 3.49 Conversion of ethyl ester 194 to the corresponding acid 23 and methyl ester 179. 
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These crystals were then taken for X-ray analysis and gave the structure for the relative 
stereochemistry of 201 in Figure 3.4 below. The alcohol 199 was chosen to be the 
intermediate for crystal analysis for two reasons. Firstly, with respect to the chiral centers at 
C-8, C-9, C-14 and C-16 on 199 are all fixed and cannot be changed with any subsequent 
reaction steps to form the E-olefin. Secondly, the structure of 199 is very similar, apart from 
the butyl moiety at C-16, to the β-keto ester 68, which is crystalline. This would mean that 
with the correct dinitro auxiliary attached to the alcohol 199 there would be a high probability 
to form a crystalline structure. As explained previously, the elucidation of the E-olefin 
produced from the alcohol 199 had been completed so it was not necessary to incorporate this 













As seen in Figure 3.4, the crystal structure of dinitro-ester 201 has the correct relative 
stereochemistry that was aimed for from the outset with this synthesis for (-)-mucosin. 
However, the 1H and 13C NMR spectral data does not match favorably with the published 
data of Casapullo58 and Whitby59. Therefore, the assumption is that the published data is 
incorrect with respect to the assigned stereochemistry. This will be discussed in more detail 
in the next chapter.  
 
 
Figure 3.4 Crystal structure of dinitro-ester 201. 
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4. Structural Analysis 
	
The relative stereochemistry of the current methyl ester stereoisomer 179 of (-)-mucosin has 
been elucidated to be the identical structure to the one given in the Casapullo58 natural 
product paper and the mucosin enantiomer given by Whitby59. This structure is shown with 














However, on analysis of the 1H and 13C NMR data for the (-)-mucosin methyl ester 
stereoisomer 179 it was noticed that it was very different to the NMR data produced by 
Casapullo and Whitby. The comparisons between all three sets of NMR data are given in two 
tables below. The notable differences between the current stereoisomer and published methyl 






Figure 4.1 Crystal structure of dinitro-ester 201. 
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1H NMR (CDCl3) – mucosin methyl ester 
Chem. Commun.59 –  
(400 MHz)  
Natural Product58 –  
(500 MHz) 
Compound 179 – 
(400 MHz) 
5.73-5.60 (m, 2H) 5.67 (m, 2H) 5.70-5.64 (m, 2H) 
5.46 (m, 1H) 5.45 (dt, 1H) 5.46-5.33 (m, 2H) 
5.38 (m, 1H) 5.39 (dt, 1H) 3.67 (s, 3H) 
3.67 (t, 3H) 3.66 (s, 3H) 2.31 (t, 2H) 
2.31 (t, 2H) 2.31 (t, 2H) 2.22-2.15 (m, 1H) 
2.23 (m, 1H) 2.25 (m, 1H) 2.12-2.01 (m, 6H) 
2.17 (m, 1H) 2.19 (m, 1H) 1.89-1.75 (m, 3H) 
2.15-2.08 (m, 2H) 2.12 (m, 2H) 1.73-1.65 (m, 3H) 
2.03 (q, 2H) 2.02 (q, 2H) 1.54-1.44 (m, 2H) 
1.80-1.65 (m, 4H) 1.72 (m, 1H) 1.34-1.16 (m, 6H) 
1.64-1.48 (m, 3H) 1.70 (m, 1H) 1.12-1.04 (m, 1H) 
1.46-1.33 (m, 2H) 1.69 (m, 2H) 0.88 (t, 3H) 
1.33-1.23 (m, 3H) 1.59 (m, 1H)  
1.19-1.13 (m, 2H) 1.55 (m, 1H)  
1.13-1.08 (m, 2H) 1.50 (m, 1H)  
0.89 (t, 3H) 1.40 (m, 2H)  
 1.33 (m, 1H)  
 1.28 (m, 2H)  
 1.15 (m, 2H)  
 1.12 (m, 1H)  
 1.11 (m, 1H)  
 0.88 (t, 3H)  


























Table 4.2 13C NMR environments of the three methyl ester stereoisomers of (-)-mucosin (23).  
 
 
Contained in the two tables above are the 1H and 13C NMR data for the elucidated (-)-
mucosin methyl esters; firstly the methyl ester enantiomer of (+)-mucosin (ent-23) 
synthesised by Whitby et al.,59 secondly the methyl ester of the (-)-mucosin natural product 
(23) isolated from Reniera mucosa by Casapullo et al.,58 and the methyl ester stereoisomer of 
(-)-mucosin 179 previously discussed in this thesis.  
 
13C NMR (CDCl3) – mucosin methyl ester 
Chem. Commun.59 –  
(100 MHz) 
Natural Product58 – 
(125 MHz) 
Compound 179 –  
(100MHz) 
174.2 174.2 174.2 
130.3 130.0 130.4 
129.8 129.8 129.9 
127.3 127.0 126.3 
127.1 127.0 126.1 
52.2 52.1 51.4 
51.4 51.4 51.0 
47.2 47.1 44.0 
42.3 42.1 40.3 
40.1 39.9 38.1 
37.0 36.7 37.7 
36.74 36.5 37.1 
36.68 36.4 34.9 
33.4 33.2 33.4 
32.4 32.0 31.9 
31.9 31.7 31.0 
31.6 31.5 27.8 
30.7 30.7 27.7 
24.7 24.5 24.8 
22.9 22.6 22.9 
14.1 13.8 14.1 
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At first glance, comparing the Whitby and Casapullo 1H, 13C NMR spectra and optical 
rotation values show that they are most likely enantiomers. This is especially noticeable when 
comparing the 13C NMR data. On comparison with the current methyl ester stereoisomer of (-
)-mucosin 179 and the Whitby and Casapullo methyl ester enantiomers both the 1H and 13C 
NMR spectra have glaring differences, which have been highlighted in both tables. In the 1H 
NMR spectra, the cyclohexene and E-olefin proton shifts at 5.70-5.64 ppm and 5.46-5.33 
ppm respectively, the methoxy proton shift at 3.67 ppm, the α-methylene shift adjacent to the 
ester at 2.31 ppm and the methyl proton shift at 0.88 ppm all match very closely. However, 
the alkyl proton shifts between 2.22-1.04 ppm differ, especially with respect to multiplicity 
and integration values. This is mainly due to the complex alkyl region of 179, as shown in 
Figure 4.2. The Casapullo methyl ester of the natural product 23 gives a much more detailed 
alkyl region with individual proton environments. The Whitby methyl ester of enantiomer 
ent-23, although identical in relative stereochemistry to the Casapullo structure, gives a much 
more generalized alkyl region, but again this is contrasting with the current methyl ester 
stereoisomer of (-)-mucosin 179.  
 
	
Figure 4.2 Alkyl region of the 1H NMR of diastereoisomer 179. 
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These differences are also portrayed in the 13C NMR data shown in the table above. The 
majority of the carbon environments differ dramatically apart from the E-olefin, carbonyl, 
methoxy, methyl and a few sp2 hybridized moieties. The other dissimilar carbon peaks relate 
to alkyl sp3 or sp2 hybridized regions only. This is almost a parallel of the differences with 
the 1H NMR data. One noticeable difference that is not seen in the 1H NMR data is the shift 
values for the cyclohexene moiety as they match up on comparison with each other. For the 
current methyl ester stereoisomer 179 they are given as 126.3 ppm and 126.1 ppm. With the 
Whitby methyl ester enantiomer of ent-23 they are given as 127.3 ppm and 127.1 ppm and 
with the Casapullo methyl ester of natural product 23 they are given at exactly 127.0 ppm for 
both carbons. This implies that the structural environment around these carbons, when 
comparing 179 with the Whitby and Casapullo methyl esters, is considerably different.  
 
A NOESY NMR, as shown in Figure 4.2, was also performed on the (-)-mucosin methyl 
ester stereoisomer 179. The results from the analysis showed extensive overlaps in the 
aliphatic region (2.31-1.04 ppm), which meant that it was impossible to disseminate every 
separate correlation clearly. This is at odds with the Casapullo paper for the methyl ester of 
23. He is clearly able to distinguish correlations at all the aliphatic regions on the 
cyclopentane ring apart from the H-8 and H-9 environments, which seem to overlap on the 
natural product. Close analysis of the NOESY data and the correlations elucidated by 
Casapullo leads to some discrepancies with the structure he has given, especially when cis-
fused bridgehead environments are analysed. The H-9 environment correlates to both the H-
14 and H-16 environments, which corresponds to the structure given by Casapullo. However, 
H-16 gives no correlation to the H-14 environment, which is what one would expect for a cis-
fused system. The same can be said with respect to the H-14 environment, as there is no 
correlation with the H-16 environment. Futhermore, the overlap of the NOESY environments 
with the H-8 and H-9 environments leads to a disparity when assigning the stereochemical 
configuration of the methyl ester of (-)-mucosin 23. This could mean that both correlations 
seen between the H-9 to H-14 environments and H-14 to H-9 environments could both 
actually be from the H-8 environment instead of the H-9. Based on this analysis of the 
NOESY spectrum and the inconsistencies around the cis-fused bridgehead it seems that a 
more likely candidate for the structure would be a trans-fused bridgehead system. A question 
remains as to whether the NOESY spectrum, taken by Casapullo of the methyl ester of 23, 
gives a clear indication of the environments given in the structure he is portraying.  
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Figure 4.2 NOESY NMR of the aliphatic region (2.3-0.7ppm) of 179. 
This leads to the conclusion that although the general structure of the methyl ester of (-)-
mucosin 23 is correct but the relative and absolute configuration given by Casapullo is not 
and must be investigated. This error with the absolute configuration is not uncommon as seen 
with other isolated natural products and their final elucidation.181 This can be seen notably 
when comparing the current stereoisomers’ (179) side-chain bridgehead 13C NMR shift 
values at 51.0 ppm and 44.0 ppm in Table 4.2. A note must also be made with respect to the 
optical rotation values of 23, ent-23 and 179. It must be concluded that the Whitby 
enantiomer ent-23 and the Casapullo natural product 23 must be enantiomers due to their 
specific optical rotation values of [α]26D = +38.2° (c = 0.8, nhexane)  and [α]26D = -35.5° (c = 
0.8, nhexane), respectively, and their complementary 1H and 13C NMR shifts. The current 
stereoisomer 179 has a specific optical rotation value, which is markedly different, at [α]26D = 
-9.8° (c = 0.8, nhexane) as are the 1H and 13C NMR shifts for the chiral centers.  
 
Using the elucidated crystal structure of the dinitro compound 201 it must be deduced that 
Casapullo has not assigned the correct stereocenters in his natural product elucidation of the 
methyl ester of 23, even with NOESY analysis. As a comparison, the NOESY and Mosher 
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analysis of (-)-dictyosphaerin (42), by Rochfort and co-workers,75 also gave inconclusive 
absolute or relative stereochemistry at the bicyclic fused-bridgeheads and alcohol moiety for 
42. This means, that due to the structural similarity of the ring system and side-chain lengths 
of both 23 and 42 it is not inconceivable that Casapullo has made a mistake with assigning 
the stereocenters of 23. 
 
Whitby, on closer analysis of his publication, has used an intermediate for crystallographic 
analysis that is not directly related to the intermediates used in his final synthetic pathway 
towards his (+)-mucosin (ent-23) enantiomer. On closer inspection of the synthesis carried 
out by Whitby et al., it seems that he ends up with a mixture of diastereoisomers, which are 
then separated. It is possible that he might have proceeded with the wrong diastereoisomer, 
which might also indicate that the appendage points have been erroneously assigned. This is 
not so difficult to envision as the NOESY data obtained for the current mucosin methyl ester 
stereoisomer 179 is almost impossible to decipher with respect to the bridgehead 
stereochemistry, as shown in Figure 4.2. Based on this argument, it appears that the 
elucidated structure of 179 discussed here and the elucidated structures of the methyl esters 
of 23 and ent-23 discussed in the literature are not the correct naturally occurring C20 fatty 
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5. Results & Discussion of the Synthesis of (+)-crucigasterin 277 
 
5.1 Literature Synthesis of Aldehyde 83 
For the total synthesis of (+)-crucigasterin 277 there were two routes (A and B) postulated in 
the retrosynthesis discussion in Chapter 2. Both Route A and Route B involved a common 















To synthesize this ω-3 allylic aldehyde 83, with a E,Z,Z,Z-olefinic configuration, it was 
necessary to use commercially available EPA-EE (85) as the starting material. In a five-step 
synthesis, starting with 85, 83 was made by a hydrolysis and iodolactonization to form 
iodolactone 183, hydrolysis of 183 with LiOH.H2O to form diol acid 202 and periodate 
oxidation of diol acid 202 to form aldehyde 84. The final step, which isomerized the Z-olefin 
to an E-olefin, involves the use of DBU. The ω-3 allylic aldehyde, 83, was given in a 73% 
total yield over five steps, as shown above in Scheme 5.1. 
 
5.2 Synthesis of Bromide 82 and N-Boc-D-alaninal for a Grignard Reaction 
The next stage was to create an intermediate from this ω-3 allylic aldehyde 83 that would 
yield a carbanion species that could directly attack the aldehyde on the N-Boc-protected 
alaninal (81). Using the Route A retrosynthetic strategy, a Grignard procedure119 with a C15 
Scheme 5.1 Five-step synthesis of the allylic aldehyde 83 from EPA-EE (85). 
O
OEt
2) KI, KHCO3, I2
THF:H2O:EtOH,





5% LiOH.H2O MeOH:H2O, (19:1),
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allylic bromide intermediate 82 was postulated with N-Boc-protected alaninal (81). 
Employing the C15 allylic aldehyde 83, a reduction with NaBH4 and bromination with Br2 
and Ph3P under Appel conditions gave the bromide 82 as shown in Scheme 5.2, which could 





The next step was forming N-Boc-D-alaninal (81), which could be synthesised in a number of 
methods from the commercially available N-Boc-D-alanine methyl ester (203) or N-Boc-D-
alaninol (204). Synthesis of 81 was first attempted by reducing the commercially available N-
Boc-D-alanine methyl ester (203) with DIBAL-H at -78 °C in toluene/nhexane following the 
literature procedure by Rinehart et al.100 After multiple attempts at replicating the yield and 
optical purity reported, we obtained crystals of 81 in moderate optical purity and poor yield 
(29%). The optical purity was then improved (lit.100 [α]26D = +40.7°, exp. [α]26D = +41.0°) by 
substituting toluene for CH2Cl2, as shown in Scheme 5.3, but again the yield remained 





Other reducing protocols were also attempted to improve the yield but without success. It was 
then decided to attempt oxidation protocols on the commercially available N-Boc-D-alaninol 
(204). Several oxidation procedures, including TEMPO121-123 and DMP, were tried but with 
no success. Following on from this, another protocol by Hamada and co-workers,124 treats 
204 with a Parikh-Doering oxidation using DMSO, a Pyr-SO3 complex and Et3N to yield 81, 





This oxidation proceeded without racemization, good yields (63%) and excellent optical 
purity (lit.100 [α]26D = +40.7°, exp. [α]26D = +39.0°). This method was then chosen to 
Scheme 5.2 Synthesis of allylic bromide 82 from 83. 
Scheme 5.3 Synthesis of N-Boc-D-alaninal (81) from N-Boc-D-alanine methyl ester (203). 
Scheme 5.4 Synthesis of N-Boc-D-alaninal (81) from N-Boc-D-alaninol (204). 
O 1) NaBH4, MeOH,
0 oC, 30 min.
2) Br2, Ph3P,
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synthesize N-Boc-D-alaninal for use with the allylic bromide 82 and the Grignard reaction 







Unfortunately, on analysis of results from the Grignard reaction with the N-Boc-protected 
alaninal 81 and the bromide 82 the major products were the Wurtz coupling products in a 
70% yield and not diastereomeric mixture 80. Another organometallic coupling reaction 
using either Zn or Sn is the Barbier reaction,182 which is a reaction with an alkyl halide and a 
carbonyl group in the presence of the aforementioned metals. This was attempted on the 
bromide 82 and N-Boc-protected alaninal 81 but to no avail. The next attempt was to use a 
Rieke metals procedure183 with highly activated magnesium. This is reported to reduce the 
Wurtz coupling effect. However, this did not give any desired results as the Wurtz product 
still prevailed.  
 
5.3 Conversion of Bromide 82 to Phenyl Sulfone 205 
The next concept was to convert the bromide 82 to a phenyl sulfone 205, which could then 
undergo a similar nucleophilic attack on the N-Boc-protected alaninal (81). This would then 
form four diastereoisomers but a subsequent desulfonation would leave only two 
diastereoisomers, which could then possibly be separated by silica column chromatography. 
A literature procedure by Trost and Curran184 shows the ability to synthesize a phenylsulfone 
from a bromide in two steps using thiophenol and oxone. This procedure was attempted on 
the bromide 82 firstly, with thiophenol in the presence of LiOH.H2O and secondly oxidizing 
the subsequent phenylsulfide with oxone to form the phenylsulfone 205 in 78% yield as 





Scheme 5.5 Attempted Grignard reaction between 82 and 81 to form diastereomeric amino 
alcohols mixture 80. 
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Another second shorter literature method, to make the sulfone 205 in two steps rather than 
three steps compared to the first method, is by Nakagawa and co-workers.185 Taking the 
alcohol precursor 206 of the bromide 82 and reacting it with diphenyl disulfide to form the 
sulfide 207 directly and again use oxone to make the desired sulfone 205. However, this 
protocol was discarded due to a low conversion of the alcohol and a mixture of final product 
and starting material. A third literature method by Corbel et al.,186 employed a mesylate 208, 
also synthesized from the alcohol 206, and reacted it with thiophenol together with KOH in 
MeOH to give quantitative yields of the corresponding sulfide 207. Subsequent oxidation 
with oxone leads to the desired sulfone 205 in a total yield of 83%. These protocols were 
both attempted on the alcohol 206, as shown in Scheme 5.7. The Corbel et al. protocol gave a 














A final method to make the sulfone in one step, by Guerrero et al.,187 directly from the 
bromide 82 involves the use of sodium phenyl sulfinate in DMF. This was successfully 







Scheme 5.7 Nakagawa and Corbel protocols to form phenyl sulfone 205 from alcohol 206. 
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5.4 Nucleophilic Addition Between N-Boc-D-alaninal and Phenyl Sulfone 205 
An initial nucleophilic addition reaction with a N,N’-diisopropylcarbodiimide (DIC) activated 
N-Boc-D-alanine precursor 209 and the deprotonated sulfone 205 via nBuLi was attempted as 
shown in Scheme 5.9.188 This was attempted to make the diastereomeric ketone 210, which 
could then be desulfonated and stereoselectively reduced at C-3 to make the necessary (S)-
isomer at C-3, which would yield (+)-crucigasterin 277 (57). However, this reaction proved 
ineffective. It was then envisaged that a similar reaction could occur between a corresponding 
Weinreb amide, or a thioacetal or protected cyanohydrin analogues of N-Boc-D-alanine. 
However, these three methods seemed problematic. The Weinreb amide could be susceptible 
to epimerisation of the keto-amine moiety and possible racemization of the N-Boc-amine 
once the reaction had taken place with the deprotonated sulfone. The thioacetal and 
cyanohydrin analogues would have to be synthesised from the aldehyde directly as they are 
not commercially available. This leaves the synthesis and employment of the aldehyde as the 










Subsequently, a reaction between the deprotonated sulfone and the optically active N-Boc-D-
alaninal (81) was initiated. This was again attempted by first deprotonating the phenyl 
sulfone 205 with nBuLi at -78 °C in THF to form the α-sulfonyl carbanion. The N-Boc-D-
alaninal (81) was then added to the reaction and after workup furnished the N-Boc-protected 
amino alcohol phenyl sulfone diastereomeric mixture 211 in 69% yield as a mixture of four 





Scheme 5.9 Attempted reaction between phenyl sulfone 205 and DIC-activated N-Boc-D-
alanine 209. 
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5.5 Desulfonation and Purification of Diastereoisomers 
The next stage was to remove the sulfone group from all four of the diastereoisomers in the 
mixture of 211 and separate the remaining two by column chromatography. The 
desulfonation, as shown in Scheme 5.11, was successfully accomplised by using a protocol, 
by Kotake and co-workers, consisting of LiBH4 and Pd(Ph3P)2Cl2.189,190 However, separation 
of the corresponding diastereoisomeric mixture 212 proved extremely difficult as both 
diastereoisomers always co-eluted by column chromatography. It was then decided to 
separate the four diastereoisomers in 211 before desulfonation and desulfonate each isomer 
separately. This also proved problematic as two of the diastereoisomers always co-eluted via 
column chromatography, which in turn reduced the yield dramatically. It is also noteworthy 
that the reactions of the sulfone are rather sensitive as elimination of the hydroxyl group to 
give the conjugated sulfone occurred when trying different temperatures and increasing 






Another option was to stop the oxidation of the sulfide 207 with oxone before full conversion 
to the sulfone 205 and obtain the sulfoxide analogue.184 The hope was that the change in 
polarity from sulfoxide to sulfone would make separation on the column more manageable. 
However, separation of the four diastereoisomers of the sulfoxide amino alcohol analogues 
was even more problematic to separate by column chromatography, so this methodology was 
abandoned.  
 
Following on from this, the sulfone methodology was then repeated to form 205 and this was 
subsequently reacted with N-Boc-D-alaninal (81) to form the same mixture of the four 
diastereoisomers 212. Column chromatography was carefully repeated on this diastereomeric 
mixture and two pure compounds were eluted from the column in a 23% and 45% yield, 
respectively. When the two pure isomers were separately desulfonated via the Kotake 
protocol one single amino alcohol was obtained in each case 212a and 212b, as shown in 
Scheme 5.12. Based on the NMR data for these diastereoisomers (212a and 212b) they only 
differed in configuration at C-3, but the absolute configuration of each one could not be 
Scheme 5.11 Desulfonation of diastereomeric mixture 211, via LiBH4 and Pd(Ph3P)2Cl2, to form 
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identified. This pointed towards both isomers being the 3R and 3S N-Boc-protected analogues 










5.6 Differentiation of Diastereoisomers 212a and 212b 
The next stage was to differentiate which diastereoisomer of 212a and 212b was the correct 
analogue to take forward to the final stage. In literature, cis- and trans-substituted isomers of 
1,3-oxazolidones exhibit significantly different values for the vicinal coupling constants of 
the protons at C-4 and C-5, with the coupling constant being smaller for the trans isomer191 
as would also be anticipated from the Karplus rule. Both diastereoisomers were then 
separately converted to their corresponding 1,3-oxazolidones 213a and 213b with 2,2-
dimethoxypropane in the presence of p-TsOH in a 74% yield respectively, as shown in 
Scheme 5.13. NMR analysis of both compounds was perturbed at room temperature by the 
presence of rotamers, which is a common phenomena for 1,3-oxazolidones.192 To remove this 
problem the NMR spectra were recorded at 60 °C, which was above the coalescence 
temperature. The vicinal coupling constants for the protons at C-4 and C-5 of the ring were 
5.0 Hz for isomer 213a and 6.3 Hz for isomer 213b. This result was certainly not conclusive, 
and the spectra were further analysed by NOESY experiments. They showed for isomer 213a 
a correlation of the methylene protons attached to C-4 and the methyl protons at C-5, while 
no correlation was observed for 213b. This result was further confirmed by ROESY 
experiments. This concluded that the correct diastereoisomer for the final conversion to (+)-





Scheme 5.12 The two diastereoisomers (212a and 212b) resulting from the column 


























5.7 Removal of the N-Boc-Protecting Group to Form (+)-crucigasterin 277 
The final stage of the synthesis was then to simply remove the N-Boc-protecting group on 
212a. Literature precedents to remove the N-Boc-group with TFA and HCl caused partial 
isomerization of the olefins.193 However, stirring 212a in 80% formic acid or 1% HF 
overnight gave the correct compound of (+)-crucigasterin 277 (57) in 82% yield, giving a 
total yield of 7%.194 The optical rotation of the diacetyl derivatives of the natural product and 
the synthesised analogue of (+)-crucigasterin 277 (57) were also in accordance with the 
literature (lit.100 [α]26D = +45.0°, exp. [α]26D = +41.0°). This confirmed the absolute 













Scheme 5.13 Structures of the 1,3-oxazolidones formed from the diastereoisomers 213a and 213b. 
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6. Future Work and Biosynthetic Speculations 
	
6.1 Remodeled Retrosynthesis of (-)-dictyosphaerin 
The retrosynthesis of the second target molecule, (-)-dictyosphaerin (42), can be remodeled 
based on the knowledge gained by the total synthesis of (-)-mucosin (23). A much shorter 
retrosynthesis, than the one explained previously in Chapter 2, can be formulated to give the 
cis-fused diastereoisomers of (-)-dictyosphaerin, with varying alcohol chiral centers. This is 


















Starting with the (S)-alcohol diastereoisomer of (-)-dictyosphaerin 72a it is possible to make 
a scission at ∆8,9 and form a Suzuki cross-coupling reaction, using the Littke and Fu 
protocol.195 This can be undertaken with a vinylic triflate 214 and a preformed pinacolborane 
interemediate 215 with an E-olefin and (S)-configured chiral center at C-6. This Suzuki 
cross-coupling between 214 and 215 allows for the full skeleton of (-)-dictyosphaerin 
diastereoisomer 72a to be formed. Subsequent selective deprotection of the TES group at C-1 
with Swern oxidation196 to the aldehyde, Pinnick oxidation of the aldehyde to the carboxylic 
acid and the subsequent deprotection of the TES group at C-6 with TBAF196 will yield the 
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(S)-alcohol of (-)-dictyosphaerin 72a with the cis-fused hydrogens on the 
bicyclo[4.3.0]nonene ring.  
 
Following on from the Suzuki cross-coupling, the vinylic triflate 214 will be dissected at 
∆17,18 to form an unsaturated bromo-triflate intermediate 216. This intermediate can undergo a 
selective Negishi cross-coupling, again using the Littke and Fu protocol195, with 
commercially available pentylzinc bromide 217 to form intermediate 214 with retention of 
the triflate. This gives an orthogonal reaction pathway and there is also scope to do a two-step 
one-pot synthesis similar to the cross-coupling procedure, as shown in Scheme 3.48 that 
forms the E-olefin. The formation of the unsaturated bromo-triflate 216 can be formed from 
the enantiomeric keto-bromide 218 using a bulky base and LiHMDS with Tf2O.197 The 
synthesis of the enantiomeric bromo-ketone 218 can be made via the Gais et al. protocol.110 
This will involve the use of the already synthesised meso-ketone 69, converting it into the 
corresponding silyl-enol ether and adding NBS to form 218. The synthesis of meso-ketone 69 
can be undertaken by utilizing the aforementioned three-step synthesis starting from 1,4-
cyclohexadiene (92). 
 
The synthesis of the pinacolborane intermediate 215, for the Suzuki cross-coupling, can be 
formed in five steps as shown in Scheme 6.2. The commercially available cyclohexanone 
(219) can be converted directly to the lactol 220 using the Bayer-Villiger reaction with 
mCPBA and NaBH4. The lactol can then undergo an enantioselective addition protocol,198 
with a TMS-acetylene and (+)-N-methyl ephedrine, and a subsequent TES protection reaction 
at the alcohol moieties to form 221. The use of (-)-N-methyl ephedrine would lead to the (R)-
analogue, which would be useful to form the (R)-alcohol diastereoisomer of (-)-
dictyosphaerin 72b. The pinacolborane intermediate 215 can be formed via the alkyne 221 
using a catalytic amount of Cp2ZrCl2 and pinacolborane.199 This reaction will selectively give 
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6.2 Postulated Syntheses of the trans-Fused Bicyclo[4.3.0]nonene Skeleton  
Another possibility for the structure of (-)-mucosin would of course be a trans-fused 
bicyclo[4.3.0]nonene ring system. In literature, there are two identical methods109,200 to 
produce the enantiomeric trans-fused version (227) of the meso-ketone 69, which is shown in 
Scheme 6.3. Both start with an asymmetric Diels-Alder reaction using commercially 
available 1,3-butadiene (88), (-)-dimenthyl fumarate (222) and diisobutylaluminium chloride. 
This forms enantiomer 223, a cyclohexene ring with two menthol esters in an anti-
relationship to each other in a very high d.e. of ≥ 96%. From here the next reactions 
involving 223 are analogous to the Mundy and Theodore procedure111 to produce the meso-
ketone 69. However, they seem to elongate the ring-closing procedure by ignoring the 
Ruzicka-type cyclisation with the bis-acid 225, formed from diol 224, and continue with an 
esterification, Dieckmann cyclisation with NaH to give 226 in a mixture of epimers (R:S = 
11:1), sequential hydrolysis and decarboxylation of 226 to form the trans-fused 












Using the same procedure to make the methyl ester 179 with the trans-fused 
bicyclo[4.3.0]nonene skeleton can now take place. However, employment of this procedure 
to synthesize the trans-fused 179 does not have to begin with ketone 227. The possibility of 
using β-keto ester 226 as the starting point and using this to form the vinyl-triflate species 
removes any stereochemical issues with epimers from 226 and gives the opportunity for the 
synthesis of the trans-fused bicyclo[4.3.0]nonene diastereoisomer of 179 based on the current 
pathway. Future conversion of the vinyl-triflate to the saturated butyl ester and the 
subsequent analysis of the stereochemistry cannot be discussed in detail here and will only 
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become apparent once attempted. There is also the contingency here to employ the opposite 
enantiomer of (-)-dimenthyl fumarate and undertake the identical synthesis to give the 
opposite trans-fused bridgehead configuration to the one in Scheme 6.3.  
 
Another method to make both the trans-fused bridgehead analogues of the keto-ester, shown 
in Scheme 6.4, would be to employ the commercially available acid anhydride 71 as 
discussed in Chapter 2. This could be reacted with an excess of NaOMe to create a ring 
opened bis-methyl ester analogue 228. This could then be treated again with excess NaOMe 
to equilibrate itself to a mixture of racemic trans-fused bis-methyl ester analogues 229a and 
229b. This mixture of two racemic esters can undergo chiral resolution with an optically 
active reagent, such as (-)-menthol, via an esterification to form two diastereoisomers, which 
could then hopefully be separated by column chromatography. There is also an option of 
converting the racemic mixture to the acid and making chiral amine salts from the acid, 
which could be separated by crystallization. This would furnish the two desired analogues of 
the trans-fused ring system 230a and 230b separately, both of which can then be taken 
forward to their corresponding keto-ester epimer analogues 231a and 231b by the method 
explained in Scheme 6.3. These keto-ester analogues 231a and 231b could then of course be 
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6.3 A Postulated Shorter Synthon Towards the (-)-mucosin 
Diastereoisomer 179 
Future synthons on synthesizing the correct structure of (-)-mucosin will be focused towards 
shortening the number of steps in the total synthesis. One postulated synthon, as shown in 
Scheme 6.5, would be the direct addition of a C7 side-chain directly onto the aforementioned 
optically active β-keto-ester 68. An interesting and novel method of doing this would be 
undertaking an enantioselective Carroll-rearrangement reaction201 with the pre-made trans-
esterified intermediate 233, which is made from 68 and alcohol 232. Using a complex of a 
chiral ligand and a Pd(0) catalyst, such as [Pd2(dba)3], with 233 should form an intermediate 
π-allyl species with the terminal olefin. Once formed, this can then undergo the Carroll-
rearrangement with the neighboring ester carbonyl and form the intermediate compound 234 
with extrusion of CO2. The hope is, based on the previous (-)-mucosin synthon, is that the 
reaction will favor the exo-face of the bicyclic skeleton and the β-position, with respect to the 
ketone moiety, will remain in the same (R)-configuration as shown on compound 234. This 
would be analogous to what we have found when equilibrating with NaOMe to form 164. 
The other hope is that the olefin at Δ5,6 will be the E-isomer. This is based on the fact that the 
bulky Pd(0) catalyst and the steric hindrance of the side-chain should favor the E-isomer.  
A subsequent Grignard reaction202 with nbutylmagnesium bromide on 234 will give an 
alcohol as a mixture of diastereoisomers. The alcohol can then be deoxygenated by a Barton-
McCombie protocol,203,204 by first forming the xanthate intermediate 235, which then can be 
subsequently reduced by BMe3 and H2O rather than Bu3SnH to give intermediate 236. This is 
to stop any unwanted lipophilic side-products from the use of Bu3SnH being present in the 
final compound. Once the xanthate has been removed the C4 butyl side-chain should be 
trans-related to the C7 side-chain, again due to steric hindrance and the results obtained on 
the previous synthon with NaOMe. Final removal of the TES-group at C-1 by Swern 
oxidation196 to an aldehyde, oxidation of the aldehyde to the corresponding acid by a Pinnick 
protocol and esterification by TMS diazomethane167, as previously discussed, should give the 



















The C7 side-chain intermediate 232 can be made via a simple three-step reaction using 
commercially available 3,4-Dihydro-2H-pyran (237) as a starting material. The first step 
involves the treatment of 237 with aq. HCl to form a lactol,205 which subsequently undergoes 
a ring-opening Grignard reaction with vinylmagnesiumbromide in THF.205 The final step 
protects the terminal alcohol moiety with a TES-group via a reaction with 1.0 equiv. of TES 
and 2,6-lutidine to give the C7 side-chain intermediate 232 as shown in Scheme 6.6. 
 
 
Scheme 6.5 Postulated shorter synthesis towards mucosin methyl ester 179. 
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6.4 Scope of Biological Testing on (-)-mucosin Diastereoisomer 179  
The bioactivity of the (-)-mucosin diastereoisomer 179 will also have to be addressed. Both 
the methyl ester and acid analogues could be biologically evaluated as well as the Z-isomer 
238 and alkyne derivative 239 of 179, as shown in Figure 6.1. There is also the scope to 
synthesize the 15 stereoisomers of 179 with varying hybridization on the C7 side-chain at ∆5,6 
to see the complete range of bioactivity across all structures. The hope is that they will have 
some bioactivity, which could be comparable to the natural products with bicyclic ring 





Another interesting side-note, with regards to the bioactivity of (-)-mucosin and its 
analogues, are the computerized docking experiments carried out (-)-dictyosphaerin (42). 
These experiments show the propensity for a chosen molecule to interact with an array of 
amino acids, which would mimic the active sites of enzymes in the body. When the cis-fused 
bicyclo[4.3.0]nonene structure of (-)-dictyosphaerin, with an (R)-configured alcohol moiety 
at C-6, was tested using this program the results showed a very close match with a bioactive 
prostanoid called (+/-)-rosaprostol (240).206 The structure of this C18 prostanoid with trans-
related side-chains is shown in Figure 6.2. The sodium salt of (+/-)-rosaprostol is marketed as 
Rosal®, which is a mixture of racemic 1,2-trans-1,5-cis and 1,2-trans-1,5-trans 
diastereoisomers.207 Rosal® is used for the treatment of gastric duodenal ulcers. This could 
give an indication of the type of bioactivity that could be expected for (-)-dictyosphaerin and 
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6.5 A More Effective Postulated Synthesis of (+)-crucigasterin 277 
Another aspect of future work will be the exploration of a more efficient and 
diastereoselective method to synthesize (+)-crucigasterin 277 (57). The current method 
produces four diastereoisomers that are difficult to separate via silica-gel chromatography. 
Whilst it is notable that one of the two of the diastereoisomers purified by column 
chromatography, 213a, can ultimately give the correct compound there are still problems 
with co-elution, which has an adverse effect on the yield. One method shown in Scheme 6.7, 
as explained in Chapter 2 with Route B in Scheme 2.3, would be the employment of an anti-
selective Henry reaction protocol127 between an aldehyde 87 and nitroethane with 
employment of a heterobimetallic Cu/Sm/aminophenol sulfonamide complex. This reaction 
has the propensity to give better yields (99%), a high d.r. (30:1) and an excellent e.e. 
(98%).127 This is shown by the postulated formation of nitro alcohol 86 with the correct 2R 
and 3S absolute stereochemistry. The aldehyde 87, the homologated version of aldehyde 83, 
used to synthesize bromide 82 in Route A, could be synthesised via a similar homologation 
using the reduction/mesylation/cyanation/modified reduction protocol129 employed during the 
total synthesis of the (-)-mucosin stereoisomer 179. The subsequent reduction of the nitro 
group on 86 via a SmI2 protocol128 would yield (+)-crucigasterin 277 (57) in conceivably 







There has already been a similar organocatalysed synthesis, employing a stereoselective anti-
Henry reaction by our group at UiO and NMBU, to synthesize Obscuraminol A.96 
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One postulated biosynthesis of a trans-fused diastereoisomer of (-)-mucosin 244 is shown 
above in Scheme 6.8. Starting from AA (10) this will undergo the well-known oxygenation at 
C-5 by 5-LOX in the 5-lipoxygenase pathway to form leukotriene A4 (LTA4) (241).208 LTA4 
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(241) is then subjected to a nucleophilic attack by water to form 5S,6S-diHETE (242) that has 
been reported in the marine environment.209 Intermediate 242 is now ready to undergo an 
enzyme-catalysed or spontaneous cycloaddition reaction to form 243 with the cyclohexene 
moiety, which is present on the (-)-mucosin structure. This also leaves a trans-fused 
bridgehead system, which is what we would now expect with the true structure of (-)-
mucosin. Following on from this the cyclopentyl moiety is formed from another enzyme-
catalysed or spontaneous cycloaddition reaction via a dehydratization and migration, to give 
the trans-diastereoisomer 244 of (-)-mucosin (23). This is one of several possible biogenesis 
for (-)-mucosin, but as mentioned above, 242 is found in the ocean.  
 
Another postulated biogenesis could be with use of Diels-Alderase enzymes (Diels-
Alderases) as discussed in Chapter 1. These Diels-Alderases have the propensity to from a 
trans-fused bicyclic ring system with four-contiguous stereocenters. Many examples of this 
have been found in nature as shown in Schemes 1.2-1.4. However, as discussed by Minami 
and Oikawa, the Diels-Alderases are not necessarily participating in just a concerted process. 
Formal Diels-Alderases catalyze formation of a cyclohexene ring from a conjugated diene 
and olefin in a stereoselective manner.210 Yet, this may include double Michael reactions, 
aldol-Michael reactions, bi-radical reactions and other stepwise reactions.210 Based on the 
structure of 244, with the four chiral centers and trans-fused bicyclic ring system, it is 
entirely possible that a Diels-Alderase could be involved in the biosynthesis of 244 and its 
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7. Conclusion 
	
This thesis describes the successful synthesis of a methyl ester (-)-mucosin diastereoisomer 
179 in a seventeen-step synthesis, with 4% total yield. The synthesis also has a high optical 
purity with respect to the β-keto ester intermediate 68 and an excellent enantiomeric excess 
of ≥99% on comparison of the chiral and racemic alcohol intermediate 199. The total 
synthesis consists of a novel three-step one-pot reaction to obtain the desired E-olefin in a 
combined total yield of 51%. The total synthesis also consists of an improved methodology to 
synthesize the meso-ketone 69 in three steps rather than five and almost doubling the total 
yield when compared to the literature methods. 
 
After analysis of the spectral data from the methyl ester analogues of 23 and ent-23 in the 
literature and the synthesized methyl ester stereoisomer 179 of 23 in this thesis, it has been 
deduced that true structure of (-)-mucosin is yet to be elucidated. This is due to Casapullo 
incorrectly assigning the stereocenters during his analysis of the natural product methyl ester 
of 23. Similarly, Whitby et al. has most likely incorrectly assigned the stereocenters of his 
methyl ester enantiomer ent-23 as he has taken forward the incorrect diastereoisomer during 
his synthesis and he has also undertaken X-ray crystallography on an intermediate, which has 
no direct relation to the synthesis of ent-23. This leaves the interesting question as to the true 
structure of (-)-mucosin. The same question is also true of (-)-dictyosphaerin and will become 
apparent when the all the stereoisomers of 42 have been synthesized. The same can also be 
said of the biogenesis for both (-)-mucosin and (-)-dictyosphaerin, whether they utilize an 
enzyme-catalysed intramolecular cycloaddition or a Diels-Alderase type formation still needs 
to be resolved. The bioactivity of (-)-mucosin and (-)-dictyosphaerin also needs to be tested 
and see whether they will have a similar bioactive range as PGs such as (+/-)-rosaprostol in 
Figure 6.2 and/or the sesquiterpenoids in Figures 1.9 and 1.10.  
 
Another added benefit of this total synthesis is that 23 mg of the pure methyl ester (-)-
mucosin diastereoisomer 179 was obtained. When compared to the amount of the (-)-mucosin 
methyl ester isolated from Reniera mucosa, by Casapullo et al.,58 (8.5 mg from 1.35 Kg of 
sponge) this is nearly three times the amount, even synthesizing on a small scale. The total 
synthesis of 179 and its postulated analogues already seems to be beneficial towards 
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protecting the marine environment using this method and also has the scope to undertake in-
depth biological testing when synthesised on a larger scale. 
 
This thesis also describes the total synthesis of the cytotoxic amino alcohol (+)-crucigasterin 
277 (57) via a ten-step synthesis in a 7% total yield. The diacetyl synthetic analogue of (+)-
crucigasterin 277 also has a high optical purity on comparison with the diacetyl derivative 
found from nature. However, the synthon itself is not optimized, especially with respect to 
the lack of stereoselectivity of the reactions chosen and the total yield. The prospect now is to 
attempt the synthesis in Scheme 6.7 to make (+)-crucigasterin 277 and improve the 
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Total synthesis based on the originally claimed
structure of mucosin†
Harrison C. Gallantree-Smith,a Simen G. Antonsen,a Carl H. Görbitz,b
Trond V. Hansen,a,c Jens M. J. Nolsøe*a and Yngve H. Stenstrøm*a
The first total synthesis aimed at the naturally occurring eicosanoid
bicycle mucosin is reported. A practical route has been devised
allowing the issues relating to the previous assignment of stereo-
chemistry to be examined. X-ray crystallography was performed on
a late stage intermediate to pinpoint the topological relationship
displayed by the featured bicyclo[4.3.0]non-3-ene scaffold.
Marine organisms continue to be a rich source of novel
natural products,1 constituting a pharmacopeia of biological
response and evolutionary adaption that is yet to be explored
within the context of human physiology. In particular, com-
pounds originating from polyunsaturated fatty acid meta-
bolites, such as eicosanoids and docosanoids, have a key role
in the cascade triggered by injurious stimuli, both in terms of
the inflammatory feedback as well as the catabasis leading to
the restoration of homeostasis.2
Against this setting, our attention has been drawn towards
the structure of mucosin (1), an unusual bicyclic lipid sur-
mised to be the progeny of arachidonic acid (3) (Fig. 1).
Isolated as methyl ester 2 from the Mediterranean sponge
Reniera mucosa, Casapullo et al. assigned the structure and
relative stereochemistry by applying several analytical tech-
niques (MS, IR and various NMR experiments).3 Given the
assumed biogenetic origin, the most noticeable feature is the
cis-fused bicyclo[4.3.0]non-3-ene core, indicating a formal dis-
rotatory ring closure.4 In view of mounting evidence implicat-
ing enzymes effectuating the Diels–Alder reaction in biological
systems,5 one might also venture this to be the case for a host
of other pericyclic transformations, like the ene reaction.
Thus, allylic carbocations have been invoked as conceptual
intermediates in the biogenesis of marine carbocyclic oxyli-
pins, such as prostaglandin A2 (PGA2).6 From a biological pers-
pective, the structural resemblance between mucosin (1) and
the prostane scaffold calls for attention, considering the vaso-
modulation associated with the latter compound class.2a
Prompted by the aspects related above and, in particular, the
intriguing findings presented by Casapullo et al.,3 we herein
wish to report the first total synthesis of mucosin (1) according
to the nominal structure.
As a pivotal point in our synthetic strategy (Scheme 1), it
was envisioned that desymmetrization of meso-ketone 4 could
be used as a means to furnish a chiral handle.7 With this
installed, the plan was to further elaborate the functional
pattern and prepare the route to the remaining stereocenters
contained within the ring system. Taking advantage of the
innate conformational aspects, it was anticipated that hydride
addition from the less hindered exo face of the conjugated
ester 7 would establish the chiral configuration attributed to
mucosin (1).
Synthesis of meso-ketone 4 was executed in three steps
according to a novel protocol, starting from the commercially
available 1,4-cyclohexadiene (9) (Scheme 2). Commencing with
a [2 + 2] cycloaddition between the preformed dichloroketene
and 9,8 the cis-fused junction was installed. Next, the resulting
8,8-dichlorobicyclo[4.2.0]oct-3-en-7-one (10) was subjected to
ring expansion by applying the Büchner–Curtius–
Schlotterbeck reaction.9 Finally, zinc mediated hydrodehalo-
genation of gem-dichloroketone 11 completed the sequence
Fig. 1 Relationship between the mucosin scaffold and arachidonic acid.
†Electronic supplementary information (ESI) available: Experimental procedures
and characterisation data for all new compounds; crystal data and refinement
details are included to give evidence of the relative stereochemistry of a late
stage intermediate. CCDC 1484546. For ESI and crystallographic data in CIF or
other electronic format see DOI: 10.1039/c6ob01511e
aDepartment of Chemistry, Norwegian University of Life Sciences, PO box 5003,
1432 Ås, Norway. E-mail: yngve.stenstrom@nmbu.no, jens.mj.nolsoe@nmbu.no
bDepartment of Chemistry, University of Oslo, PO box 1033, 0315 Oslo, Norway
cDepartment of Pharmaceutical Chemistry, University of Oslo, PO box 1068,
0316 Oslo, Norway




































































































and provided an expedient entry to the desired starting
material 4.
The planned stereochemical iteration of meso-ketone 4 to
obtain mucosin (1) (Scheme 3) was undertaken by nominating
a chiral base with some suitable electrophiles. Combining the
lithium amide derived from (+)-bis[(R)-phenylethyl]amine with
methyl cyanoformate achieved desymmetrization to yield the
known ketoester 12 in excellent agreement with reported
values.10 Considering the more encumbered six step procedure
of Nagao et al., which is hinged on asymmetric Dieckmann
condensation of a chiral diamide,10a the preparation of the
optically active ketoester 12 delineated in the present work is
less involved.
Converting 12 to the corresponding enol triflate 13, and
subsequent cross coupling to introduce the alkyl group at C16,
gave a conjugated ester 14. Rather than taking advantage of
some Pd-catalysed protocols, concomitant addition/elimin-
ation via a stoichiometric cyanocuprate was opted for.11
Given that the two diastereotopic faces of the conjugated
system in 14 are distinguishable, due to the different steric
requirements of the exo and endo stance, one would expect
this to be borne out during a hydride reduction. Thus, a priori,
it was assumed that addition from the exo face would be
highly preferred and give rise to the projected stereoisomer 15
(Fig. 2). The constellation of magnesium in methanol12 pro-
ceeded to afford a 2 : 1 mixture of C8 epimers, which could be
equilibrated to the desired diastereomer 15 in the presence of
sodium methoxide. Further reduction of ester 15 yielded an
advanced intermediate 16, which was also found amenable for
derivatization in order to obtain crystals for X-ray analysis.
This established the relative stereochemistry of the four contig-
Scheme 1 Key strategic points towards synthesis of mucosin (1).
Scheme 2 Synthesis of meso-ketone 4. Reagents and conditions: (a)
Zn in Et2O with sonication, 0 °C, 0.25 h, then slow addition of trichloro-
acetyl chloride, 0 °C, 2 h, then NaHCO3 (aq., satd.); (b) slow addition of
CH2N2 in Et2O, 0 °C, 0.25 h, then 0.5 h, 0 °C, followed by 2 h, rt, then
abs. AcOH; (c) Zn in abs. AcOH, 70 °C, 16 h. Scheme 3 The total synthesis of mucosin (1) and its methyl ester 2.
Reagents and conditions: (a) (+)-bis[(R)-phenylethyl]amine hydro-
chloride with BuLi in THF, −78 °C, 0.25 h, then briefly at rt, re-cooled to
−78 °C, dropwise addition of 4, −78 °C, 0.75 h, then methyl cyanofor-
mate, −78 °C, 2 h, water quenching; (b) NaH in toluene, rt, 10 min, then
85 °C, 1.5 h, Tf2O added under cold conditions, 0 °C, 1 h, water quench-
ing; (c) CuCN in Et2O, −50 °C, then BuLi, 1 h, added to 13, −50 °C, 1 h,
then NH4Cl (aq., satd.); (d) Mg in MeOH, 40 °C, 3h, then abs. AcOH, rt;
(e) Na in MeOH, Δ, 3h (f ); DIBAL-H in hexane, 0 °C to rt, 0.5 h, then
Rochelle’s salt (aq., satd.), 0 °C; (g) Et3N in CH2Cl2, followed by MsCl,
briefly 0 °C then rt, 2 h; (h) KCN in DMSO, 70 °C, 2 h; (i) DIBAL-H in
hexane, −78 °C, 0.33 h, then Rochelle’s salt (aq., satd.) under cold con-
ditions; ( j) the Ohira–Bestmann reagent and K2CO3 in MeOH, rt, over-
night; (k) (1) DIBAL-H added to Cp2ZrCl2 in THF, 0 °C, 1 h, then 18, 0 °C,
1 h. (2) I2 added under cold conditions, then rt, 1 h. (3) 4-Ethoxy-4-oxo-
butylzinc bromide and (Ph3P)4Pd (10 mol%), rt, 1 h, then HCl (1 M, aq.);
(l) LiOH in THF/MeOH/H2O, rt, 3 h; (m) TMSCHN2 in toluene/MeOH,
rt, 3 h.
Fig. 2 Hydride attack on the distinguishable diastereotopic faces of
conjugated ester 14.
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uous centres (Fig. 3). Moreover, analysis of 16 by GLC on a
chiral column showed an enantiomeric excess better than
99%.
Having installed the assigned topology, 16 was sequentially
elaborated into alkyne 18 via a four step procedure, featuring
Ohira–Bestmann homologation as the key.13 The final step was
executed in an untested three step one-pot approach, taking
advantage of the facile alkyne hydrometallation,14 followed by
halodemetallation15 to form the corresponding E-vinyl halide
as a substrate for Pd-catalysed cross-coupling with a commer-
cial zinc reagent.16 Finally, the portrayed natural compound
mucosin (1) was obtained after hydrolysis of ethyl ester 19. In
order to compare with data cited in the literature, the free acid
was re-esterified to methyl ester 2.
The recordings made on the material furnished by our syn-
thetic route are at odds with the values reported in the litera-
ture,3,17 both with regard to optical rotation and resonances
quoted in 13C NMR. Thus Casapullo et al. have provided [α]26D =
−35.5° (c = 0.8, hexane),3 while Whitby and co-workers have
found [α]26D = +38.2° (c = 0.8, hexane) for the enantiomer.
17 We,
on the other hand, have observed a reading of [α]26D = −9.8° (c =
0.8, hexane). However, the physical difference between our
compound and the methyl ester of naturally occurring
mucosin is more tangible when the 13C NMR spectra are
placed side by side: of the 20 atoms that constitute the carbon
framework, excluding the methoxy group, there are 12 reson-
ances that deviate (Table 1).
To summarise, based on the reported structure of mucosin
(1), we have devised a synthetic strategy to access the four con-
tiguous stereocentres. A novel route was conceived for the
known meso-ketone 4, which was manipulated during the
course of 11 discrete steps to achieve the target molecule 1 in
an overall yield of 16.9%, delivering multi-milligram quan-
tities. With the cumulative information obtained in this
process, and in particular underpinned by X-ray crystallogra-
phy of the late stage intermediate 16, we raise the question
about the true identity of mucosin. In the absence of a
thorough discussion of stereochemistry3,18 and the lack of
structural evidence directly linked to the main synthetic
events,17 the risk of misassignment is a looming peril.19 Thus,
by executing our sequence, it has been demonstrated that
structure 1 does not represent naturally occurring mucosin.
The cis-fused bicyclo[4.3.0]non-3-ene system inferred to be
present in mucosin by Casapullo et al.3 is not a widespread
motif in nature. In fact, to our knowledge, the only other
example surmised to incorporate the pertinent structural
element is dictyosphaerin, a marine natural product isolated
from the green algae Dictyosphaeria sericea.20 However, in this
case, neither the absolute nor the relative stereochemistry has
been established.
Considering mucosin, depending on the extent of concert
between enzyme promoted and spontaneous processes, the
biogenetic machinery leading to the formation of a cis-config-
ured bicyclo[4.3.0]non-3-ene system may involve one or several
of the following basic steps: (i) a disrotatory ring closure,4 (ii) a
Diels–Alder reaction,5 or (iii) an ene reaction.21 In all events,
arachidonic acid (3) is the most plausible substrate, based on
its presence in the marine environment22 and the structural
elements identified in mucosin.3 Regardless of the cyclo-
addition invoked, it is necessary that 3 is biosynthetically
transformed into a suitable conjugated precursor, in terms of
the downstream process leading to the claimed structure 1 of
mucosin. Interconversion of 3 into E,E- and E,Z-conjugated
olefins is known to occur in several marine species.22,23 The
resulting conjugated C20 fatty acids are obtained either by an
enzymatic isomerization of the skipped all-Z polyenic
system,24 or by dehydration of the corresponding E- or Z-allylic
carbinol derivative.6,22,23 The action of lipoxygenase enzymes
on the polyene backbone of 3 leads to the stereoselective for-
mation of secondary alcohols,6,24 providing natural products
that incorporate mono- and dihydroxylated E,E-diene motifs.
Such conjugated motifs participate in enzyme catalysed Diels–
Alder reactions to form bicyclo[4.4.0]deca-3-ene systems. The
action of a Diels–Alderase in the biosynthesis of natural
products is exemplified by statins,25 anthramycins,26 solano-
Fig. 3 Single crystal X-ray structure obtained from the 3,5-dinitro-
benzoate of alcohol 16 at 110 K. The n-butyl conformation is shown
with a trans, trans, gauche+ orientation relative to the dark C atom. For
clarity, a minor trans, gauche−, gauche− orientation with occupancy
0.26(3) has been omitted.
Table 1 Observed 13C NMR resonances for methyl ester 2 (δ-values)
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pyrones,27 spinosyns28 and macrophomic acids.29 Most con-
spicuously, all of the listed compound classes display a trans-
disubstituted cyclohexene. In contrast, the involvement of a
Diels–Alderase in the formation of cis-bicyclo[4.4.0]deca-3-ene
systems has not yet been reported.
In the instance of non-enzymatic cycloaddition, formation
of the marine carbocyclic oxylipins takes place via an allylic
carbocation.6,22 For the overwhelming majority of the provided
examples, the outcome of the annealing process is a trans-1,2-
disubstituted cyclopentane ring.30
In light of the discussion above and the flawed assignment
of mucosin, it is clear that thorough biosynthetic studies and/
or preparation of stereochemical permutations based on struc-
ture 1 are needed.
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All commercially available reagents and solvents were used in the form they were supplied 
without any further purification. (+)-bis[(R)-1-phenylethyl]amine hydrochloride (optical 
purity ≥ 99% e.e. by GLC) was purchased from Sigma-Aldrich. The stated yields are based 
on isolated material. The melting points are uncorrected. Thin layer chromatography was 
performed on silica gel 60 F254 aluminium-backed plates fabricated by Merck. Flash column 
chromatography was performed on silica gel 60 (40-63 µm) fabricated by Merck. NMR 
spectra were recorded on a Bruker AscendTM 400 at 400 MHz for 1H NMR and at 100 MHz 
for 13C NMR. Coupling constants (J) are reported in hertz and chemical shifts are reported in 
parts per million (δ) relative to the central residual protium solvent resonance in 1H NMR 
(CDCl3 = δ 7.27) and the central carbon solvent resonance in 13C NMR (CDCl3 = δ 77.00 
ppm). Mass spectra were recorded at 70 eV on Waters Prospec Q spectrometer using EI as 
the method of ionization. IR spectra (4000–600 cm−1) were recorded on a Perkin-Elmer 
Spectrum BX series FT-IR spectrophotometer using a reflectance cell (HATR). Optical 
rotations were measured using a 1 mL cell with a 1.0 dm path length on a Perkin Elmer 341 
polarimeter using the stated solvents. Determination of enantiomeric excess was performed 
by GLC on an Agilent Technologies 7820A GC instrument with split (1:30) injection, FID 
detector and equipped with a chiral stationary phase (Agilent J&W GC columns, CP-Chirasil-
DEX CB, 25 m, 0.25 mm, 0.25 µm) applying the conditions stated. X-ray crystallography 
was performed on a Bruker D8 Venture diffractometer with InCoatec ImuS Microfocus 
radiation source and Photon 100 CMOS detector. Data collection with Apex2,1 data 
integration and cell refinement with SAINT,1 absorption correction by SADABS,1 structure 



























1,4-Cyclohexadiene 9 (5 g, 62.5 mmol, 1.0 equiv.) was added to a suspension of zinc powder 
(8.2 g, 125 mmol, 2.0 equiv.) in dry Et2O (100 mL) and sonicated at 0 °C for 15 min. Then 
trichloroacetylchloride (22.75 g, 125 mmol, 2.0 equiv.) in dry Et2O (100 mL) was added 
dropwise over 2 h while the reaction mixture was still sonicating. After complete addition the 
reaction mixture was sonicated for a further 2 h at 0-10 °C. The colour changed from 
colourless to dark yellow. The sonication was then stopped and the reaction mixture filtered 
and concentrated in vacuo. The resulting orange slurry was diluted in Et2O (400 mL) and 
washed with H2O (2 x 400 mL) and sat. aq. NaHCO3 (1 x 400 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. The resulting crude dark yellow oil was 
purified by column chromatography on silica (nhexane/EtOAc 99:1) to afford the title 
compound as a colourless oil. All spectroscopic and physical data were in full agreement with 
those reported in the literature.5 Yield: 2.25 g (47%); 1H NMR (400 MHz, CDCl3) δ 5.90-
5.81 (m, 2H), 4.07-4.01 (m, 1H), 3.32 (ddt, J = 2.0, 7.9, 10.4 Hz, 1H), 2.63-2.50 (m, 2H), 
2.39-2.32 (m, 1H), 2.17-2.10 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 198.3, 127.3, 126.3, 
88.5, 53.7, 45.2, 23.1, 21.3; IR (neat, cm-1) 3041 (w), 2939 (w), 2895 (w), 2841 (w) 1799 (s), 
1644 (w), 1433 (m); HRMS (EI+): Exact mass calculated for C8H8OCl2 [M]+: 189.9952, 
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To a stirring solution of rac-(1R,6S)-8,8-dichlorobicyclo[4.2.0]oct-3-en-7-one 10 (2 g, 10.47 
mmol, 1.0 equiv.) in dry Et2O (50 mL), at 0 °C, was added diazomethane (2.47 g, 104.7 
mmol, 10.0 equiv.) in dry Et2O (50 mL) dropwise over 15 min. The reaction mixture bubbled 
and turned a deep golden yellow colour. After 30 min the reaction was warmed to room 
temperature and left to stir for 2 h. The reaction was then quenched with glacial AcOH (5 
mL) dropwise until there was no more gas evolution and the colour changed from golden 
yellow to almost colourless. The resulting mixture was then washed with H2O (2 x 300 mL), 
sat. aq. NaHCO3 (1 x 300 mL), brine (1 x 300 mL), dried with MgSO4, filtered and 
concentrated in vacuo. The resulting dark yellow oil was purified by column chromatography 
on silica (nhexane/EtOAc 9:1) to afford the title compound as a colourless oil. Yield: 1.6 g 
(75%); 1H NMR (400 MHz, CDCl3) δ; 5.64-5.57 (m, 2H), 2.86-2.80 (m, 1H), 2.74-2.69 (m, 
1H), 2.54 (dd, J = 7.5, 19.2 Hz, 1H), 2.38-2.29 (m, 2H), 2.07-2.00 (m, 2H), 1.72-1.64 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ 201.7, 123.9, 123.1, 89.5, 46.7, 36.6, 28.1, 25.8, 23.5; IR 
(neat, cm-1) 3033 (m), 2916 (m), 2842 (m), 1764 (s) 1662 (w) 1434 (m), 1402 (m); HRMS 
(EI+): Exact mass calculated for C9H10OCl2 [M]+: 204.0109, found 204.0103; TLC (nhexane 








To a stirring suspension of zinc powder (1.71 g, 26.34 mmol, 2.0 equiv.) in glacial AcOH (50 
mL) was added rac-(1R,6R)-7,7-dichlorobicyclo[4.2.0]oct-3-en-7-one (11) (2.7 g, 13.17 
mmol, 1.0 equiv.) in glacial AcOH (30 mL) dropwise. The resulting reaction mixture was 
stirred for 16 h at 70 °C. The reaction mixture was then cooled to room temperature and 











washed with H2O (2 x 300 mL), sat. aq. NaHCO3 (1 x 300 mL), brine (1 x 300 mL), dried 
with MgSO4, filtered and concentrated in vacuo. The resulting crude pale yellow oil was 
purified by column chromatography on silica (nhexane/EtOAc 95:5) to give the meso 
compound as a colourless oil. All spectroscopic and physical data were in full agreement with 
those reported in the literature.6 Yield: 2.45 g (72%); 1H NMR (400 MHz, CDCl3) δ 5.70-
5.69 (m, 2H), 2.46-2.41 (m, 2H), 2.34-2.25 (m, 4H), 2.10 (dd, J = 6.4, 18.6 Hz, 2H) 1.89-1.83 
(m, 2H); 13C NMR (100 MHz, CDCl3) δ 219.6 124.6 (2C), 44.6 (2C), 32.3 (2C), 26.2 (2C); 
IR (neat, cm-1) 3024 (m), 2834 (m), 2901 (s), 1744 (s), 1655 (w), 1439 (m), 1407 (s); HRMS 
(EI+): Exact mass calculated for C9H12O [M]+: 136.0888, found 136.0983; TLC (nhexane 

























Figure S-1 1H-NMR spectrum of compound 10. 
 
Figure S-2 13C-NMR spectrum of compound 10. 
	 S7	 	
 
Figure S-3 1H-NMR spectrum of compound 11. 
 
Figure S-4 13C-NMR spectrum of compound 11. 
	 S8	 	
 
Figure S-5 1H-NMR spectrum of compound 4. 
 
Figure S-6 13C-NMR spectrum of compound 4. 
	 S9	 	
 
Figure S-7 HRMS of compound 10. 
 
 
















Figure S-9 HRMS of compound 4. 
 
 













Figure S-11 IR of compound 11. 
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(+)-Bis[(R)-1-phenylethyl]amine hydrochloride (2.5 g, 9.60 mmol, 1.58 equiv.) was added in 
one portion to dry THF (10 mL) at room temperature and stirred for 5 min. The stirring 
suspension was then cooled to -78 °C and nBuLi (2.5M in nhexane, 7.67 mL, 19.18 mmol, 
3.16 equiv.) was added dropwise. The suspension changed colour from cloudy white to pale 
orange. After stirring at -78 °C for 15 min the suspension was warmed to room temperature 
whereby a transparent yellow solution was formed.  This was then cooled to -78 °C again and 
meso-(1S,6R)-bicyclo[4.3.0]non-3-ene-8-one 4 (826 mg, 6.07 mmol, 1.0 equiv.) was added 
dropwise over 10 min in dry THF (10 mL). This mixture was then stirred for 45 min whereby 
a purple colour evolved. Methyl cyanoformate (0.96 mL, 12.14 mmol, 2.0 equiv.) was then 
added dropwise over 5 min. and the mixture immediately turned bright yellow in colour. This 
mixture was left stirring for 2.5 h and then quenched by addition of H2O (2 mL) at -78 °C. 
The mixture was then warmed to r.t and extracted with EtOAc (2 x 50 mL). The resulting 
organic layer was then washed with H2O (2 x 100 mL), 0.5 M HCl (1 x 100 mL) and brine (1 
x 100 mL). The organic layer was then dried over MgSO4, filtered and concentrated in vacuo. 
The resulting crude keto-ester was purified by column chromatography (nhexane/EtOAc 5:1) 
to form a colourless oil. This oil was then recrystallised from nhexane at 0°C, filtered and air 
dried to obtain the title compound as white crystals. All spectroscopic and physical data were 
in full agreement with those reported in the literature.7 Yield: 812 mg (69%); [!]!!" -161.2° (c 
= 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.73-5.66 (m, 2H), 3.76 (s, 3H), 3.04 (d, J = 
11.1 Hz, 1H), 2.88-2.83 (m, 1H), 2.52-2.38 (m, 3H), 2.33-2.21 (m, 2H), 2.04 (dd, J = 1.9, 
18.2 Hz, 1H), 1.67-1.61 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 211.6, 169.7, 124.9, 123.9, 
57.7, 52.4, 46.6, 37.3, 29.7, 26.8, 25.3; IR (neat, cm-1) 3034 (w), 2945 (m), 2908 (m), 2837 
(w), 1751 (s), 1718 (s) 1656 (w) 1433 (s) 1404 (m); HRMS (EI+): Exact mass calculated for 
C11H14O3 [M]+: 194.9033, found 194.0943; m.p.: 59-61 °C; TLC (nhexane/EtOAc 4:1, 

















LDA (1M in THF/nhexane) (1.65 mL, 1.65 mmol, 1.5 equiv.) was added dropwise to dry 
THF (5 mL) at -78 °C and stirred for 30 min. Then meso-(1S,6R)-bicyclo[4.3.0]non-3-ene-8-
one 4 (150 mg, 1.10 mmol, 1.0 equiv.) was added dropwise in dry THF (5 mL) over 5 min 
and left to stir for 45 min. To the resulting yellow solution was added methyl cyanoformate 
(0.174 mL, 2.2 mmol, 2.0 equiv.) dropwise over 5 min and the reaction changed from yellow 
to colourless. After 30 min and monitoring the reaction via TLC the reaction was quenched at 
-78 °C by sat. aq. NH4Cl (2 mL) and the reaction mixture was left to slowly warm to room 
temperature. The reaction mixture was then poured over H2O (1 x 20 mL) and the organic 
phase separated. The aqueous phase was then extracted with EtOAc (2 x 20 mL). The organic 
phases were then combined, washed with H2O (2 x 50 mL), brine (1 x 50 mL), dried over 
MgSO4, filtered and concentrated in vacuo to from a crude yellow oil. This yellow oil was 
purified by column chromatography on silica (nhexane/EtOAc, 5:1) to afford the racemic 
keto-ester. This was recrystallised in the same fashion as the optically active keto ester to 
afford pure white crystals. Yield: 166 mg, (78%).  
 










NaH (60% disp. in min. oil, 148 mg, 3.71 mmol, 1.8 equiv.) was added to dry toluene (10 
mL). The suspension was stirred for 5 min and then methyl (1S,6S,7R)-8-














dry toluene (7 mL), was added dropwise over 10 min during which bubbling occurred. After 
the full addition of 12 the reaction mixture was heated to 85 °C for 1.5 h during which time 
the mixture turned to a brown colour. The reaction mixture was then cooled to 0 °C and the 
triflic anhydride (0.52 mL, 3.09 mmol, 1.5 equiv.), was added dropwise. The reaction mixture 
changed colour from brown to a pale yellow/white slurry. After stirring at 0 °C for 1 h and 
monitoring by TLC the reaction mixture was quenched carefully with H2O (10 mL). The 
resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were 
washed with H2O (1 x 150 mL), brine (1 x 150 mL), dried over MgSO4, filtered and 
concentrated in vacuo. This afforded a brown oil, which was purified by column 
chromatography on silica (nhexane/EtOAc 95:5) to afford the unsaturated triflate as a 
colourless oil. Yield: 527 mg (83%); [!]!!" +100.8° (c = 1.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.95-5.89 (m, 1H), 5.86-5.81 (m, 1H), 3.81 (s, 3H), 3.10 (q, J = 6.7 Hz, 1H), 2.84-
2.77 (m, 1H), 2.72-2.63 (m, 1H), 2.57-2.42 (m, 2H), 2.34-2.26 (m, 1H), 2.05-1.96 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 162.6, 153.9, 127.9, 127.3, 126.6, 118.3 (q, JCF = 320 Hz), 
51.8, 39.5, 38.9, 32.0, 27.3, 26.2; IR (neat, cm-1) 3036 (w), 2953 (m), 2845 (w), 1723 (s), 
1662 (m), 1425 (s); HRMS (EI+): Exact mass calculated for C12H13O5SF3 [M]+: 326.0436, 
found 326.0438; TLC (nhexane /EtOAc 4:1, KMnO4 stain): Rf = 0.75. 
 
Following the same procedure as above, racemic synthesis was performed to obtain 
reference material for chiral GLC analysis. 
 






Solid Cu(I)CN (1.45 g, 16.18 mmol, 2.5 equiv.) was added to dry Et2O (5mL) at room 
temperature. This was stirred for 5 min, cooled to -50 °C and then nBuLi (2.5 M in hexane, 
6.47 mL, 16.18 mmol, 2.5 equiv.) was added dropwise over 5 min. This mixture was stirred 
for 1 h at -50 °C and a dark brown suspension occurred. Methyl (1S,6S)-8-
(((trifluoromethyl)sulfonyl)oxy)bicyclo[4.3.0]non-3,7-diene-7-carboxylate 13 (1.98 g, 6.47 
mmol, 1.0 equiv.) was then added via cannula at -50 °C in dry Et2O (5 mL). The reaction 








monitoring by TLC. Once the reaction was finished sat. aq. NH4Cl (5 mL) was added 
dropwise. The reaction turned from black to dark purple and was left to warm to room 
temperature. The subsequent ethereal slurry was filtered through celite and the celite filter 
washed with EtOAc (3 x 15 mL). The organic layer was then separated and the aqueous layer 
extracted with EtOAc (2 x 15 mL). The organic layers were then combined, washed with 
H2O (1 x 100 mL), brine (1 x 100 mL), dried over MgSO4, filtered and concentrated in 
vacuo. This afforded a crude yellow oil, which was purified by column chromatography in 
silica (nhexane/EtOAc 98:2) to afford the unsaturated butyl diene as a colourless oil. Yield: 
1.33 g (88%); [!]!!" +124.5° (c = 3.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.88-5.83 (m, 
1H), 5.79-5.73 (m, 1H), 3.72 (s, 3H), 2.94 (q, J = 7.6 Hz, 1H), 2.64-2.54 (m, 1H), 2.52-2.38 
(m, 4H) 2.32-2.23 (m, 2H), 1.97-1.90 (m, 1H), 1.84-1.77 (m, 1H), 1.46-1.28 (m, 4H), 0.91 (t, 
J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.6, 159.9, 132.5, 127.9, 126.4, 50.8, 43.7, 
42.3, 34.2, 30.1, 29.8, 27.5, 27.2, 22.7, 13.9; IR (neat, cm-1) 3025 (w), 2926 (s), 1709 (s), 
1630 (w), 1433 (s); HRMS (EI+): Exact mass calculated for C15H22O2 [M]+: 234.1620, found 
234.1628; TLC (nhexane/EtOAc 9:1, KMnO4 stain): Rf = 0.85. 
 
Following the same procedure as above, racemic synthesis was performed to obtain 
reference material for chiral GLC analysis. 
 






1) Methyl (1S,6S)-8-butylbicyclo[4.3.0]non-3,7-diene-7-carboxylate 14 (1.33 g, 5.68 mmol, 
1.0 equiv.) was dissolved in MeOH (5 mL) at room temperature. This was stirred for 5 min 
then magnesium turnings (3.75 g, 156.31 mmol, 27.5 equiv.) were added in one portion. The 
turnings were stirred at room temperature for 10 min and then heated to 40 °C. A violent 
reaction occurs with lots of bubbling. After all the magnesium turnings had been consumed 
the addition of 27.5 equiv. of magnesium turnings in one portion was repeated at 40 °C. After 
3 h the reaction was then cooled to r.t to give a white cloudy mixture. Glacial AcOH (5mL) 
was added dropwise until the cloudy suspension had dissolved to leave a colourless solution. 








poured over EtOAc/H2O 1:1 (100 mL). The organic phase was separated and the aqueous 
layer was extracted again with EtOAc (2 x 50 mL). The organic phases were combined and 
washed with sat. aq. NaHCO3 (1 x 100 mL), brine (1 x 100 mL), dried over MgSO4, filtered 
and concentrated in vacuo, to give a crude product. This crude product was analysed by 1H 
and 13C NMR to show the reaction had gone to completion by the formation of two 
unconjugated diastereomeric esters in a 2:1 ratio, no further purification was carried out. The 
crude diastereomeric esters were then equilibrated with NaOMe as shown below. 
 
2) To MeOH (10 mL) at room temperature was added sodium metal (760 mg, 33.05 mmol, 
6.0 equiv.). This was left to stir until all the sodium metal had dissolved. The crude 
diastereomeric esters were then added dropwise in MeOH (5 mL) and the reaction mixture 
was heated to 70 °C and monitored by TLC. After 3 h the reaction had gone to completion, 
was cooled to r.t and concentrated in vacuo but not to dryness. The crude mixture was then 
poured over Et2O (50 mL) and H2O (50 mL). The organic layer was separated and the 
aqueous layer was extracted with Et2O (2 x 50 mL). The organic layers were then combined, 
washed with H2O (1 x 50 mL), brine (1 x 50 mL), dried over MgSO4, filtered and 
concentrated in vacuo to form a crude yellow oil. This crude yellow oil was purified by 
column chromatography on silica (nhexane/EtOAc 98:2) to give the title compound as a 
colourless oil. Yield: 1.24 g (93%); [!]!!" -4.32° (c = 2.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.73-5.66 (m, 2H), 3.69 (s, 3H), 2.32-2.22 (m, 1H) 2.22-2.14 (m, 5H), 2.09-2.02 
(m, 1H), 1.91-1.77 (m, 2H), 1.54-1.49 (m, 1H), 1.36-1.21 (m, 5H), 1.15-1.09 (m, 1H), 0.87 (t, 
J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 177.2, 126.3, 125.5, 55.5, 51.5, 42.7, 41.2, 
38.3, 36.9, 35.4, 30.6, 28.0, 26.5, 22.8, 14.0; IR (neat, cm-1) 3024 (m), 2927 (s), 2856 (s), 
1726 (s), 1657 (w), 1628 (w), 1541 (w), 1520 (w), 1458 (m), 1434 (s); HRMS (EI+): Exact 
mass calculated for C15H24O2 [M]+: 236.1776, found 236.1783; TLC (nhexane/EtOAc 9:1, 
KMnO4 stain): Rf = 0.85. 
 
Following the same procedure as above, racemic synthesis was performed to obtain 













Methyl (1S,6S,7S,8R)-8-butylbicyclo[4.3.0]non-3-ene-7-carboxylate 15 (1.24 g, 5.25 mmol, 
1.0 equiv.) was dissolved in nhexane (20 mL) at room temperature and stirred for 5 min. The 
solution was then cooled to 0 °C and DIBAL-H (1M in nhexane) (10.51 mL, 10.51 mmol, 2.0 
equiv.) was added dropwise over 5 min. The reaction was then left to warm to r.t. After 30 
min the reaction was cooled back to 0 °C and quenched with sat. aq. NH4Cl (6 mL). The 
reaction mixture was allowed to warm to room temperature whereby a cloudy suspension 
occurred. This suspension was poured over sat. aq. NH4Cl (30 mL) and the organic layer 
separated. The aqueous layer was extracted with EtOAc (2 x 25 mL) and the organic layers 
combined, washed with H2O (1 x 100 mL), brine (1 x 100 mL), dried over MgSO4, filtered 
and concentrated in vacuo to give a crude cloudy oil. This was then purified by column 
chromatography on silica (nhexane/EtOAc 95:5) to afford the title compound as a colourless 
oil. Yield: 1.01 g, (93%); [!]!!" -10.33° (c = 8.0, CHCl3); 1H NMR (400 MHz, CDCl3) 5.70-
5.64 (m, 2H), 3.61-3.52 (m, 2H), 2.24-2.03 (m, 3H), 1.92-1.81 (m, 4H), 1.57-1.42 (m, 4H), 
1.33-1.22 (m, 5H), 1.18-1.11 (m, 1H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 126.0, 125.8, 65.7, 54.0, 41.0, 37.8, 37.7, 37.4, 35.0, 31.0, 27.7, 27.3, 22.9, 14.1; IR (neat, 
cm-1) 3316 (br.), 3020 (m), 2918 (s), 1657 (m), 1464 (m), 1433 (m); HRMS (EI+): Exact 
mass calculated for C14H24O [M-H2O]+: 190.1722, found 190.1723; TLC (nhexane/EtOAc 
4:1, KMnO4 stain): Rf = 0.35. The enantiomeric excess was determined by chiral GLC 
analysis (CP-Chirasil-DEX CB, using the following program: 80 oC (30 min) - 3 degrees/min 
to 150 oC - 150 oC (5 min)): tr(e1, major) = 38.97 min and tr(e2, minor) = 39.95 min; e.e.: > 
99%. 
 
Following the same procedure as above, racemic synthesis was made to obtain reference 













To a stirring solution of (1S,6S,7S,8R)-8-butyl-7-(hydroxymethyl)bicyclo[4.3.0]non-3-ene 16 
(1.01 g, 4.81 mmol, 1.0 equiv.) in dry CH2Cl2 (10 mL) at room temperature, was added Et3N 
(1.34 mL, 9.62 mmol, 2.0 equiv.) dropwise. This solution was left stirring for 5 min then 
cooled to 0 °C. Then methanesulfonyl chloride (1.12 mL, 14.43 mmol, 3.0 equiv.) was added 
dropwise and the reaction was left at 0 °C for 10 min then warmed to room temperature and 
left for 2 h. The reaction mixture turned colourless to yellow. After 2 h brine (5 mL) was 
added dropwise and the volatiles concentrated in vacuo to afford a yellow liquid. This was 
poured over EtOAc (50 mL) and sat. aq. NaHCO3 (50 mL) was added. The organic layer was 
separated and the aqueous layer extracted with EtOAc (2 x 50 mL). The organic layers were 
combined and washed with brine (1 x 50 mL), dried over MgSO4, filtered and concentrated in 
vacuo to afford a crude yellow oil. This was then purified by column chromatography on 
silica (nhexane/EtOAc 95:5) to afford the title compound as a colourless oil. Yield: 1.30 g, 
(94%); [!]!!" -11.65° (c = 8.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.69-5.62 (m, 2H), 
4.18-4.10 (m, 2H), 2.99 (s, 3H), 2.24-2.07 (m, 3H), 1.94-1.79 (m, 4H), 1.68-1.50 (m, 3H), 
1.33-1.22 (m, 5H), 1.19-1.12 (m, 1H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 126.0, 125.2, 72.0, 50.3, 40.9, 38.0, 37.5, 37.2, 36.8, 34.9, 30.7, 27.2, 27.1, 22.7, 14.0; IR 
(neat, cm-1) 3024 (w), 2926 (s), 1657 (w), 1464 (m) 1435 (w); HRMS (EI+): Exact mass 
calculated for C15H26O3S2 [M]+: 286.1603, found 286.1606; TLC (nhexane/EtOAc 4:1, 




To a stirring solution of (1S,6S,7S,8R)-8-butyl-7-












in dry DMSO (10 mL) was added solid KCN (1.77 g, 27.27 mmol, 6.0 equiv.) in one portion. 
The reaction mixture was then heated to 70 °C for 2 h. The reaction mixture changed from 
colourless to yellow. After 2 h the reaction was cooled to r.t and H2O (5 mL) was added 
dropwise. The reaction mixture turned from yellow to colourless. This was then poured over 
EtOAc (20 mL) and the organic layer separated. The aqueous layer was then extracted with 
EtOAc (2 x 20 mL) and the organic layers combined. They were then washed with brine (1 x 
50 mL), dried over MgSO4, filtered and concentrated in vacuo to afford a crude brown oil. 
This was then purified by column chromatography on silica (nhexane/EtOAc 98:2) to give the 
title compound as a colourless oil. Yield: 906 mg, (92 %); [!]!!" -19.15° (c = 8.0, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 5.73-5.65 (m, 2H), 2.41 (d, J = 6.7 Hz, 2H), 2.27-2.14 (m, 3H), 
2.04-1.96 (m, 1H), 1.93-1.76 (m, 3H), 1.67-1.49 (m, 3H), 1.36-1.19 (m, 5H), 1.15-1.08 (m, 
1H), 0.90 (t, J = 6.8 Hz, 3H) 13C NMR (100 MHz, CDCl3) δ 126.5, 125.4, 119.0, 46.4, 43.9, 
41.3, 37.9, 36.0, 34.6, 30.6, 27.9, 26.3, 22.8, 21.0, 14.0; IR (neat, cm-1) 3024 (m), 2921 (s), 
1658 (w), 1465 (m) 1436 (m); HRMS (EI+): Exact mass calculated for C15H23N [M]+: 




A stirring solution of (1S,6S,7S,8R)-8-butyl-7-(cyanomethyl)bicyclo[4.3.0]non-3-ene pre-17b 
(906 mg, 4.18 mmol, 1.0 equiv.) in nhexane (10 mL) was cooled to -78 °C. Then DIBAL-H 
(1M in nhexane) (6.26 mL, 6.26 mmol, 1.5 equiv.) was added dropwise over 5 min and the 
reaction left to stir for 20 min. Then sat. aq. Rochelle salt (5 mL) was added dropwise to the 
reaction mixture and then left to warm to room temperature. The resulting cloudy suspension 
was poured over EtOAc (20 mL) and sat. aq. Rochelle salt (20 mL). The organic layer was 
separated and the aqueous phase extracted with EtOAc (2 x 20 mL). The organic phases were 
combined and washed with brine (1 x 50 mL), dried over MgSO4, filtered and concentrated in 
vacuo to afford a crude cloudy oil. This was then purified by column chromatography on 
silica (nhexane/EtOAc, 95:5) to afford the aldehyde as a colourless oil. Yield: 813 mg, (88%); 
[!]!!" -14.40° (c = 8.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.77 (t, J = 2.5 Hz, 1H), 5.71-







(m, 4H), 1.55-1.49 (m, 2H), 1.33-1.15 (m, 5H), 1.13-1.08 (m, 1H), 0.88 (t, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 203.0, 126.3, 125.6, 49.5, 45.3, 45.0, 41.8, 37.9, 36.4, 34.9, 
30.8, 27.7, 27.1, 22.8, 14.0; IR (neat, cm-1) 3023 (m), 2923 (s), 2718 (m), 1720 (s), 1657 (w), 
1465 (m), 1434 (m); HRMS (EI+): Exact mass calculated for C15H24O [M]+: 220.1827, found 




To a stirring solution of (1S,6S,7S,8R)-8-Butyl-7-(formylmethyl)bicyclo[4.3.0]non-3-ene 17 
(300 mg, 1.36 mmol, 1.0 equiv.) in dry MeOH (15 mL) at 0 °C was added solid K2CO3 (451 
mg, 3.27 mmol, 2.4 equiv.) in one portion and Ohira-Bestmann reagent (10% w/w in MeCN, 
4.9 mL, 3.9 g, 2.05 mmol, 1.5 equiv.). The suspension was then warmed to room temperature 
and left stirring overnight. After analysis by TLC the mixture was treated with sat. aq. 
NaHCO3 (20 mL), and the resulting mixture poured over CH2Cl2 (20 mL). The organic phase 
was separated and the aqueous phase was washed with CH2Cl2 (3 x 10 mL). The organic 
phases were then combined, dried over Na2SO4, filtered and concentrated in vacuo to afford a 
crude oil. This was purified by column chromatography on silica (nhexane/EtOAc, 95:5) to 
afford title compound as a colourless oil. Yield: 253 mg, (86%); [!]!!" -16.95° (c = 8.0, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.73-5.66 (m, 2H), 2.28 (dd, J = 2.6, 5.9 Hz, 2H), 
2.23-2.08 (m, 3H), 1.97-1.79 (m, 5H), 1.70-1.53 (m, 2H), 1.44-1.38 (m, 1H), 1.36-1.16 (m, 
5H), 1.13-1.06 (m, 1H), 0.90 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ; 126.4, 
126.0, 83.6, 68.6, 49.0, 43.5, 40.6, 38.2, 36.6, 34.8, 30.9, 28.1, 27.0, 22.9, 22.3, 14.1; IR 
(neat, cm-1) 3310 (m), 3021 (m), 2954 (s), 2915 (s), 1657 (w), 1465 (m), 1435 (m); HRMS 
(EI+): Exact mass calculated for C16H24 [M]+: 216.1878, found 216.1870; TLC (nhexane, 













To a stirring solution of Cp2ZrCl2 (95 mg, 0.324 mmol, 2.0 equiv.) in dry THF (2 ml) at 0 °C 
was added DIBAL-H (1M in nhexane) (0.32 mL, 0.324 mmol, 2.0 equiv.) via dropwise 
addition. The resulting homogenous mixture was then protected from light and stirred at 0 °C 
for 1 h after which time a colourless heterogeneous mixture formed. Then (1S,6S,7S,8R)-8-
butyl-7-(prop-2'-yn-1'-yl)bicyclo[4.3.0]non-3-ene 18 (35 mg, 0.162 mmol, 1.0 equiv.) 
dissolved in dry THF (2 mL) was added dropwise to the reaction mixture at 0 °C. After 1 h at 
0 °C iodine (63 mg, 0.248 mmol, 1.5 equiv.) was added in one portion to the homogeneous 
yellow reaction mixture. The reaction mixture was then warmed to room temperature and 
stirred for 1 h. To the preformed vinyl iodide was successively added 4-ethoxy-4-
oxobutylzinc bromide solution (0.5M in THF) (0.648 mL, 0.324 mmol, 2.0 equiv.) dropwise 
and (Ph3P)4Pd (19 mg, 0.016 mmol, 0.01 equiv.) in one portion. The resulting tea brown 
mixture was stirred at room temperature for 1 h and monitored by TLC. Once the reaction 
had gone to completion 1M HCl (10 mL) was added dropwise and the reaction poured over 
Et2O (15 mL). The aqueous phase was extracted with Et2O (3 x 15 mL) and the organic 
phases combined, dried over MgSO4, filtered and concentrated in vacuo to form a crude 
brown oily mixture. This oily mixture was purified by column chromatography on silica 
(nhexane/EtOAc, 95:5) to afford the title compound as a colourless oil. Yield: 27 mg, (51%); 
[!]!!" -11.15° (c = 2.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.70-5.64 (m, 2H), 5.47-5.33 
(m, 2H), 4.13 (q, J = 7.1 Hz, 2 H), 2.29 (t, J = 7.5 Hz, 2H), 2.22-2.15 (m, 1H), 2.12- 2.01 (m, 
6H), 1.89-1.76 (m, 3H), 1.73-1.66 (m, 3H), 1.53-1.47 (m, 2H), 1.34-1.16 (m, 9H), 1.12-1.04 
(m, 1H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.8, 130.3, 129.9, 126.2, 
126.1, 60.2, 51.0, 44.0, 40.3, 38.1, 37.7, 37.1, 34.9, 33.7, 31.9 31.0, 27.8, 27.7, 24.8, 22.9, 
14.2, 14.1; IR (neat, cm-1) 3021 (m), 2920 (s), 1734 (s), 1657 (w), 1438 (m); HRMS (EI+): 
Exact mass calculated for C22H36O2 [M]+: 332.2715, found 332.2722; TLC (nhexane/EtOAc 











To a stirring solution of the (1S,6S,7S,8R)-8-butyl-7-((E)-7'-ethoxy-7'-oxohept-2'-
enyl)bicyclo[4.3.0]non-3-ene 18 (27 mg, 0.081 mmol, 1.0 equiv.) in THF/MeOH/H2O (2:2:1) 
(5 mL) at room temperature was added lithium hydroxide monohydrate (119 mg, 2.84 mmol, 
35.0 equiv.) in one portion. The reaction mixture was left stirring and monitored by TLC. 
After 3 h the reaction had gone to completion and was acidified to pH 2 by 1M HCl (5 mL). 
The reaction mixture was then poured over EtOAc (5 mL) and the aqueous phase extracted 
with EtOAc (3 x 5 mL). The organic phases were then combined and washed with brine (1 x 
20 mL), dried over MgSO4, filtered and concentrated in vacuo to form a colourless oil. This 
was then purified by column chromatography on silica (nhexane/EtOAc, 3:2) to afford the 
title compound as a colourless oil. Yield: 24 mg, (97%); [!]!!" -10.19° (c = 2.0, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 11.24 (br, 1H), 5.71-5.64 (m, 2H), 5.48-5.33 (m, 2H), 2.35 (t, J = 
7.5 Hz, 2H), 2.23-2.14 (m, 1H), 2.13-2.02 (m, 6H), 1.89-1.75 (m, 3H), 1.73-1.65 (m, 3H), 
1.55-1.44 (m, 2H), 1.36-1.15 (m, 6H), 1.12-1.05 (m, 1H), 0.89 (t, J = 6.7 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 180.3, 130.6, 129.7, 126.2, 126.0, 51.0, 44.0, 40.3, 38.1, 37.7, 37.1, 
34.9, 33.3, 31.8, 31.0, 27.8, 27.7, 24.4, 22.9, 14.1; IR (neat, cm-1) 3021 (m), 2920 (s), 1708 
(s), 1457 (m), 1436 (m), 1412 (m); HRMS (EI+): Exact mass calculated for C20H32O2 [M]+: 




To a stirring solution of (1S,6S,7S,8R)-8-butyl-7-((E)-7'-hydroxy-7'-oxohept-2'-
enyl)bicyclo[4.3.0]non-3-ene 1 (24 mg, 0.079 mmol, 1.0 equiv.) in toluene/MeOH (3:2) (5 












0.119 mmol, 1.5 equiv.) dropwise over 2 min. The reaction mixture bubbled and turned 
transparent yellow. The reaction was monitored by TLC and after 1 h had gone to 
completion. The reaction mixture was then concentrated in vacuo and directly purified by 
column chromatography on silica (nhexane/EtOAc, 95:5) to afford the title compound as a 
colourless oil. Yield: 23 mg, (92%); [!]!!" -9.8° (c = 0.8, nhexane); 1H NMR (400 MHz, 
CDCl3) δ 5.70-5.64 (m, 2H), 5.46-5.33 (m, 2H), 3.67 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 2.22-
2.15 (m, 1H), 2.12-2.01 (m, 6H), 1.89-1.75 (m, 3H), 1.73-1.65 (m, 3H), 1.54-1.44 (m, 2H), 
1.34-1.16 (m, 6H), 1.12-1.04 (m, 1H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ; 174.2, 130.4, 129.9, 126.3, 126.1, 51.4, 51.0, 44.0, 40.3, 38.1, 37.7, 37.1, 34.9, 33.4, 31.9, 
31.0, 27.8, 27.7, 24.8, 22.9, 14.1; IR (neat, cm-1) 3020 (w), 2952 (m), 2923 (s), 1741 (s), 1657 
(w), 1603 (w), 1541 (w), 1508 (w), 1458 (m), 1436 (m); HRMS (EI+): Exact mass calculated 












Figure S-13 1H-NMR spectrum of compound 12. 
 
 
Figure S-14 13C-NMR spectrum of compound 12. 
	 S26	 	
	
Figure S-15 1H-NMR spectrum of compound 13. 
 
 
Figure S-16 13C-NMR spectrum of compound 13. 
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Figure S-17 1H-NMR spectrum of compound 14. 
 
 
Figure S-18 13C-NMR spectrum of compound 14. 
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Figure S-19 1H-NMR spectrum of compound 15. 
	
	
Figure S-20 13C-NMR spectrum of compound 15. 
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Figure S-21 1H-NMR spectrum of compound 16. 
	
	
Figure S-22 13C-NMR spectrum of compound 22. 
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Figure S-23 1H-NMR spectrum of compound pre-17a. 
	
	
Figure S-24 13C-NMR spectrum of compound pre-17a. 
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Figure S-25 1H-NMR spectrum of compound pre-17b. 
	
	
Figure S-26 13C-NMR spectrum of compound pre-17b. 
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Figure S-27 1H-NMR spectrum of compound 17. 
 
 
Figure S-28 13C-NMR spectrum of compound 17. 
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Figure S-29 1H-NMR spectrum of compound 18. 
 
 
Figure S-30 13C-NMR spectrum of compound 18. 
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Figure S-31 1H-NMR spectrum of compound 19. 
 
 
Figure S-32 13C-NMR spectrum of compound 19. 
	 S35	 	
	
Figure S-33 1H-NMR spectrum of compound 1. 
 
 
Figure S-34 13C-NMR spectrum of compound 1. 
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Figure S-35 1H-NMR spectrum of compound 2. 
 
 
Figure S-36 13C-NMR spectrum of compound 2. 
	












Figure S-39 HRMS of compound 12. 
 
 

















Figure S-41 HRMS of compound 14. 
 
 















Figure S-43 HRMS of compound 16. 
 
 













Figure S-45 HRMS of compound pre-17b. 
 
 














Figure S-47 HRMS of compound 18. 
 
 












Figure S-49 HRMS of compound 1. 
 
 












Figure S-51 IR of compound 12. 
 
 

















Figure S-53 IR of compound 14. 
 
 


















Figure S-55 IR of compound 16. 
 
 
















Figure S-57 IR of compound pre-17b. 
 
 
















Figure S-59 IR of compound 18. 
 
 














Figure S-61 IR of compound 1. 
 
 













Figure S-63 Chiral GLC of compound 16. 
=====================================================================
Acq. Operator   : SYSTEM                       
Sample Operator : SYSTEM                       
Acq. Instrument : 7820 GC                         Location : Vial 1
Injection Date  : 5/2/2016 15:28:06            
                                                Inj Volume : Manually
Method          : C:\CHEM32\1\METHODS\CP7502\CP7502.M
Last changed    : 5/2/2016 14:05:55 by SYSTEM
Sample Info     : 80 grader 30 min, 3 grader/min til 150 grader, 5 min hold time
 
Additional Info : Peak(s) manually integrated
























                      External Standard Report                       
=====================================================================
 
Sorted By             :      Signal
Calib. Data Modified  :      Tuesday, August 20, 201311:04:49
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
 
Signal 1: FID1 B, Back Signal
 
RetTime  Type     Area     Amt/Area    Amount   Grp   Name
 [min]          [pA*s]                [ng/ul]  
-------|------|----------|----------|----------|--|------------------
  3.710            -          -          -         tridekan                                          
  4.351            -          -          -         tetradekan                                        
  4.970            -          -          -         pentadekan                                        
  5.557            -          -          -         hexadekan                                         
 
Totals :                                0.00000
 
Data File C:\CHEM32\1\DATA\TEST\STD TEST303.D
Sample Name: RAC








Figure S-64 Report from chiral GLC of compound 16. 
 1 Warnings or Errors :
 




                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Calib. Data Modified  :      Tuesday, August 20, 201311:04:49
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: FID1 B, Back Signal
 
Peak RetTime  Type   Width     Area      Area    Name
  #   [min]          [min]   [pA*s]        %
----|-------|------|-------|----------|--------|---------------------
   1   3.710         0.0000    0.00000  0.00000 tridekan                                          
   2   4.351         0.0000    0.00000  0.00000 tetradekan                                        
   3   4.970         0.0000    0.00000  0.00000 pentadekan                                        
   4   5.557         0.0000    0.00000  0.00000 hexadekan                                         
   5  39.264 MM      0.4356 2580.60645 1.000e2  ?                                                 
 
Totals :                    2580.60645
 
 
1 Warnings or Errors :
 
Warning : Calibrated compound(s) not found
 
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\TEST\STD TEST303.D
Sample Name: RAC
7820 GC 5/2/2016 16:37:50 SYSTEM Page 2 of 2
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Figure S-65 Chiral GLC of compound rac-16. 
=====================================================================
Acq. Operator   : SYSTEM                       
Sample Operator : SYSTEM                       
Acq. Instrument : 7820 GC                         Location : Vial 1
Injection Date  : 5/10/2016 14:46:51           
                                                Inj Volume : Manually
Method          : C:\CHEM32\1\METHODS\CP7502\CP7502.M
Last changed    : 5/2/2016 14:05:55 by SYSTEM
Sample Info     : 80 grader 30 min, 3 grader/min til 150 grader, 5 min hold time
 
Additional Info : Peak(s) manually integrated


































                      External Standard Report                       
=====================================================================
 
Sorted By             :      Signal
Calib. Data Modified  :      Tuesday, August 20, 201311:04:49
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
 
Signal 1: FID1 B, Back Signal
 
RetTime  Type     Area     Amt/Area    Amount   Grp   Name
 [min]          [pA*s]                [ng/ul]  
-------|------|----------|----------|----------|--|------------------
  3.710            -          -          -         tridekan                                          
  4.351            -          -          -         tetradekan                                        
  4.970            -          -          -         pentadekan                                        
  5.557            -          -          -         hexadekan                                         
 
Totals :                                0.00000
 
Data File C:\CHEM32\1\DATA\TEST\STD TEST309.D
Sample Name: Rac fort 1:5








Figure S-66 Report from chiral GLC of compound rac-16. 
 1 Warnings or Errors :
 




                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Calib. Data Modified  :      Tuesday, August 20, 201311:04:49
Multiplier            :      1.0000
Dilution              :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: FID1 B, Back Signal
 
Peak RetTime  Type   Width     Area      Area    Name
  #   [min]          [min]   [pA*s]        %
----|-------|------|-------|----------|--------|---------------------
   1   3.710         0.0000    0.00000  0.00000 tridekan                                          
   2   4.351         0.0000    0.00000  0.00000 tetradekan                                        
   3   4.970         0.0000    0.00000  0.00000 pentadekan                                        
   4   5.557         0.0000    0.00000  0.00000 hexadekan                                         
   5  38.968 MM      0.4812 3572.11621 49.93671 ?                                                 
   6  39.949 MM      0.5835 3581.17065 50.06329 ?                                                 
 
Totals :                    7153.28687
 
 
1 Warnings or Errors :
 
Warning : Calibrated compound(s) not found
 
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\TEST\STD TEST309.D
Sample Name: Rac fort 1:5
7820 GC 5/10/2016 15:48:48 SYSTEM Page 2 of 2
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Preparation 3,5-dinitrobenzoate derivative of (16). 
 





A stirring solution of (1S,6S,7S,8R)-8-butyl-7-(hydroxymethyl)bicyclo[4.3.0]non-3-ene 16 
(120 mg, 0.577 mmol, 1.0 equiv.) in dry DCM (10 mL) was added Et3N (0.241 mL, 1.73 
mmol, 3.0 equiv.) dropwise. The solution was then cooled to 0 °C and 3,5-dinitrobenzoyl 
chloride (173 mg, 0.75 mmol, 1.3 equiv.) was added in one portion. The reaction was slowly 
warmed to room temperature and monitored by TLC until completion. After 2h, the reaction 
mixture was poured over H2O (10 mL) and the organic layer separated. The aqueous layer 
was then extracted with DCM (2 x 10 mL) and the organic layers combined. The organic 
layers were then washed with H2O (1 x 30 mL), brine (1 x 30 mL), dried with MgSO4, 
filtered and concentrated in vacuo to form a crude orange oil. This was purified by column 
chromatography on silica (nhexane/EtOAc, 95:5) to afford the title compound as a slightly 
off-white powder. Yield: 185 mg, (82%), [!]!!" -3.67 (c = 0.1, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 9.25-9.24 (m, 1H), 9.16-9.15 (m, 2H), 5.74-5.67 (m, 2H), 4.45-4.37 (m, 2H), 2.27-
2.14 (m, 3H), 2.01-1.90 (m, 4H), 1.85-1.79 (m, 1H), 1.74-1.68 (m, 1H), 1.66-1.60 (m, 1H), 
1.42-1.19 (m, 6H), 0.89-0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 162.6, 148.6, 134.1, 
129.3 (2C), 126.2, 125.2, 122.3, 69.7, 50.0, 41.8, 38.7, 37.7, 37.2, 35.1, 30.9, 27.4, 27.3, 22.8, 
14.0; IR (neat, cm-1) 3012 (m), 3022 (m), 2922 (s), 1728 (s), 1628 (m), 1597 (w), 1540 (s), 
1460 (m); HRMS (EI+): Exact mass calculated for C21H26N2O6 [M]+: 402.1791, found 

























Figure S-67 1H-NMR spectrum of compound 16-DNB. 
 
Figure S-68 13C-NMR spectrum of compound 16-DNB. 
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Figure S-69 HRMS spectrum of compound 16-DNB. 
 
 































Figure S-71 Single crystal X-ray structure of the 3,5-dinitrobenzoate of alcohol 16 at 110 K. 
The disordered nbutyl group (H-atoms omitted) has a major orientation [occupancy 0.74(3)] 
with trans,trans,gauche+ torsion angles along C9-C10-C18-C19-C20-C21, while the minor 
orientation (atoms in lighter tone) is trans,gauche–,gauche–. 
 
Table S-1 Crystal Data for 16-DNB.* 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
                                                                     (I) 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
Crystal data 
Chemical Formula                                       C21H26N2O6 
Mr                                                                402.44 
Crystal system, Space Group                       Monoclinic, P21 
a (Å)                                                           10.866(5) 
b (Å)                                                           5.196(2) 
c (Å)                                                           18.617(10) 
ß (°)                                                            106.703(11) 
V (Å3)                                                         1006.8(9) 
Z                                                                 2 
Radiation                                                   Mo Kα 
Wavelength (Å)                                         0.71073 
µ (mm−1)                                                   0.098 
Temperature (K)                                       110(2) 
	 S58	 	
Crystal Size (mm)                                                              0.21 × 0.19 × 0.01 
Tmin, Tmax                                                                           0.692, 1.000 
No. of Measured, Independent and Observed [I > 2σ(I)] Reflections              5899, 2089, 1718 
Rint                                                                                 0.140 
θmax (°)                                                                         20.86 
Refinement R[F2 > 2σ(F2)], wR(F2), S                        0.085, 0.225, 1.03 
No. of Reflections                                                        2089 
No. of Parameters                                                          278 
Δρmax, Δρmin (e Å−3)                                              0.30, −0.28 
CCDC                                                                    1484546 
 
*Bruker D8 Venture diffractometer with InCoatec ImuS Microfocus radiation source and 
Photon 100 CMOS detector. Data collection with Apex2,1 data integration and cell 
refinement with SAINT,1 absorption correction by SADABS,1 structure solution with 




























First total synthesis of mucosin based on its structural assignment
Harrison C. Gallantree-Smith, Simen. G Antonsen, Carl Henrik Görbitz,* Trond V. Hansen, Jens M. J. Nolsøe
and Yngve H. Stenstrøm
Experimental
Very fragile, small platelets were obtained by slow evaporation from a methanol/pentane mixture.
Refinement
Two disorder positions, with occupancies 0.74 (3) and 0.26 (3) were refined for the C18—C21 n-butyl group attached to
C10. Their covalent geometries were restrained by a SHELXL SAME 0.004 0.008 command, additional restraints were
imposed on the C—C bond lengthes in this substituent. Corresponmding atoms in the two conformations shared the same






a = 10.866 (5) Å
b = 5.196 (2) Å
c = 18.617 (10) Å
β = 106.703 (11)°
V = 1006.8 (9) Å3
Z = 2
F(000) = 428
Dx = 1.327 Mg m−3
Mo Kα radiation, λ = 0.71073 Å
Cell parameters from 2295 reflections
θ = 2.3–20.9°
µ = 0.10 mm−1
T = 110 K
Plate, colourless
0.21 × 0.19 × 0.01 mm
Data collection
Bruker D8 Venture with Photon 100 CMOS detector 
diffractometer
Radiation source: InCoatec ImuS Microfocus
Graphite monochromator
Detector resolution: 8.3 pixels mm-1
Sets of exposures each taken over 0.5° ω rotation
scans
Absorption correction: multi-scan 
SADABS (Bruker, 2014)
Tmin = 0.692, Tmax = 1.000
5899 measured reflections
2089 independent reflections
1718 reflections with I > 2σ(I)
Rint = 0.214













Primary atom site location: structure-invariant direct
methods
Secondary atom site location: difference Fourier map
Hydrogen site location: inferred from neighbouring
sites
H-atom parameters constrained
w = 1/[σ2(Fo2) + (0.0936P)2 + 2.6032P] 











































Δρmax = 0.30 e Å−3
Δρmin = −0.28 e Å−3
Special details
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The
cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds
in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used
for estimating esds involving l.s. planes.
Refinement. Two disorder positions refined for n-butyl group attached to C10. Occupancies 0.74 (3) and 0.26 (3).
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
x y z Uiso*/Ueq Occ. (<1)
O1 0.4965 (7) 0.0115 (19) 0.3931 (4) 0.034 (2)
N1 0.7700 (10) 0.288 (2) 0.6525 (7) 0.034 (3)
C1 0.5467 (10) 0.212 (3) 0.3832 (7) 0.023 (3)
O2 0.5244 (7) 0.3323 (19) 0.3180 (5) 0.032 (2)
N2 0.8755 (9) 0.896 (2) 0.4771 (7) 0.025 (2)
C2 0.6411 (11) 0.353 (3) 0.4451 (7) 0.028 (3)
O3 0.7262 (8) 0.077 (2) 0.6594 (5) 0.040 (2)
C3 0.6602 (11) 0.265 (2) 0.5163 (7) 0.028 (3)
H31 0.6121 0.1220 0.5254 0.033*
C4 0.7491 (10) 0.382 (3) 0.5752 (6) 0.025 (3)
O4 0.8317 (8) 0.420 (2) 0.7046 (5) 0.044 (2)
C5 0.8206 (10) 0.596 (2) 0.5648 (7) 0.024 (3)
H51 0.8798 0.6815 0.6053 0.029*
O5 0.9445 (7) 1.0018 (19) 0.5311 (5) 0.039 (2)
C6 0.7990 (10) 0.672 (2) 0.4921 (7) 0.021 (3)
O6 0.8619 (7) 0.9540 (18) 0.4128 (5) 0.036 (2)
C7 0.7120 (10) 0.562 (2) 0.4316 (6) 0.023 (3)
H71 0.7003 0.6265 0.3823 0.028*
C8 0.4292 (12) 0.208 (3) 0.2553 (7) 0.036 (3)
H81 0.3491 0.1772 0.2692 0.044*
H82 0.4626 0.0397 0.2445 0.044*
C12 0.3164 (15) 0.342 (3) 0.0499 (8) 0.055 (4)
H121 0.3329 0.1800 0.0253 0.066*
C13 0.2879 (13) 0.270 (3) 0.1245 (7) 0.041 (4)
H131 0.2890 0.0776 0.1285 0.049*
C14 0.1617 (12) 0.364 (3) 0.1326 (8) 0.046 (4)
H141 0.0929 0.2417 0.1076 0.055*
H142 0.1663 0.3703 0.1865 0.055*
C15 0.1292 (13) 0.625 (3) 0.0990 (9) 0.050 (4)
H151 0.0928 0.7505 0.1241 0.059*
C16 0.1501 (12) 0.682 (3) 0.0365 (10) 0.049 (4)
H161 0.1334 0.8508 0.0167 0.059*
C17 0.2006 (14) 0.483 (3) −0.0052 (8) 0.053 (4)
H171 0.2286 0.5653 −0.0458 0.063*
H172 0.1321 0.3573 −0.0281 0.063*
C9 0.4010 (11) 0.375 (3) 0.1869 (7) 0.032 (3) 0.74 (3)
H91 0.3797 0.5522 0.2003 0.038* 0.74 (3)
C11 0.4409 (12) 0.494 (3) 0.0739 (8) 0.048 (4) 0.74 (3)










































H112 0.4911 0.4696 0.0377 0.058* 0.74 (3)
C10 0.5144 (12) 0.391 (4) 0.1509 (8) 0.044 (4) 0.74 (3)
H10 0.5419 0.2108 0.1440 0.053* 0.74 (3)
C18 0.6307 (14) 0.537 (6) 0.1938 (9) 0.060 (6) 0.74 (3)
H181 0.6668 0.4529 0.2431 0.072* 0.74 (3)
H182 0.6039 0.7130 0.2033 0.072* 0.74 (3)
C19 0.7354 (15) 0.558 (7) 0.1554 (11) 0.084 (7) 0.74 (3)
H191 0.7465 0.3889 0.1335 0.101* 0.74 (3)
H192 0.7092 0.6839 0.1139 0.101* 0.74 (3)
C20 0.8620 (16) 0.641 (4) 0.2089 (12) 0.067 (8) 0.74 (3)
H201 0.8470 0.8021 0.2333 0.081* 0.74 (3)
H202 0.9211 0.6827 0.1787 0.081* 0.74 (3)
C21 0.932 (4) 0.453 (7) 0.271 (2) 0.096 (13) 0.74 (3)
H211 1.0170 0.5212 0.2964 0.145* 0.74 (3)
H212 0.9403 0.2862 0.2482 0.145* 0.74 (3)
H213 0.8819 0.4328 0.3066 0.145* 0.74 (3)
C9B 0.4010 (11) 0.375 (3) 0.1869 (7) 0.032 (3) 0.26 (3)
H91B 0.3750 0.5474 0.2013 0.038* 0.26 (3)
C11B 0.4409 (12) 0.494 (3) 0.0739 (8) 0.048 (4) 0.26 (3)
H11B 0.4217 0.6809 0.0720 0.058* 0.26 (3)
H12B 0.4929 0.4588 0.0392 0.058* 0.26 (3)
C10B 0.5162 (13) 0.418 (5) 0.1535 (9) 0.044 (4) 0.26 (3)
H10B 0.5570 0.2473 0.1510 0.053* 0.26 (3)
C18B 0.619 (2) 0.598 (8) 0.1954 (11) 0.060 (6) 0.26 (3)
H18B 0.6533 0.5355 0.2476 0.072* 0.26 (3)
H19B 0.5803 0.7695 0.1975 0.072* 0.26 (3)
C19B 0.730 (3) 0.630 (9) 0.162 (3) 0.084 (7) 0.26 (3)
H20B 0.6960 0.6514 0.1073 0.101* 0.26 (3)
H21B 0.7786 0.7876 0.1829 0.101* 0.26 (3)
C20B 0.820 (3) 0.402 (9) 0.179 (3) 0.050* 0.26 (3)
H22B 0.8733 0.4081 0.1438 0.060* 0.26 (3)
H23B 0.7673 0.2438 0.1673 0.060* 0.26 (3)
C21B 0.911 (13) 0.37 (3) 0.258 (5) 0.096 (13) 0.26 (3)
H24B 0.9659 0.2227 0.2605 0.145* 0.26 (3)
H25B 0.8605 0.3521 0.2939 0.145* 0.26 (3)
H26B 0.9645 0.5281 0.2714 0.145* 0.26 (3)
Atomic displacement parameters (Å2)
U11 U22 U33 U12 U13 U23
O1 0.026 (4) 0.016 (5) 0.058 (6) −0.013 (4) 0.011 (4) −0.002 (4)
N1 0.017 (6) 0.025 (7) 0.061 (9) 0.008 (5) 0.014 (6) 0.009 (6)
C1 0.011 (5) 0.026 (5) 0.034 (6) 0.001 (5) 0.008 (4) 0.002 (5)
O2 0.020 (4) 0.027 (5) 0.047 (6) −0.008 (4) 0.005 (4) −0.005 (4)
N2 0.017 (4) 0.019 (5) 0.037 (5) 0.006 (4) 0.005 (4) 0.001 (5)
C2 0.021 (5) 0.023 (5) 0.037 (6) 0.004 (5) 0.005 (5) 0.000 (5)
O3 0.045 (5) 0.031 (6) 0.047 (6) −0.004 (5) 0.017 (5) 0.012 (4)
C3 0.024 (5) 0.023 (5) 0.038 (6) 0.006 (4) 0.013 (5) 0.004 (5)
C4 0.022 (5) 0.025 (5) 0.030 (6) 0.009 (5) 0.011 (5) 0.007 (5)
O4 0.039 (5) 0.043 (6) 0.043 (6) 0.002 (5) 0.000 (5) −0.012 (5)










































O5 0.023 (5) 0.024 (5) 0.073 (7) 0.001 (4) 0.019 (5) −0.007 (5)
C6 0.011 (5) 0.019 (5) 0.034 (6) 0.007 (4) 0.007 (4) 0.000 (4)
O6 0.021 (4) 0.026 (5) 0.062 (7) 0.001 (4) 0.013 (4) 0.015 (4)
C7 0.018 (5) 0.019 (5) 0.033 (6) 0.003 (4) 0.008 (5) 0.003 (5)
C8 0.029 (7) 0.028 (7) 0.051 (9) 0.006 (6) 0.009 (7) −0.006 (7)
C12 0.072 (12) 0.044 (9) 0.045 (9) 0.003 (9) 0.011 (9) −0.014 (7)
C13 0.057 (10) 0.018 (7) 0.044 (8) −0.005 (6) 0.009 (7) −0.010 (6)
C14 0.040 (8) 0.052 (9) 0.046 (9) −0.001 (7) 0.012 (7) −0.007 (8)
C15 0.045 (9) 0.042 (10) 0.059 (11) 0.004 (7) 0.011 (9) −0.001 (8)
C16 0.038 (9) 0.022 (8) 0.075 (12) −0.005 (7) −0.004 (8) 0.006 (8)
C17 0.067 (10) 0.029 (8) 0.057 (9) −0.006 (7) 0.010 (8) 0.000 (8)
C9 0.029 (7) 0.021 (7) 0.047 (8) 0.001 (6) 0.014 (7) 0.005 (7)
C11 0.035 (8) 0.060 (9) 0.057 (10) −0.008 (8) 0.023 (7) 0.002 (8)
C10 0.034 (8) 0.048 (9) 0.056 (10) 0.001 (7) 0.021 (8) 0.006 (8)
C18 0.029 (8) 0.089 (15) 0.071 (10) −0.013 (9) 0.028 (8) −0.007 (10)
C19 0.041 (10) 0.132 (19) 0.087 (13) −0.005 (12) 0.031 (9) 0.019 (13)
C20 0.026 (12) 0.099 (19) 0.078 (17) 0.002 (12) 0.016 (11) 0.021 (14)
C21 0.09 (2) 0.10 (3) 0.104 (19) 0.00 (2) 0.029 (14) 0.045 (19)
C9B 0.029 (7) 0.021 (7) 0.047 (8) 0.001 (6) 0.014 (7) 0.005 (7)
C11B 0.035 (8) 0.060 (9) 0.057 (10) −0.008 (8) 0.023 (7) 0.002 (8)
C10B 0.034 (8) 0.048 (9) 0.056 (10) 0.001 (7) 0.021 (8) 0.006 (8)
C18B 0.029 (8) 0.089 (15) 0.071 (10) −0.013 (9) 0.028 (8) −0.007 (10)
C19B 0.041 (10) 0.132 (19) 0.087 (13) −0.005 (12) 0.031 (9) 0.019 (13)
C21B 0.09 (2) 0.10 (3) 0.104 (19) 0.00 (2) 0.029 (14) 0.045 (19)
Geometric parameters (Å, º) for (I)
O1—C1 1.213 (14) C17—H171 0.9900
N1—O3 1.218 (13) C17—H172 0.9900
N1—O4 1.219 (12) C9—C10 1.565 (17)
N1—C4 1.474 (15) C9—H91 1.0000
C1—O2 1.326 (14) C11—C10 1.524 (18)
C1—C2 1.498 (16) C11—H111 0.9900
O2—C8 1.467 (14) C11—H112 0.9900
N2—O5 1.202 (11) C10—C18 1.495 (19)
N2—O6 1.202 (11) C10—H10 1.0000
N2—C6 1.502 (15) C18—C19 1.512 (17)
C2—C3 1.361 (16) C18—H181 0.9900
C2—C7 1.397 (16) C18—H182 0.9900
C3—C4 1.377 (16) C19—C20 1.51 (2)
C3—H31 0.9500 C19—H191 0.9900
C4—C5 1.403 (15) C19—H192 0.9900
C5—C6 1.364 (16) C20—C21 1.53 (2)
C5—H51 0.9500 C20—H201 0.9900
C6—C7 1.368 (15) C20—H202 0.9900
C7—H71 0.9500 C21—H211 0.9800
C8—C9 1.497 (17) C21—H212 0.9800
C8—H81 0.9900 C21—H213 0.9800
C8—H82 0.9900 C10B—C18B 1.50 (2)
C12—C11 1.52 (2) C10B—H10B 1.0000










































C12—C17 1.558 (19) C18B—H18B 0.9900
C12—H121 1.0000 C18B—H19B 0.9900
C13—C14 1.504 (19) C19B—C20B 1.51 (2)
C13—C9 1.530 (17) C19B—H20B 0.9900
C13—H131 1.0000 C19B—H21B 0.9900
C14—C15 1.49 (2) C20B—C21B 1.53 (2)
C14—H141 0.9900 C20B—H22B 0.9900
C14—H142 0.9900 C20B—H23B 0.9900
C15—C16 1.28 (2) C21B—H24B 0.9800
C15—H151 0.9500 C21B—H25B 0.9800
C16—C17 1.49 (2) C21B—H26B 0.9800
C16—H161 0.9500
O3—N1—O4 124.5 (11) C13—C9—C10 104.6 (10)
O3—N1—C4 116.4 (11) C8—C9—H91 109.0
O4—N1—C4 119.0 (10) C13—C9—H91 109.0
O1—C1—O2 125.0 (11) C10—C9—H91 109.0
O1—C1—C2 122.8 (11) C12—C11—C10 105.9 (11)
O2—C1—C2 112.2 (10) C12—C11—H111 110.5
C1—O2—C8 114.9 (9) C10—C11—H111 110.5
O5—N2—O6 125.9 (10) C12—C11—H112 110.5
O5—N2—C6 116.5 (10) C10—C11—H112 110.5
O6—N2—C6 117.7 (10) H111—C11—H112 108.7
C3—C2—C7 120.0 (11) C18—C10—C11 117.2 (12)
C3—C2—C1 117.6 (11) C18—C10—C9 116.5 (11)
C7—C2—C1 122.3 (11) C11—C10—C9 99.0 (10)
C2—C3—C4 120.2 (11) C18—C10—H10 107.8
C2—C3—H31 119.9 C11—C10—H10 107.8
C4—C3—H31 119.9 C9—C10—H10 107.8
C3—C4—C5 122.0 (11) C10—C18—C19 114.7 (13)
C3—C4—N1 120.6 (11) C10—C18—H181 108.6
C5—C4—N1 117.5 (10) C19—C18—H181 108.6
C6—C5—C4 115.0 (10) C10—C18—H182 108.6
C6—C5—H51 122.5 C19—C18—H182 108.6
C4—C5—H51 122.5 H181—C18—H182 107.6
C5—C6—C7 125.3 (10) C20—C19—C18 112.0 (14)
C5—C6—N2 117.5 (10) C20—C19—H191 109.2
C7—C6—N2 117.2 (10) C18—C19—H191 109.2
C6—C7—C2 117.5 (11) C20—C19—H192 109.2
C6—C7—H71 121.2 C18—C19—H192 109.2
C2—C7—H71 121.2 H191—C19—H192 107.9
O2—C8—C9 110.3 (10) C19—C20—C21 118 (2)
O2—C8—H81 109.6 C19—C20—H201 107.8
C9—C8—H81 109.6 C21—C20—H201 107.8
O2—C8—H82 109.6 C19—C20—H202 107.8
C9—C8—H82 109.6 C21—C20—H202 107.8
H81—C8—H82 108.1 H201—C20—H202 107.1
C11—C12—C13 104.7 (10) C20—C21—H211 109.5
C11—C12—C17 115.6 (12) C20—C21—H212 109.5
C13—C12—C17 111.8 (12) H211—C21—H212 109.5










































C13—C12—H121 108.2 H211—C21—H213 109.5
C17—C12—H121 108.2 H212—C21—H213 109.5
C14—C13—C9 111.3 (10) C18B—C10B—H10B 107.8
C14—C13—C12 115.6 (11) C10B—C18B—C19B 114.8 (15)
C9—C13—C12 105.6 (11) C10B—C18B—H18B 108.6
C14—C13—H131 108.0 C19B—C18B—H18B 108.6
C9—C13—H131 108.0 C10B—C18B—H19B 108.6
C12—C13—H131 108.0 C19B—C18B—H19B 108.6
C15—C14—C13 111.5 (12) H18B—C18B—H19B 107.5
C15—C14—H141 109.3 C20B—C19B—C18B 112.1 (16)
C13—C14—H141 109.3 C20B—C19B—H20B 109.2
C15—C14—H142 109.3 C18B—C19B—H20B 109.2
C13—C14—H142 109.3 C20B—C19B—H21B 109.2
H141—C14—H142 108.0 C18B—C19B—H21B 109.2
C16—C15—C14 120.3 (14) H20B—C19B—H21B 107.9
C16—C15—H151 119.9 C19B—C20B—C21B 118 (2)
C14—C15—H151 119.9 C19B—C20B—H22B 107.8
C15—C16—C17 120.2 (13) C21B—C20B—H22B 107.8
C15—C16—H161 119.9 C19B—C20B—H23B 107.8
C17—C16—H161 119.9 C21B—C20B—H23B 107.8
C16—C17—C12 109.4 (11) H22B—C20B—H23B 107.1
C16—C17—H171 109.8 C20B—C21B—H24B 109.5
C12—C17—H171 109.8 C20B—C21B—H25B 109.5
C16—C17—H172 109.8 H24B—C21B—H25B 109.5
C12—C17—H172 109.8 C20B—C21B—H26B 109.5
H171—C17—H172 108.3 H24B—C21B—H26B 109.5
C8—C9—C13 111.3 (10) H25B—C21B—H26B 109.5
C8—C9—C10 113.6 (10)
O1—C1—O2—C8 1.1 (15) C17—C12—C13—C9 −128.2 (11)
C2—C1—O2—C8 −178.0 (8) C9—C13—C14—C15 83.5 (14)
O1—C1—C2—C3 −6.8 (16) C12—C13—C14—C15 −37.0 (16)
O2—C1—C2—C3 172.3 (10) C13—C14—C15—C16 40.9 (18)
O1—C1—C2—C7 170.7 (10) C14—C15—C16—C17 3 (2)
O2—C1—C2—C7 −10.2 (14) C15—C16—C17—C12 −47.5 (18)
C7—C2—C3—C4 0.2 (16) C11—C12—C17—C16 −74.5 (15)
C1—C2—C3—C4 177.7 (10) C13—C12—C17—C16 45.1 (15)
C2—C3—C4—C5 1.2 (16) O2—C8—C9—C13 −171.4 (9)
C2—C3—C4—N1 179.8 (10) O2—C8—C9—C10 70.8 (13)
O3—N1—C4—C3 14.6 (14) C14—C13—C9—C8 86.1 (13)
O4—N1—C4—C3 −167.3 (10) C12—C13—C9—C8 −147.7 (10)
O3—N1—C4—C5 −166.7 (9) C14—C13—C9—C10 −150.8 (11)
O4—N1—C4—C5 11.4 (14) C12—C13—C9—C10 −24.6 (13)
C3—C4—C5—C6 −2.4 (14) C13—C12—C11—C10 29.4 (14)
N1—C4—C5—C6 179.0 (9) C17—C12—C11—C10 152.9 (12)
C4—C5—C6—C7 2.5 (15) C12—C11—C10—C18 −169.6 (13)
C4—C5—C6—N2 −178.4 (8) C12—C11—C10—C9 −43.5 (14)
O5—N2—C6—C5 −4.6 (13) C8—C9—C10—C18 −70.5 (16)
O6—N2—C6—C5 175.9 (9) C13—C9—C10—C18 167.9 (14)
O5—N2—C6—C7 174.6 (9) C8—C9—C10—C11 163.0 (11)










































C5—C6—C7—C2 −1.2 (15) C11—C10—C18—C19 −60 (2)
N2—C6—C7—C2 179.6 (8) C9—C10—C18—C19 −177.4 (19)
C3—C2—C7—C6 −0.2 (15) C10—C18—C19—C20 −164 (2)
C1—C2—C7—C6 −177.7 (10) C18—C19—C20—C21 68 (4)
C1—O2—C8—C9 173.8 (9) C9B—C10B—C18B—C19B 178 (2)
C11—C12—C13—C14 121.2 (13) C10B—C18B—C19B—C20B −76 (4)
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a b s t r a c t
Starting from eicosapentaenoic acid (EPA) and D-alanine, the first synthesis of (2R, 3S)-crucigasterin 277,
a polyunsaturated C-18 amino alcohol from the Mediterranean tunicate, Pseudodistoma crucigaster, is
described.
! 2016 Elsevier Ltd. All rights reserved.
1. Introduction
The a-amino alcohol structural moiety is present in a large
number of naturally occurring compounds.1 Amino alcohols re-
lated to sphingosines have been isolated from marine organ-
isms,2 and several of these compounds have in common
a polyunsaturated carbon chain with methylene interrupted
double bonds, terminated by either one or two a-amino alcohol
residues.
Some years ago Rinehart and co-workers3 isolated two
polyunsaturated C-18 amino alcohols from the Mediterranean
tunicate, Pseudodistoma crucigaster. The compounds named cru-
cigasterin 277 (1) and 275 (2), shown in Fig. 1, exhibited mod-
erate cytotoxic and antimicrobial activity. All but one of the
double bonds of 1 have the Z-configuration, and at first glance it
seems that the compound is derived biosynthetically from D-al-
anine and an u-3 polyunsaturated fatty acid. The absolute con-
figuration was assigned based on comparison of a degradation
product with that of an authentic compound.4 The compounds 1
and 2 have not yet been synthesized. The present paper describes
the synthesis of crucigasterin 277 (1), starting from commercially
available N-Boc-protected D-alanine (3) and (all-Z)-eicosa-
5,8,11,14,17-pentaenoic acid (EPA, 4) (see Scheme 2).
2. Results and discussion
Retrosynthetic analysis suggested cleavage of the C3eC4 bond
in the target molecule 1 introducing chirality utilizing an a-amino
acid derivative as outlined in Scheme 1. In the synthesis it was
contemplated that this bond would be formed by reaction of the N-
Boc-protected aldehyde 5 derived from 3, with a carbanion equiv-
alent corresponding to the polyunsaturated C-15 residue. We





Fig. 1. Structures of crucigasterins.3
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envisioned that the latter could be obtained from 1-bromo-
2E,6Z,9Z,12Z-pentadecatetraene (6), a compound that is readily
available from EPA in better than 50% overall yield.5,6
A second approach to the target molecule would involve re-
action of the carbanion with the commercially available N-Boc-
protected reactive amide 7. This should afford the amino ketone
and subsequently the amino alcohol by reduction. A third way of
forming the C3eC4 bond involves reversal of polarities; the amino
ketone might be formed by reaction of the bromide 6 with the
carbanion derived either from the protected cyanohydrin 8 or the
thioacetal 9. Subsequent reduction should yield the target amino
alcohol. It was also observed that preparation of the compounds
with the stereogenic center a to a carbonyl group was problematic
due to fast racemization. The first alternative seemed the most
promising, particularly since it would lead directly to the N-Boc-
protected amino alcohol. It was anticipated that the protecting
group could be removed without problems.
The N-Boc-protected D-alaninal (5) is known in the literature,3,4
and several methods for the preparation 5 are reported. Accord-
ingly commercially available N-Boc-protected D-alanine was con-
verted to the methyl ester by standard conditions.3,4 Reduction of
the ester with DIBAL-H in THF at!78 "C furnished the aldehyde 5 in
moderate yield.4 The main problem with this reaction was the lack
of reproducibility with regard to optical purity because of racemi-
zation. A second approach involved the oxidation of commercially
available N-Boc-protected D-alaninol. Use of the Dess-Martin re-
agent furnished the aldehyde 5 in 80% yield, but with considerable
racemization, but switching to the Parikh-Doering oxidation
method gave N-Boc D-alaninal in excellent optical purity and
moderate to good yield.7 The optical purity was determined by
optical rotation and comparison with the literature value. The al-
dehyde was used immediately to avoid any racemization.
Having the precursors for the vicinal amino alcohol moiety in
place, we turned to the problem of transforming the bromide 6 into
a carbanion equivalent, corresponding to the C-15 polyunsaturated
residue.
We anticipated that the bromide 6 could be converted into the
corresponding Grignard, zinc or lithium derivatives, which are all
allylic carbanion equivalents. Reactions at both the a- and g-carbon
atoms were expected, the latter being actually the preferred re-
action mode with aldehydes,8 but examples of a preference have
been reported.9 Reaction of the bromide 6 with magnesium metal
in THF proceeded smoothly with partial consumption of the metal,
and was followed by addition of the aldehyde 5. However, the
product obtained consisted according to GLC analysis of essentially
Scheme 1. Retrosynthetic analysis for the synthesis of 1.
Scheme 2. Synthesis of crucigasterin 277.


















two compounds which we have tentatively assigned the dimeric
structures 10 and 11 (see Fig. 2). The same dimers were also the sole
products from reactions of the bromide with either zinc metal or
methyllithium. We were unable to separate the dimers by chro-
matography and the assignments are based on spectral data ob-
tained on the mixture. It has been reported1,11,12 that the use of
Rieke magnesium in this kind of reactions caused less Wurtz cou-
pling, but insignificant change was observed in the present case.
The Grignard type approach was abandoned and different ways
of generating the carbanion analog were explored.
It is well known that allylic a-sulfonyl carbanions react with
aldehydes at the a-carbon furnishing the straight chain com-
pound,13 usually as an erythro-threo product mixture. A reductive
elimination of the sulfonyl group should then provide the desired
alcohol 13 as outlined in Scheme 2.
The phenyl sulfone 12 was originally obtained in 58% overall
yield from reaction of the bromide 6 with thiophenol, followed by
oxidation of the intermediate sulfide with oxone, but subsequently
we found that the sulfone was formed in one step and higher yield
by reacting the same bromide with NaSO2Ph in DMF.14
The a-sulfonyl carbanion was generated in THF with n-butyl-
lithium at !78 "C, and the reaction with aldehyde 5 furnished the
N-Boc-protected amino alcohol 13 in 69% yield, as a mixture of four
stereoisomers. Only the two major isomers were obtained pure by
column chromatography, in 45% and 23% yield, respectively. Several
methods are known to reductively remove the phenylsulfonyl
group, but in the case of compound 13 the possibilities of elimi-
nation and double bond migration had to considered when
choosing a reagent. The use of sodium amalgamwas excluded (Julia
elimination) and magnesium metal elimination as well. On the
other hand, the palladium(II) catalyzed reduction with lithium
borohydride as reported by Kotake and co-workers appeared
successful.14e16
When the two pure isomers were reactedwith this constellation
of reagents, one single product was obtained in each case.
According to spectral data the compounds were the N-Boc amino
alcohols 14a and 14b, differing only in the configuration at C-3.
Based on the NMR data, we were unable to establish their absolute
configurations. However, according to the literature cis- and trans-
substituted isomers of 1,3-oxazolidines exhibit significantly differ-
ent values for the vicinal coupling constants of the protons at C-4
and C-5, the constant being smaller for the trans isomer.17 Hence,
the two diastereoisomers were converted with 2,2-
dimethoxypropane in the presence of PTSA in 74% yield to the
1,3-oxazolidines 15a and 15b, respectively. The NMR measure-
ments were hampered by the presence of rotamers at room tem-
perature, which was particularly apparent for the isomer 15a. This
is apparently a common phenomenon for 1,3-oxazolidines,18 and
the spectra were therefore recorded at about 60 "C, above the co-
alescence temperature. The vicinal coupling constants for the
protons at C-4 and C-5 of the ring were 5.0 Hz for isomer 15a and
6.3 Hz for isomer 15b. This result was certainly not conclusive, and
the spectra were further analyzed by NOESY experiments. They
showed for isomer 15a a correlation of the methylene protons at-
tached to C-4 and the methyl protons at C-5, while no correlation
was observed for 15b. This result was further confirmed by ROESY
experiments.
Reagents and conditions: i) PhSO2Na, DMF, 80 !C.;
ii), n-BuLi, THF, 0 !C, 5; i ) LiBH4, Pd(PPh3)2Cl2, e25 !C;
v) 2,2-dimethoxypropane, PTSA, PhH, D; v) 80% aq formic acid, 82%
(only on ).
It remained only to remove the protecting group of the (2R, 3 )
isomer 14a in order to complete the synthesis of crucigasterin 277
(1). This was expected to be a simple operation, but standard
conditions for deprotection, including reactions with either tri-
fluoroacetic acid or hydrochloric acid, caused partial isomerization
of the double bonds. However, the removal of the N-Boc group of
the isomer 14a was successfully achieved using 80% formic acid
giving crucigasterin 277 (1) in 82% yield. The diacetate was pre-
pared according to the procedure reported previously.3 The spec-
troscopic and physical data of both 1 and the corresponding
diacetate was in agreement with data reported by Rinehart and co-
workers3 and thus confirmed the absolute configuration of the
natural product.
3. Experimental section
The NMR spectra were recorded in CDCl3, with a Bruker Avance
DPX 200 or DPX 300 instruments. The IR spectra were obtained
with a PerkineElmer 1310 infrared spectrophotometer or a Nicolet
Magna-IR 550 spectrometer. Mass spectra were recorded at 70 eV
with a Fisons VG Pro spectrometer. Optical rotations were mea-
sured with a Perkin Elmer 241 Polarimeter. Optical purity was de-
termined using a Chrompack GC column: 3% OV 17 ON CHROM
WHP. All reactions were performed under a nitrogen or argon at-
mosphere. The synthesis of 6 has previously been described by our
group.5,19
3.1. N-Boc-D-Alaninal (5)
3.1.1. Method A. The compound was prepared from N-Boc-D-ala-
nine methyl ester, according to literature3 to give the D-alaninal
(39% total yield) as crystals. Mp 74e76 "C; [a]D25 ¼þ41 (c¼0.10,
MeOH) (lit.4 mp 76e78 "C and [a]D25 ¼þ40.8 (c¼1.10, MeOH)). 1H
NMR (300MHz, CDCl3) d 1.31 (d, J¼7.3 Hz, 3 H),1.43 (s, 9 H), 4.21 (m,
1 H), 5.17 (br s, 1 H, NH), 9.54 (s,1 H).
3.1.2. Method B. The compound was prepared from D-alaniol,
according to literature to give the D-alaninal in 63% yield as crys-
tals.7 Mp 75e77, [a]D25 ¼þ39 (c¼0.10, MeOH).
3.2. C-30 Hydrocarbons 10 and 11
A solution of the bromide 6 (0.64 g, 2.3 mmol) in dry ether
(4 mL) was added dropwise to a stirred mixture of magnesium
turnings (0.082 g, 3.4 mmol) and dry ether (1 mL). Once the re-
action had started, the remaining bromide solution was added
dropwise over a period of 20 min. After 2 h of gentle reflux, the
mixture was cooled to !50 "C. A solution of N-Boc D-alaninal (5)
(0.078 g, 0.45 mmol) in anhydrous THF (5 mL) was added. The
mixture was left stirring at ambient temperature for 1 h. The re-
action mixture was poured into a solution of 1 M aq NaH2PO4 and
extractedwith ether. The extract waswashedwith 1M aqNaH2PO4,
water, brine and dried (MgSO4). Evaporation of solvents followed
by flash chromatography (silica gel, 95:5 hexane/EtOAc) gave
a mixture of dimers 10 and 11 (0.60 g, 65%). m/z (EI): 406 (1.0), 108
(48), 93 (63), 79 (100), 67 (83), 41 (54); (HRMS: found:
Mþ406.3607, C30H46 requires 406.3600).
Fig. 2. Dimeric structures from Grignard reaction.



















3.3.1. Method A. To a stirred solution of LiOH!H2O(1.1 g,
26.2 mmol) and thiophenol (1.7 g, 15.5 mmol) in MeOH (130 mL)
was added, at room temperature, a solution of the bromide 6 (4.0 g,
14.1 mmol) in MeOH (20 mL). After stirring for 3 h at rt, water
(100 mL) was added and the mixture extracted with hexane. The
extract was washed with brine and dried (MgSO4). Evaporation of
solvents under reduced pressure followed by filtration through
a plug of silica (hexane as eluent) gave (2E, 6Z, 9Z, 12Z)-1-
Phenylthio-2,5,9,12-pentadecatetraene (4.1 g, 93%) as an oil. Rf
(20% EtOAc/hexane): 0.80; IR: 3011, 2962, 2931, 1652, 1585, 1480,
1452 cm"1; 1H NMR (300 MHz, CDCl3) d 0.95 (t, J¼7.5 Hz, 3 H),
2.03e2.21 (m, 6 H), 2.75e2.93 (m, 4 H), 3.43e3.52 (m, 2 H),
5.20e5.44 (m, 7 H), 5.45e5.55 (1 H), 7.17e7.25 (m, 1 H), 7.27e7.40
(m, 4 H); 13C NMR (75 MHz, CDCl3) d14.2 (CH3), 20.5, 25.5, 25.6,
26.8, 32.2, 36.4 (6!CH2), 125.4, 126.0, 127.0, 128.0, 128.2, 128.3
(6!CH]), 128.6 (2!CH]), 129.1 (CH]), 129.8 (2!CH]), 131.9,
133.5 (2!CH]), 136.2 (C]); m/z (EI) 312 (Mþ, 8%), 203 (22), 79
(100) (HRMS: found: Mþ 312,1919. C21H28S requires 312, 1912).
To an ice-cooled solution of the sulfide (4.0 g, 12.8 mmol) in
MeOH (30 mL) and dioxane (20 mL) was added dropwise an
aqueous solution of oxone (23.7 g, 38.4 mmol). Themixturewas left
stirring at rt overnight. Water (50 mL) was added and the mixture
extracted with CHCl3. The extract was washed with brine and dried
(MgSO4). Evaporation of solvents under reduced pressure followed
by flash chromatography (silica gel, 8:2 hexane/EtOAc) gave the
sulfone 12 (2.7 g, 62%) as an oil. Rf (30% EtOAc/hexane): 0.45; IR:
3000, 2965, 2923, 1445, 1318, 1306, 1152 cm"1; 1H NMR (500 MHz,
CDCl3) d 0.92 (t, J¼7.5 Hz, 3 H), 1.91e2.08 (m, 6 H), 2.62e2.81 (m,
4 H), 3.71 (d, J¼7.2 Hz, 2 H), 5.12e5.51 (m, 8 H), 7.49e7.57 (m, 2 H),
7.58e7.62 (m, 1 H), 7.78e7.86 (m, 2 H); 13C NMR (75 MHz, CDCl3)
d14.2 (CH3), 20.4 (CH2), 25.4 (CH2), 25.5 (CH2), 26.2 (CH2), 32.4
(CH2), 59.9 (CH2), 116.3, 126.8, 127.7 (3!CH]), 128.4 (2!CH]),
128.5 (2!CH]), 128.5 (CH]), 128.9 (2!CH]), 131.9, 133.5
(2!CH]), 138.2 (C]), 140.8 (CH]);m/z (EI) 344 (Mþ, 3%), 203 (82),
79 (100) (HRMS: found: Mþ344,1802. C21H28O2S requires 344,
1810).
3.3.2. Method B. A solution of bromide 6 (4.0 g, 17.0 mmol) and
PhSO2Na (5.55 g, 34.0 mmol) in DMF (100 mL) was heated at 80 %C
for 15 h. Mixture was cooled to rt followed by addition of water
(100 mL) and DCM (100 mL). Phases were separated, and the or-
ganic phase was washed with water (3!100 mL). Purification by
chromatography (silica gel, 8:2 hexane/EtOAc) gave the sulfone 12
(4.1 g, 85%) as an oil.
3.4. (2R,5E,9Z,12Z,15Z)-N-Boc-2-Amino-3-hydroxy-4-
phenysulfonyl-5,9,12,15-octadecatetraene (13)
n-BuLi (1.3 M in hexane, 5.50 mL, 7.15 mmol) was added to
a solution of the sulfone 12 (2.67 g, 7.76 mmol) in THF (25 mL) at
"78 %C. The mixture was stirred for 30 min before a solution of N-
Boc-D-alaninal (5, 0.80 g, 4.62 mmol) in THF (5 mL) was added
dropwise (0.5 mL/min using a syringe pump). The reaction mixture
was stirred at "78 %C for 1.5 h before the reaction was quenched by
addition of water and the mixture extracted with ether. The extract
was washed with water (3!), brine and dried (MgSO4). Evaporation
of solvents under reduced pressure gave a residue that contained
a mixture of unreacted 12 and four diastereomers. Purification by
flash chromatography (silica gel, 8:2 hexane/EtOAc) gave the sul-
fone 12 (1.05 g), diastereomer 13a (0.33 g), diastereomer 13b
(0.62 g), and an inseparable mixture of diastereomers 13c and 13d
(0.61 g, 54:46 according to NMR). The combined yield of 13was 69%
based on alaninal.
3.5. Diastereomer 13a
Rf (20% EtOAc/hexane): 0.32; [a]D25 ¼þ4.6 (c¼0.32, CH3OH); IR:
3506 (broad), 3443, 3388, 3008, 2973, 2933, 1710, 1501, 1447, 1299,
1167, 1144 cm"1; 1H NMR (300 MHz, CDCl3) d 0.93 (t, J¼7.5 Hz, 3 H),
1.17 (d, J¼6.0 Hz, 3 H), 1.39 (s, 9 H), 1.86e2.10 (m, 6 H), 2.63e2.81
(m, 4 H), 3.46 (t, J¼9.8 Hz, 1 H, H-4), 3.58e3.74 (m,1 H, H-2), 4.17 (s,
1 H, OH), (4.26 m, 1 H, H-3), 4.26 (d, J¼9.8 Hz, 1 H, H-3), 5,01e5.46
(m, 9 H), 7.44e7.54 (m, 2 H), 7.57e7.65 (m, 1 H), 7.73e7.86 (m, 2 H);
13C NMR (75 MHz, CDCl3) d12.3, 14.2 (2!CH3), 20.6, 25.4, 25.5, 26.1
(4!CH2), 28.3 (3!CH3), 32.5 (CH2), 47.6 (CHNH), 70.1 (CHOH), 72.8
(CHSO2Ph), 79.3 (CO), 118.4, 126.7, 127.7, 128.3, 128.5 (5!CH]),
128.8 (3!CH]), 129.3 (2!CH]), 132.0 (CH]), 134.1 (CH]), 136.5
(C), 141.2 (CH]), 155.0 (C]O). m/z (CI): 518 (Mþþ1, 0.9), 57 (100);
(HRMS (Electrospray): found: Mþ þ1, 518.2938. C29H44NO5S re-
quires 518.2935).
3.6. Diastereomer 13b
Rf (20% EtOAc/hexane): 0.20; [a]D25 ¼"2.45 (c¼0.41, CH3OH); IR:
3501(broad), 3447, 2970, 2932, 1716, 1499, 1441, 1297, 1158,
1136 cm"1; 1H NMR (300 MHz, CDCl3) d0.92 (t, J¼7.5 Hz, 3 H), 1.17
(d, J¼6.7 Hz, 3 H), 1.34 (s, 9 H), 1.83e2.08 (m, 6 H), 2.60e2.78 (m,
4 H), 3.56e3.77 (m, 2 H, H-2 and H-4), 4.09 (d, J¼9.5 Hz, 1 H, H-3),
4.33 (s, 1 H, OH), 4.72e4.93 (m, 1 H, NH), 4,95e5.43 (m, 8 H),
7.41e7.52 (m, 2 H), 7.53e7.64 (m, 1 H), 7.77e7.84 (m, 2 H); 13C NMR
(75 MHz, CDCl3) d14.2, 18.7 (2!CH3), 20.5, 25.4, 25.5, 25.9 (4!CH2),
28.2 (3!CH3), 32.5 (CH2), 47.7 (CHNH), 71.4 (CHOH), 72.9
(CHSO2Ph), 78.9 (CO), 117.9, 126.9, 127.8, 128.4, 128.7 (5!CH]),
128.8 (3!CH]), 129.1 (2!CH]), 132.0, 133.9 (2!CH]), 137,0 (C),
141.6 (CH]), 154.8 (C]O). m/z (CI): 518 (Mþþ1, 0.6), 57 (100). m/z
(EI): 461 (1.4), 44 (100); (HRMS (Electrospray): found: Mþ þ1,
518.2934. C29H44NO5S requires 518.2935).
3.7. Mixture of diastereomers 13c and 13d
Rf (20% EtOAc/hexane): 0.12; 1H NMR (300 MHz, CDCl3) d0.92 (t,
J¼7.5 Hz, 2!3 H), 1.12 (d, J¼6.7 Hz, 3 H), 1.34 (d, J¼6.5 Hz, 3 H), 1.37
(s, 9 H), 1.39 (s, 9 H), 1.29e2.15 (m, 2!6 H), 2.58e2.28 (m, 2!4 H),
3.38e3.77 (m, 2!2 H), 4.26e4.45 (m, 2!1 H), 4.58 (d, J¼8.6 Hz,1 H),
4.82 (d, J¼9.4 Hz,1 H), 5.05e5.48 (m, 2!8 H), 5.49e5.64 (m, 2!1 H),
7.38e7.62 (m, 2!3 H), 7.72e7.81 (m, 2!2 H); 13C NMR (75 MHz,
CDCl3) d14.1, 18.3, 20.4, 25.4 (2!CH2), 26.1, 32.5, 32.6, 49.1, 50.3,
70.4, 70.5, 71,2, 72.0, 77.2, 79.4, 117.4, 117.6, 126.8, 127.7, 128.4, 128.5,
128.6 (2!CH), 128.7, 128.8, 129.0, 129.2, 131.8, 131.9, 133.5, 133.6,
137.2, 137.3, 140.8, 142.1, 155.2, 155.7.
3.8. (2R,5E,9Z,12Z,15Z)-N-Boc-2-Amino-3-hydroxy-5,9,12,15-
octadecatetraene (14a)
To a solution of compound 13a (0.150 g, 0.29 mmol) and LiBH4
(0.032 g, 1.45 mmol) in dry THF (10 mL), cooled to "25 %C, was
added a suspension of Pd(PPh3)2Cl2 in THF (5 mL).10 The mixture
was left stirring at "25 %C overnight. 0.1 M aq NaOH (3 mL) was
added and the mixture extracted with ether/hexane 1:1. The ex-
tract was washed with water until neutral, then with brine and
dried (MgSO4). Evaporation of solvents followed by flash chroma-
tography (silica gel, 8:2 hexane/EtOAc) gave the compound 14a
(0.09 g, 82%) as an oil; Rf (40% EtOAc/hexane): 0.60; [a]D25 ¼þ11.6
(c¼0.17, CHCl3) IR:3439 (broad), 3010, 2974, 2932, 1690 (broad),
1505, 1366,1170 cm"1; 1H NMR (300MHz, CDCl3) d0.94 (t, J¼7.5 Hz,
3 H), 1.06 (d, J¼6.7 Hz, 3 H), 1,42 (s, 9 H), 1.90e2.28 (m, 9 H),
2.62e2.81 (m, 4 H), 3.51e3.72 (m, 2 H, H-2 and H-3), 4.68e4.82 (m,
1 H, NH), 5.21e5.60 (m, 8 H); 13C NMR (75 MHz, CDCl3) d 14.2, 14.5
(2!CH3), 20.5, 25.5, 25.6, 27.0 (4!CH2), 28.4 (3!CH3), 32.5, 37.2
(2!CH2), 50.1 (CHNH), 73.4 (CHOH), 79.3 (CO), 126.3, 127.0, 128.0,

















128.3, 128.4, 129.3, 132.0, 133.7 (8!CH¼), 155.7 (C]O); m/z (CI):
378 (Mþþ1, 2.6), 278 (100); (HRMS (Electrospray): found: Mþ þ1,
378.3000. C23H40NO3 requires 378.3003).
3.9. (2R,5E,9Z,12Z,15Z)-N-Boc-2-Amino-3-hydroxy-5,9,12,15-
octadecatetraene (14b)
Reduction of compound 13b (0.35 g, 0.67 mmol), as described
above for 13a, gave compound 14b (0.19 g, 75%) as an oil; Rf (40%
EtOAc/hexane): 0.60; [a]D25 ¼þ9.3 (c¼0.37, CH3OH); IR: 3390
(broad), 2988, 2935, 2900, 1670 (broad), 1485, 1350, 1155 cm$1; 1H
NMR (300 MHz, CDCl3) d0.94 (t, J¼7.5 Hz, 3 H), 1.14 (d, J¼6.8 Hz,
3 H), 1,41 (s, 9 H), 1.90e2.32 (m, 9 H), 2.66e2.83 (m, 4 H), 3.38e3.52
(m, 1 H, H-3), 3.53e3.69 (m, 1 H, H-2), 4.66e4.82 (m, 1 H, NH),
5.20e5.58 (m, 8 H); 13C NMR (75 MHz, CDCl3) d 14.2 (CH3), 18.5
(CH3), 20.5, 25.5, 25.6, 27.0 (4!CH2), 28.3 (3!CH3), 32.5, 37.7
(2!CH2), 49.7 (CHNH), 73.8 (CHOH), 79.2 (CO), 126.1, 127.0, 128.0,
128.1, 128.2, 128.3, 128.4, 129.2, 129.3, 131.9, 133.9 (11!CH]), 156.0
(C]O); m/z (EI): 321 (3.4), 44(100); m/z (CI): 378 (Mþþ1, 11.6), 278
(100). HRMS (Electrospray): found: Mþþ1, 378.3005, C23H40NO3
requires 378.3003.
3.10. 2,2-Dimethyl-1,3-oxazolidine (15a)
A solution of the amino alcohol 14a (52 mg, 0.14 mmol), 2,2-
dimethoxypropane (0.035 mL, 0.028 mmol) and p-toluenesulfonic
acid (cat. amount) in benzene (5 mL) was heated under reflux for
1 h. Ether (10mL) was added and the mixture neutralized with satd
aq NaHCO3, washed with brine and dried (MgSO4). Evaporation of
solvents followed by flash chromatography (silica gel, 95:5 hexane/
EtOAc) gave the oxazolidine 15a (45 mg, 78%) as an oil; Rf (40%
EtOAc/hexane): 0.60; [a]D25 ¼þ0.50 (c¼0.77, CHCl3); 1H NMR
(500 MHz, C6D6, 79 %C) d 0.91 (t, J¼7.5 Hz, 3 H), 1.13 (bd, J¼5.3 Hz,
3 H), 1.43 (s, 9 H), 1.56 (br s, 3 H), 1.68 (br s, 3 H), 1.93e2.14 (m, 7 H),
2.07e2.15 (m, 1 H), 2.66e2.86 (m, 4 H), 3.78e4.01 (m,1 H), 3.92 (m,
1 H), 5.31e5.52 (m, 8 H); 13C NMR (75 MHz, C6D6, 79 %C) d 13.9, 14.2
(2!CH3), 20.9, 26.0, 26.1, 27.5 (4!CH2), 28.6 (5!CH3), 32.9 (CH2),
55.7 (CHeN), 76.7 (CHeO), 79.0, (NeCeO), 92.8 (CO), 126.4, 127.6,
128.5, 128.6, 128.8, 129.7, 132.2, 132.6 (8!CH]), 151.8 (C]O).
3.11. 2,2-Dimethyl-1,3-oxazolidine (15b)
The amino alcohol 14b (0.13 g, 0.34 mmol) was treated with 2,2-
dimethoxypropane (0.085 mL, 0.069 mmol) and p-toluenesulfonic
acid (cat. amount) as described for 15a to give the oxazolidine 15b
(0.11 g, 76%) as an oil. [a]D25 ¼$10.5 (c¼0.57, CHCl3); 1H NMR
(500 MHz, CDCl3, 35 %C) d 0.94 (t, J¼7.5 Hz, 3 H), 1.25 (d, J¼5.9 Hz,
3 H), 1,45 (s, 12 H), 1,55 (s, 3 H), 1.88e2.13 (m, 6 H), 2.21e2.36 (m,
2 H), 2.68e2.82 (m, 4 H), 3.52 (br s, 1 H), 3.67 (q, J¼6.2 Hz, 1 H),
5.23e5.54 (m, 8 H); 13C NMR (75 MHz, CDCl3, 35 %C) d 14.2,18.5
(2!CH3), 20.5, 24.5, 25.6, 26.1 (4!CH2), 28.4 (5!CH3), 32.6, 36.8
(2!CH2), 57.2, (CHeN), 79.3 (NeCeO), 81.2 (CHeO), 93.8 (CO),
125.5, 127.0, 128.1, 128.2, 128.3, 129.3, 131.8, 132.9 (8!CH]), 152.1
(CH]O); HRMS (Electrospray): found: Mþ þ1, 418.3315, C26H44NO3
requires 418.3316.
(2R,3R,5E,9Z,12Z,15Z)-2-aminooctadeca-5,9,12,15-tetraen-3-ol
(Crucigasterin 277, 1). The amino alcohol (0.18 g, 0.48 mmol)
was dissolved in 80% formic acid (20 mL). The reaction mixture was
left stirring at room temperature overnight. Water (20 mL) was
added and most of the formic acid was removed by evaporation.
Saturated NaHCO3 was added to neutral pH and then the reaction
mixture was extracted with EtOAc (3!20 mL). The extract was
washed with water (20 mL) and brine (20 mL) and dried (MgSO4).
Evaporation of solvents under reduced pressure gave the amino
alcohol 1 (0.11 g, 82%) as an oil. [a]D25 ¼þ4.7 (c¼0.60, CHCl3); 1H
NMR (300 MHz, CDCl3) d 0.95 (t, J¼6, 3 H), 1.13e1.42 (m, 6H),
1.90e2.24 (m, 9H), 2.39e2.24 (m, 2 H), 2.69e2.84 (m, 4 H), 3.14 (br
s, 1H), 3.55 (s, 2H), 4.74 (br s, 3H), 5.21e5.57 (m, 8 H). 13C NMR
(75 MHz, CDCl3) d 14.47, 18.74, 20.75, 25.73, 25.86, 27.29, 32.89,
38.21, 52.11, 73.27, 125.35, 127.25, 128.24, 128.48, 128.64, 129.51,
132.19, 134.07.
The diacetyl derivative was made according to literature3 giving
[a]D25 ¼þ41 (c¼0.62, CH3OH); that is in accord with the published
one. All spectral data were consistent with the published ones.
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The NMR spectra were recorded in CDCl3, with a Bruker Avance DPX 200 or DPX 300 
instruments. The IR spectra were obtained with a Perkin-Elmer 1310 infrared 
spectrophotometer or a Nicolet Magna-IR 550 spectrometer. Mass spectra were recorded at 
70 eV with a Fisons VG Pro spectrometer. Optical rotations were measured with a Perkin 
Elmer 241 Polarimeter. Optical purity was determined using a Chrompack GC column: 3% 
OV 17 ON CHROM WHP. All reactions were performed under a nitrogen or argon 

















Scheme S-1: Preparation of bromide 6. 
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Figure S-2 13C-NMR spectrum of compound 12. 
 
 










Figure S-4 13C-NMR spectrum of intermediate sulfide. 
 
 










Figure S-6 13C-NMR spectrum of compound 13a.		
 
 










Figure S-8 13C-NMR spectrum of compound 14a. 
 
 









Figure S-10 13C-NMR spectrum of compound 15a. 
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